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Zusammenfassung
Die latente Epstein-Barr-Virus (EBV) Infektion und die damit einhergehende Expression von EBV
Nukleären Antigen (EBNA) Proteinen sind mit verschiedenen B-Zell Tumoren assoziiert. Die
Infektion von ruhenden primären B-Zellen in vivo leitet Differenzierungsprogramme ein, die
typischerweise mit B-Zellaktivierung und -proliferation korrelieren. Letztendlich entstehen
persistierende, nicht proliferierende B-Gedächtniszellen, welche durch die minimale Expression viraler
Gene gekennzeichnet sind. In vitro wird dieser Prozess in einem proliferativen Stadium blockiert,
phänotypisch ähnlich einem B-Zellblasten, und lymphoblastoide Zelllinien (LCLs) entstehen. EBNA2,
EBNA3A und EBNA3C (E2, E3A und E3C) fungieren als Transkriptionsfaktoren (TF), die in der
Lage sind die Transkription der Wirtszelle zu manipulieren. Des Weiteren sind sie essentiell für die
B-Zelltransformation und EBV-getriebene Proliferation. Differenzielle Genexpressionsstudien, unter
der Verwendung von Deletionsmutanten oder konditionellen Expressionssystemen, enthüllten
teilweise überlappende sowie einzeln regulierte EBNA Zielgene. Um gemeinsame oder unabhängige
EBNA Funktionsweisen zu untersuchen, wurden rekombinante EBV Genome und anschließend
LCLs hergestellt. Diese wurden zur Identifizierung von EBNA Bindestellen im humanen Genom
durch ChIP-seq Methoden verwendet. Die dabei erhobenen Daten wurden mit Informationen zu
Chromatinstruktur und TF-Bindestellen aus LCLs, die im Rahmen des ENCODE Projekts publiziert
wurden, kombiniert und verglichen. Ein bioinformatischer Ablauf wurde spezifisch für diesen Zweck,
unter Verwendung der Galaxy Plattform, entworfen. Dabei konnte gezeigt werden, dass E2 bereits
bestehende B-Zellenhancer bindet. Ein neuartiger Ansatz, der eine quantitative Bewertung und den
Vergleich von Bindestellen einschließt, konnte die reziproke Besetzung von B-Zellenhancern durch E2
und E3 Proteine zeigen. Diese werden begleitet durch unterschiedliche TF Kombinationen, welche die
spezifischen Bindemuster für das jeweilige EBNA Protein definieren. Des Weiteren indiziert die
auffallende Korrelation der Besetzung und Anreicherungsmuster von E3A und E3C Bindestellen eine
mögliche Kooperation in der gezielten Chromatinbindung. Alle drei EBNA Proteine sind nicht in der
Lage DNA direkt zu binden, sondern bedienen sich zellulärer Adapter, wobei CSL/CBF1, das zentrale
Effektormolekül des Notch-Signalwegs, den am umfassendsten beschriebenen darstellt. Die
Untersuchung von EBNA2 Bindestellen in CSL/CBF1 negativen Burkitt-Lymphom Zelllinien konnte
einen massiven Besetzungsverlust aufzeigen und damit CSL/CBF1 als die Haupt- jedoch nicht einzige
Determinante für den Zugang von E2 an Chromatin bestätigen. Analysen zur Motifanreicherung und
der Vergleich mit ChIP-seq Daten aus LCLs identifizierten den für B-Zellen charakteristischen TF
EBF1 als einen wichtigen Faktor für die E2 Bindung. Letztendlich konnte die Interaktion von E2 und
EBF1 in B-Zellen gezeigt werden. Zusammenfassend tragen die Ergebnisse dieser Arbeit zu einem
besseren Verständnis der zellulären Mechanismen bei, die von den EBNA Proteinen instrumentalisiert
werden, um selektiv Zielgene der Wirtszelle zu regulieren. Außerdem stellen sie einen Ausgangspunkt
für die Identifizierung von deterministischen Voraussetzungen für das selektive Binden von E2, E3A
oder E3C an Chromatin dar.
Abstract
Latent Epstein-Barr virus (EBV) infection and the accompanied expression of EBV Nuclear
Antigen (EBNA) proteins are associated with multiple B cell malignancies. Infection of resting
primary B cells in vivo triggers differentiation programs typically linked with B cell activation and
proliferation. Eventually, persistent non-proliferating memory B cells arise, characterized by
minimal expression of viral genes. This process is blocked in vitro at a proliferating state,
phenotypically similar to a B cell blast, resulting in lymphoblastoid cell lines (LCLs). EBNA2,
EBNA3A, and EBNA3C (E2, E3A, and E3C) operate as transcription factors (TFs) which are able
to manipulate host cell transcription and are vital to B cell transformation and EBV driven
proliferation. Differential gene expression studies, employing knock-out mutants or conditional
expression systems, revealed partially overlapping as well as uniquely regulated EBNA target genes.
In order to assess concerted or independent EBNA functions, recombinant EBV genomes were
constructed and subsequently LCLs were generated which were employed for identification of
EBNA binding sites within the human genome applying ChIP-seq methods. These data were
combined with and compared to information on host cell chromatin organization and cellular TF
binding sites in LCLs, published by the ENCODE project. A bioinformatics workflow specific for
this purpose was established, using the Galaxy platform. This could show the predominant
targeting of preexisting B cell enhancer elements by E2 and identify co-occurring TFs. A novel
approach, which includes a quantitative binding site evaluation and comparison, revealed the
reciprocal occupation of B cell enhancers by E2 versus E3 proteins accompanied by a distinct set
of co-occurring cellular factors, defining binding patterns specific for each EBNA protein.
Furthermore, the striking correlation of E3A and E3C binding site occupancy and enrichment
distribution in particular indicated a possible cooperation in chromatin targeting. All three
investigated EBNA proteins are not able to directly target DNA, but employ adaptor proteins
instead, the cellular TF CSL/CBF1, the major down-stream effector of the Notch signaling
pathway, being the most extensively described among them. Investigation of E2 binding site
occupancy in CSL/CBF1 knock-out Burkitt’s lymphoma cell lines disclosed an extensive loss of
these sites, confirming CSL/CBF1 as a major, but not exclusive determinant for E2 chromatin
accession. Motif enrichment analyses and comparison with published ChIP-seq data in LCLs
revealed the early B cell TF EBF1 as an important factor for mediating E2 binding. Finally, the
interaction of E2 and EBF1 in B cells were demonstrated. In conclusion, the findings of this thesis
contribute to a better understanding of the cellular mechanisms exploited by EBNA proteins to
selectively regulate host cell target genes. They also provide an initial starting point for the
identification of deterministic prerequisites for selective E2 or E3A and E3C binding to chromatin.
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1 Introduction
In 1958 the British medical officer and surgeon Denis Burkitt described the occurrence of
characteristic tumors in children in Uganda and Equatorial Africa, which are known today as
Burkitt’s lymphoma  (Burkitt, 1958). Since the prevalence of this specific lymphoma associated
strikingly with distinct climatic and geographical factors, the involvement of a biological
infectious agent was proposed (Burkitt, 1962a, Burkitt, 1962b). Soon after, in 1964 the team of
M. A. Epstein, Y.M. Barr, and B.G. Achong was able to maintain suspension cultures from
patient samples and could describe the presence of viral particles in these cells for the first time
(Epstein et al., 1964). Subsequently the fine structure of the virus was described by Hummeler
and the virologist couple Henle, and they recognized and assigned it to be a member of the
herpes viruses (Hummeler et al., 1966) which was later named Epstein-Barr Virus (EBV) (Henle
et al., 1968). Shortly after it was discovered that EBV is able to transform B cells in vitro (Henle et
al., 1967, Pope et al., 1968) and it was classified as the first human tumor inducing virus.
In the last 50 years since the discovery of EBV and its transforming properties, several
other malignancies apart from Burkitt’s lymphoma, e.g. diverse lymphomas and carcinomas, were
described to be associated with this virus (reviewed in Thorley-Lawson et al., 2015, Rickinson
and Kieff, 2007). Since the vast majority of the human population worldwide is latently infected
with EBV, intensive research is conducted to elucidate the tumor inducing or passenger
properties of EBV.
1.1 Epstein-Barr Virus
EBV, also termed human herpesvirus 4 (HHV-4), is a member of the γ-herpesvirinae, which is a
ubiquitously distributed human pathogen, with over 95% of adults being infected. Common for
all herpesviruses is its structure composed of a lipid containing envelope, a tegument, and an
icosaedric nucleocapsid containing the double stranded DNA. The EBV genome consists of
approx. 172 kb and encodes 80-100 different proteins. Characteristic for EBV is the ability to
infect resting B cells in vitro and in vivo and to induce proliferation. In vivo this process is controlled
by the immune system and the infection, which mostly happens during early childhood, remains
asymptomatic. However, an infection later in life can result in 35-50% of the cases in infectious
mononucleosis due to an excessive cytotoxic T cell response, which is a benign and self-limiting
disease (reviewed in Kieff and Rickinson, 2007). Since some of the infected cells can escape from
the immune response, EBV achieves a lifelong persistence in the host. Here, no virus particles
are produced, a state termed latency. Characteristic for γ-herpesviruses is the ability to regulate
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proliferation of the host cell also in this state. Sporadically, the virus can enter the lytic phase,
where virus particles are being produced and new B cells can be infected. In healthy adults the
viral induced proliferation as well as the lytic reactivation are strictly monitored and controlled by
the immune system. However, in immunocompromised individuals a spontaneous reactivation or
primary infection with EBV can lead to a pathological proliferation of transformed cells. For
instance, in immunosuppressed transplant recipients a highly malignant post-transplant
lymphoproliferative disease (PTLD) can occur (reviewed in Gottschalk et al., 2005). Also HIV positive
late stage AIDS patients are at risk to develop EBV induced lymphoproliferative diseases, e.g.
AIDS-associated primary central nervous system lymphoma (PCNSL) (Carbone et al., 2009). While for
PTLD and PCNSL EBV could be identified as the direct causing agent, it might display a
passenger in other malignancies (see chapter 1.1.3). In general, environmental triggers including
additional pathogens and specific genetic predisposition are considered to contribute to EBV
pathogenesis by complex mechanisms.
The life cycle of EBV1.1.1
Characteristic for EBV and other herpesviruses is the separation of its life cycle into a latent and
a lytic phase. After transmission through saliva EBV enters the epithelium of the Waldeyer’s ring
and infects resting naïve B cells there (Fig. 1). EBV glycoproteins gp350 and gp220 play an
important role in recognizing and binding the CD21 receptor at the B cell surface (Nemerow et
al., 1987, Tanner et al., 1987). Subsequently, endocytosis of the virus is mediated by the
interaction of gp42 with MHC class II molecules, which leads to fusion of the viral envelope with
the cell membrane (Silva et al., 2004). Then the viral capsid travels to the nucleus, the viral DNA
is released into the nucleus and the viral genome circularizes and is established as an episome. In
the following EBV triggers B cell differentiation and  proliferation programs, which are regularly
activated only after encountering an antigen but do not need further external signals (reviewed in
Thorley-Lawson, 2001, Thorley-Lawson and Allday, 2008, Thorley-Lawson et al., 2015)
(summarized in Fig. 1).
After the infection of a naive B cells these get activated and differentiate into proliferating
B cell blasts. In the absence of EBV this process is activated upon antigen binding to the B cell
and further needs T cell signals to proceed. However, in the case of EBV infection the
expression of only 11 viral latent genes is sufficient. Among these are six Epstein-Barr Nuclear
Antigens (EBNA1, -2, -LP, -3A, -3B, and -3C), three Latent Membrane Proteins (LMP1, -2A- and -
2B) and two genes encoding small non-polyadenylated RNAs (EBER1 and -2). This viral
expression program is termed latency III or growth program. The latency III associated viral
expression profile can be found in PTLD or PCNSL and is also expressed in in vitro established
3INTRODUCTION
LCLs. Latency III triggers excessive proliferation, however all of the expressed viral proteins but
EBNA1 exhibit epitopes, which can be presented by MHC molecules of the infected cell. This in
turn activates an immune response, where cytotoxic T cells eliminate the uncontrollably
proliferating B cells.
Figure 1. Schematic representation of the EBV life cycle. EBV enters the lymphatic tissue of the oropharynx by
passing through epithelial cells, where it supposedly initiates lytic infection which results in amplification of the virus.
Then these virions infect resting naïve B cells and drive them to become proliferating lymphoblasts. These
lymphoblasts are vastly eliminated by the T cell response, due to EBV antigen exposure. However, some cells escape
and travel to the germinal center (GC) were they undergo a GC reaction and differentiate into memory B cells. If
these memory B cells further differentiate into plasma cells, the lytic cycle is induced and EBV particles are produced
and released. Each step of the EBV latency program and the associated viral expression patterns are indicated (red
boxes) as well as the single steps of the regular B cell activation, which are imitated by EBV infection (blue boxes).
Figure adapted from Thorley-Lawson and Allday, 2008.
However, a certain percentage of EBV infected cells escape the elimination by the immune
system and travel in the germinal centers (GC) of lymph nodes, where they differentiate into
centroblasts, centrocytes, and finally memory B cells. This process is accompanied by the gradual
deactivation of the expression of latent genes. In the latency II stage, also called default program,
expression of EBNA2 and the EBNA3 proteins is shut down first and only EBNA1, the LMPs,
and EBER RNAs are expressed. The LMP proteins provide pivotal survival signals during the
GC reaction, which are essential for the differentiation into memory B cells. When this step is
accomplished no more viral proteins are being expressed, a state which is designated latency 0 or
latency program. These resulting latently infected memory B cells circulate within the periphery and
cannot be recognized by the immune system, since no EBV antigens are being expressed. In this
state the virus can persist lifelong in the host. When the memory B cell is dividing, only EBNA1
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is expressed, which ensures tethering of the viral genome to the host DNA during cell division
but is not presented on MHC molecules. This state is called latency I or EBNA1-only program.
The process of viral reactivation is not completely solved to date. Supposedly, this is
achieved by regular physiological signals, which cause the memory B cell to differentiate into a
plasma cell. Here, the lytic replication program takes place, and all viral genes are being expressed
(Laichalk and Thorley-Lawson, 2005). New virus particles are being produced and released,
which are in turn able to infect further naïve B cells or are transmitted by saliva to a new host.
Since the viral titers in the salvia of infected individuals are rather high, and EBV is also able to
infect epithelial cells (reviewed in Hutt-Fletcher, 2007) it was hypothesized that lytic replication
can also take place in epithelial cells of the oropharynx and supports virus amplification
(reviewed in Thorley-Lawson and Allday, 2008).
EBV latent genes1.1.2
The infection of B cells in vitro, without the appropriate immune response, leads to the outgrowth
of continually proliferating lymphoblastoid cell lines (LCLs), which exhibit a latency III type
expression pattern of viral genes. Since this can also be observed early after infection in vivo, these
cells display a cell culture model for the process of transformation. Furthermore, they are also
considered a model system for diseases as PTLD and PCNSL, which are also associated with
latency III expression pattern. The function of all 11 latent genes has been subject to extensive
research in the past and is still a matter of interest. The current knowledge on these proteins is
shortly summarized below (reviewed in Young and Murray, 2003).
EBNA1 is a DNA binding protein, which tethers the viral episomal genome, by binding to
its own origin of plasmid replication (oriP), to the human genome during cell division (reviewed in
Frappier, 2015).
EBNA2, in the following abbreviated to E2, is the central transactivator of EBV driven
gene regulation. Together with EBNA-LP it is the first viral gene to be expressed after infection.
The expression of both proteins is initially under control of the W promoter (Wp), but switches
to C promoter (Cp) mediated by E2 action. Cp also controls the expression of EBNA1 and the
EBNA3 proteins. Furthermore, E2 induces expression of the LMPs and regulates several cellular
genes. E2 is not able to bind directly to DNA but utilizes cellular CBF1, the key downstream
effector of Notch signaling, to access DNA (reviewed in Kempkes and Ling, 2015). Since E2
plays an essential role in this thesis, its function is further elaborated in chapter 1.2.1.
EBNA-LP cooperates with E2 in transcriptional regulation and increases the activation of
viral target genes. However, known cellular target genes of E2 are not affected by EBNA-LP
action, which indicated that EBNA-LP only displays a coactivator for a subset of E2 target genes.
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The interaction between E2 and EBNA-LP has not been solved to date. It has been proposed
that EBNA-LP acts as a coactivator by displacing repressive NCoR complexes from enhancers
(Portal et al., 2011). The analysis of EBNA-LP binding sites revealed only a moderate overlap
with E2 binding sites and a preference for promoter sites over enhancer regions, implying a
different mode of action than only being a coactivator of E2 function (reviewed in Kempkes and
Ling, 2015).
The members of the EBNA3 protein family, hereafter abbreviated E3, E3A, -3B, and -3C
were initially described as repressors of transcription. All three proteins are able to bind CBF1 as
well and therefore an antagonism of E2 function was proposed several times in the past. Since
E3A and E3C display the leading actors of this thesis, together with E2, their known functions
will be described in more detail in chapter 1.2.2.
LMP1,  -2A,  and  -2B are trans-membrane proteins which mediate signaling in a ligand
independent fashion. LMP1 mimics a constitutively active CD40 receptor, a key protein is the
activation a differentiation of B cells, and delivers proliferation and survival signals independent
of T cell interaction (Kieser and Sterz, 2015). LMP2A imitates the B cell receptor and provides
survival signal for the cell in the absence of antigen (Cen and Longnecker, 2015).
The EBERs, EBER1 and -2, are small non-polyadenylated RNAs whose function is not
fully understood yet. An immunomodulatory and anti-apoptotic role was supposed for these
highly abundant latent transcripts (Skalsky and Cullen, 2015).
None of the latent genes described above is able to induce B cell immortalization independently.
Thus a coordinated cooperation between the EBNAs and LMPs is needed, where the individual
contribution of the single factors is very different. Infection studies employing recombinant
viruses with knock-outs for the single latent genes gave insight on the dependence of EBV
induced immortalization on individual genes. These were subsequently classified as essential,
critical, or non-essential for immortalization and outgrowth of LCLs. E3B, E-LP, LMP2A, -2B,
and the EBERs are non-essential, while EBNA1 is critical for immortalization since EBNA1
deficient LCLs can only be established with low frequencies and need special culture conditions
(Humme et al., 2003). However, E2, E3A, E3C, and LMP1 were described to be absolutely
essential for B cell immortalization and therefore display a most interesting subject to study EBV
induced transformation. However, research conducted in our laboratory could show that E3A is
in fact dispensable for immortalization and knock-out LCLs can be established on a regular basis,
although they exhibit disabled proliferation and elevated apoptosis rates (Hertle et al., 2009).
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EBV associated tumors1.1.3
EBV displays a rather harmless pathogen for the healthy individual, while it can induce highly
malignant immunoblastic B cell lymphomas in immunocompromised patients, as mentioned
above, since an appropriate T cell response is not provided here. Among these are PTLD and
PCNSL as well as immunoblastic lymphomas in patients with hereditary immunodeficiencies
(reviewed in Carbone et al., 2008). However, EBV is also associated with tumors of immuno-
competent patients, including e.g. Burkitt’s or Hodgkin lymphoma, NK- and T cell lymphomas,
and also epithelial tumors (reviewed in Rochford and Moormann, 2015, Murray and Bell, 2015,
Jha et al., 2016, Raab-Traub, 2015). However, these tumors are not exhibiting the growth
program of latency III, which is the latency state investigated in this thesis, but it is speculated
that these tumor cells, which show latency II or I expression pattern, underwent a latency III
phase at some point. The described tumors can also show no viral expression except for EBNA1
and EBV could be supportive rather than driving in the multiple step tumor progression. The
most common EBV associated tumor malignancies are shortly described below.
Burkitt’s lymphoma (BL) is characterized by the reciprocal translocation of chromosome
8 and chromosome 14, 2, or 22. The translocations place the proto-oncogene c-myc under the
control of the immunoglobulin enhancers which results in a constitutive high level activation of
c-myc. Endemic BL, found in equatorial Africa, which led to the identification of EBV, is
associated with EBV infection in over 95% of the cases. The disease characteristically manifests
as a fast growing tumor involving the jaw or other facial bones and the abdomen. Before the
AIDS pandemic age, BL displayed the most frequently occurring childhood tumor in Africa. The
geographical pattern of BL led to the suggested association with Malaria infection, which might
cause a reactivation of the latent viral infection. The sporadic type of BL, occurring in adults in
moderate climate zones, is very rare and only associated with EBV in approx. 20% of the cases,
while the prevalence of EBV in AIDS-associated type was reported to reach up to 50%.
Interestingly, in EBV positive BLs only EBNA1 and the EBERs are expressed, exhibiting
latency I, which is not fully understood to date (reviewed in Rochford and Moormann, 2015).
Hodgkin lymphoma (HL) involves the secondary lymphatic organs, as lymph nodes and
the spleen, and is histologically characterized by multinuclear Reed-Sternberg cells. These
malignant cells represent only a minority of the tumor mass, a cellular infiltrate comprised of
non-neoplastic cells including T and B cells. HL represents approx. 20% of all lymphomas in the
western world, where 40-50% are associated with EBV while in developing countries the
prevalence reaches 90-100%. HIV associated HL are virtually always associated with EBV as well.
EBV positive HL express EBNA1, the LMPs, and the EBERs, a pattern characteristic for
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latency II. Also in this case the contribution of EBV to the development of HL is not fully
understood (reviewed in Murray and Bell, 2015).
Also the nasopharyngeal carcinoma (NPC) could be associated with EBV and involves
cells of the nasopharynx region and displays one of the most common tumors in southern China,
and Mediterranean Africa. Undifferentiated NPC is constantly associated with EBV and displays
latency II expression pattern. Due to the geographic distribution, genetic predispositions (e.g.
HLA type) and certain environmental factors, as nitrosamine containing food, were discussed to
play important roles in the pathogenesis of NPC (Raab-Traub, 2015).
Even 10% of gastric carcinomas are associated with EBV, which display one of the most
common human cancers. Supposedly, EBV only plays a role in a late stage of pathogenesis where
it infects neoplastic epithelial cells of the stomach. However, EBV positive gastric carcinomas do
not display a consistent latent expression pattern and range between latency I and II (Zur Hausen
et al., 2004).
1.2 Epstein-Barr Virus Nuclear Antigen 2 and 3 family
E2 and two members of the E3 family, namely E3A and E3C, were described to be essential for
B cell transformation by EBV, which was largely disproved for E3A, and function as
transcription factors (TFs) by modulating target gene transcription. The main focus of this thesis
is on these three TFs, E2, E3A, and E3C, which are described in more detail in this section.
EBNA21.2.1
1.2.1.1 The EBNA2 protein
EBNA2 (E2) displays the key transactivator of EBV in immortalization and it is absolutely
essential for B cell infection and proliferation. E2, together with EBNA-LP, is the first latent
protein to be expressed after infection and subsequently activates further viral and also cellular
genes. First E2 is expressed from the viral W promoter (Wp), which is then switched to the C
promoter (Cp) due to E2 binding and activation. Also EBNA1 and the E3 transcripts are
initiated from this Cp. Furthermore E2 induces the expression of the LMPs from different viral
promoters (reviewed in Kempkes and Ling, 2015). The E2 protein which was studied most
extensively derives from EBV strain B95.8 and consists of 487 aas (Skare et al., 1982, Baer et al.,
1984) and is schematically depicted in Figure 2.
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Figure 2. Schematic representation of E2 protein and its functional domains. E2 (B95.8 strain) exhibits two
domains which mediate dimerization (DIM) as well as two transactivation domains (TAD, blue); one is located at the
N-terminal the other at the C-terminal region of the protein. The N-terminal region (aas1-58) was studied in further
detail i.a. by structural analysis and the essential role of aas L16 and I50, which are located at the interface of an E2
homo dimer could be demonstrated (orange stars). The substitution of each aa, from a hydrophobic aa to negatively
charged aspartic acid (D), led to a complete loss of dimerization. Furthermore H15 and aas 35-39 (red), which form
an α-helix, are exposed on the protein surface and were found to be very important in E2 mediated transactivation
(Friberg et al., 2015). CBF1 binding was mapped to aas 318-327 with the E2 protein (Ling and Hayward, 1995).
E2 features two dimerization domains (DIM), which mediate homo dimerization, where the
N-terminal one (aas 1-58) was studied in more detail by heteronuclear NMR-spectroscopy.
Subsequent structure-guided mutational analysis revealed two aas within the hydrophobic
homodimer interface (L16 and I50) to be essential for dimerization. Furthermore, the surface
exposed aa H15 and an α-helix consisting of aas 35-39 were found to be important for E2
mediated transactivation (Friberg et al., 2015). This N-terminal DIM was also found to exhibit
transactivation function (TAD) and was also described to interact with EBNA-LP (Gordadze et
al., 2004, Harada et al., 2001, Peng et al., 2004). The second TAD at the C-terminal region (aas
448-479) of E2 was described to bind to TFIIB, TAF40, and TFIIH, factors of the transcription
initiation complex, as well as RPA70, the replication protein A (Tong et al., 1995b, Tong et al.,
1995a). Both TADs are able to recruit histone acetyltransferases CBP, p300, and PCAF as well
(Wang et al., 2000), and the structure of this E2 TAD with CBP/300 and TFIIH was recently
solved by NMR (Chabot et al., 2014). The structure of full-length E2 could not be solved to date,
due to high proline content and RG repeats, which most likely prevent structured folding in the
absence of specific binding partners.
1.2.1.2 DNA accession of EBNA2
Interestingly, E2 is not able to directly access DNA but utilized the ubiquitously expressed
cellular transcription factor, C promoter  binding  factor  1 (CBF1), which is also termed Suppressor of
Hairless (Su(H)) in D. melanogaster, Lag-1 in C. elegans and therefore summarized as CSL, and is
sometimes also referred to as RBPJ (Grossman et al., 1994, Henkel et al., 1994). CBF1, a
sequence specific DNA binding protein, is the downstream effector of Notch signaling pathway
and is described to recruit co-repressor complexes to DNA in the absence of Notch to repress
specific target genes. These co-repressor complexes include combinations of proteins including
SMRT, NCoR, HDAC1/2, Sin3A, SAP30, CIR, SKIP, and CtBP (reviwed in Lai, 2002). E2 is
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able to displace this co-repressor complex, supposed to bind to CBF1 in complex with DNA,
and recruits co-activators of transcription in a second step (Hsieh and Hayward, 1995). Since
CBF1 plays a pivotal role in Notch signaling and also displays the DNA adaptor for Notch, a
potential mimicry of Notch function by E2 was proposed and investigated (reviewed in Hayward
et al., 2006). Indeed it could be shown that E2 and Notch both bind to a hydrophobic pocket
within the repression domain of CBF1, yet to distinct aas, (Fuchs et al., 2001, Kovall and
Hendrickson, 2004) and therefore binding of these two TFs is mutually exclusive. However,
target gene comparison of E2 and Notch revealed a negligible overlap and favored a scenario
where E2 rather hijacks CBF1 as a DNA adaptor than fully mimicking Notch signaling. A
genome wide search for E2 and CBF1 binding sites by Chromatin Immunoprecipitation
experiments followed by deep sequencing of the associated DNA fragments (ChIP-seq) revealed
an overlap of approx. 70% of E2 and CBF1 sites and indicated CBF1 as the major DNA adaptor
for E2. Furthermore, the cellular B cell lineage defining TF PU.1 was described to mediate E2
binding to DNA, in concert with CBF1,  in activation of the viral LMP1 promoter (Johannsen et
al., 1995, Laux et al., 1994a, 1994b). However, this was not reported for cellular regulatory
elements and complex formation of both proteins could only be demonstrated once (Yue et al.,
2004).
EBNA3A and EBNA3C1.2.2
1.2.2.1 E3A and E3C proteins – Regulators of transcription
The E3 gene family consists of three members, E3A, E3B, and E3C, which are only expressed in
latency III and are located as a tandem array in the EBV genome. All E3 transcripts are initiated
from the viral promoter Cp, which can be activated by E2 action, gives rise to all EBNA
transcripts by different splicing events, and is only active during latency III. These three genes are
thought to be derived from gene duplication events due to their similarity in genomic and protein
structure, which display a conserved region of approx. 30% aa identity, specific for this family, in
the N-terminal region (Allday et al., 2015) (Fig. 3). All three members were described to be
regulators of transcription which are able to bind to the DNA binding protein CBF1 as well.
However, a functional redundancy within the E3 family could not be confirmed (O'Nions and
Allday, 2004). Furthermore, E3B is not essential for B cell immortalization while E3A and E3C
were described to be indispensable. However, this statement was disproven for E3A, since LCLs
deficient for E3A could be established in our laboratory on a regular basis. These LCLs are
impaired in proliferation and showed elevated apoptosis rates during the first three months post
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infection (Hertle et al., 2009). Due to their very critical functions in B cell immortalization E3A
and E3C were further investigated in this thesis.
Figure 3. Schematic representation of E3A and E3C proteins and summarized information on CBF1
interaction and hetero dimerization. B95.8 strain E3A and E3C proteins and the aas involved in divers protein-
protein interaction are displayed linearly. The E3 homology domain is indicated (grey) as well as potential activation
(blue) or repression domains (red). Aas described to be important for CBF1 interaction are indicated and the
experimental evidence is specified in the boxes below. Also the aas mediating hetero dimerization of E3A and E3C
are highlighted and the underlying data described in the boxes below.
E3A and E3C were initially described as regulators of transcription in GAL4 reporter assays,
when tethered to DNA by the fusion to GAL4-DBD (Bain et al., 1996, Bourillot et al., 1998,
Cludts and Farrell, 1998, Marshall and Sample, 1995). Hence, a functional repression domain was
mapped to aas 524-666 of E3A (Bourillot et al., 1998) but also activating properties could be
assigned to a fragment of aas 627-805 (Dalbies-Tran et al., 2001). Similarly, a repression domain
comprising aas 280-525 of E3C was described as well as a second, less potent one, including
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aas 580-992. Also in the case of E3C an “activation domain” (aas 724-826) could be mapped,
residing within the C-terminal repression domain (Bain et al., 1996). Since both proteins, E3A
and E3C, mediate repression as full length proteins in reporter assays, it seems very likely that the
identified “activation domains” are actually masked within the secondary protein structure and
therefore are not important in gene regulation.
1.2.2.2 Protein-protein interactions of E3A and E3C
E3A and E3C are able to form hetero-dimers by interaction of the C-terminal regions,
respectively, as initially described by yeast two-hybrid (Y2H) experiments (Calderwood et al.,
2007), which was confirmed by Co-IP experiments in LCLs for full length proteins (Paschos et
al., 2012). Mutational analyses using recombinant proteins expressed in human cells mapped the
interaction domains within the N-terminal part of the E3 proteins (dissertation S. Petermann,
2009) (Fig. 3). Therefore, a functional cross-talk between E3A and E3C seems possible.
Both viral TFs were shown to bind to the cellular co-repressor of transcription CtBP
(C-terminal binding protein) and binding could be mapped to aas 857-861 and 886-89 within E3A
(Hickabottom et al., 2002) and aas 728-732 within E3C (Touitou et al., 2001). In the case of E3A
this interaction was described to be critical for B cell transformation (Maruo et al., 2005).
Furthermore, E3A and E3C interact with various other co-factors repressing transcription,
including histone deacetylases HDAC1 and HDAC2, Sin3A and NCoR (Radkov et al., 1999,
Knight et al., 2003). Especially E3C was extensively analyzed in search for interacting proteins,
and indeed several cellular factors could be identified, including cyclin A, cyclin D1, SUMO1/3,
SCF, RB, MYC, p300, MDM2, CHK2, and H2AX (reviewed in Allday et al., 2015). However,
most approaches consisted of pull-down assays after co-transfection of recombinant proteins
which were not confirmed in endogenous settings and therefore were not further elaborated in
this thesis.
1.2.2.3 DNA accession of E3A and E3C
As mentioned above, E3A and E3C are also able to bind to the cellular TF CBF1 and involved
aas within the viral proteins could be mapped to the E3 homology domain, respectively, and
showed a somewhat contradictory picture of CBF1 binding with E3 proteins (Fig. 3) (Robertson
et al., 1996, Zhao et al., 1996, Cludts and Farrell, 1998, Dalbies-Tran et al., 2001). However,
mutation analyses confirmed the importance of aas 198-202 of full-length E3A or E3C proteins
for CBF1 binding (Dalbies-Tran et al., 2001, West et al., 2004). Additionally, a WTP motif
discovered in E3C which resembles WΦP motif of Notch (WFP) or E2 (WWP), known to
mediate CBF1 interaction, was shown to be responsible for the interaction with the beta trefoil
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domain (BTD) of CBF1. E3A and E3C mutants deleted for fragments in the E3 homology
domain, including these aas, did not interact with CBF1 and failed to repress E2 mediated
activation of reporter genes and more importantly could not maintain lymphoblastoid cell growth
(Maruo et al., 2005, 2009, Lee et al., 2009). Interestingly, E3A and E3C bind to the same site as
E2 within the CBF1 protein (Robertson et al., 1995, 1996) and therefore E2 and E3 interaction
with CBF1 is most likely mutually exclusive. However, the structures of the different protein
complexes have not been solved to date and even if E2 and E3 proteins do not bind to the very
same aas within CBF1, displacement would be possible.
The regulation of the bidirectional viral LMP1/LMP2B promoter by E3C in concert with
E2 was shown to be dependent on a PU.1 binding site and a direct interaction between E3C and
PU.1 was demonstrated in vitro (Zhao and Sample, 2000). Subsequently, recruitment of E3C to
this promoter could be shown in E3C inducible EBV positive B cells, a mechanism which did
not apply to E2 regulated Cp which was responsive to E3C in reporter assays (Jimenez-Ramirez
et al., 2006).
Partly antagonistic gene regulation by E2 and E3 proteins1.2.3
In the past, the regulation of individual genes by the different EBNAs was reported applying
divers assays and cell lines, yet did not reveal a general strategy in gene regulation. Not until the
application of micro-arrays, genome wide differential gene expression patterns of knock-out (ko),
mutant, or conditional EBV positive cell lines could be revealed. These included E2 target genes
identified using conditionally active E2 in the EBV positive LCL background (Spender et al.,
2006, Zhao et al., 2006) as well as conditional E2 expression in EBV negative BL cell lines (Maier
et al., 2006, Lucchesi et al., 2008). Summarized, in these studies FCER23 (CD23), CR2 (CD21),
CCR7, HES1, BATF, BCL2A1, FCRL5, ABHD6, CCL3, CCL4, CDK5R1, DNASE1L3, MFN1,
RAPGEF2, RHOH, SAMSN1, SLAMF1, and CXCR7 could be identified as E2 target genes in
EBV negative B cells, independent of the expression of other viral factors. In the EBV positive
cells the proto-oncogene MYC, the p55α subunit of PIK3R1, FCER23, CR2, RUNX3, and
FCRL5 were shown to be direct targets of E2, since their induction was independent of de novo
protein synthesis, while the induction of CCND1 (cyclin D), CDK4, CSF3, and LT (lymphotoxin
alpha) genes required additional cellular or viral factors.
Also for the E3 proteins the application of micro arrays revealed cellular target genes on a
genome wide scale. To this end EBV negative BL cells, conditionally expressing E3A or E3C
(White et al., 2010, McClellan et al., 2012), E3A ko LCLs (Hertle et al., 2009), or LCLs expressing
conditionally active E3C (Zhao et al., 2011a, Skalska et al., 2013) were applied and showed many
target genes involved in apoptosis, cell cycle progression and lymphocyte differentiation
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(reviewed in Allday et al., 2015). Interestingly, the overlap of target genes was very small
comparing different cellular backgrounds and already pointed towards the importance of certain
cellular factors, as TFs and chromatin landscape, in EBNA specific target gene regulation.
Most interestingly, the comparison of E2, E3A, and E3C target genes, identified in the
Kempkes laboratory, revealed a significant overlap for these gene sets (Fig. 4). It could be shown
that 16.2 and 13.1% of E3A and E3C target genes, respectively, are counter-regulated by E2
action. But also co-regulation for 9.1 and 6.3% of E3A and E3C targets, respectively, by E2 was
demonstrated (Fig. 4A and B). Furthermore, the comparison of E3A and E3C targeted revealed
significant cooperation in target gene regulation with 12.2 or 16.2% of co-regulated genes,
depending on the reference target gene set due to differences in absolute numbers of E3A and
E3C regulated genes. But also some E3A and E3C counter-regulated genes could be identified
(Fig. 4C and D).
Figure 4. Comparison of E2, E3A, and E3C target genes identified in the Kempkes laboratory. E2 target
genes derived from BJAB and BL41 EBV negative cell lines expressing inducibly active E2 (Maier et al., 2006), while
E3A and E3C target genes were obtained by comparing wt with ko LCLs (Hertle et al., 2009, diploma thesis A.
Nowak, 2008). Percentages of identified (A) E3A or (B) E3C target genes which are also co- or counter-regulated by
E2. The overlap between E3A and E3C regulated genes using (C) E3A or (D) E3C target gene set as basis for
analysis (percentages differ due to different absolute numbers of regulated genes). Percentages of co- and counter-
regulated genes are indicated (Harth-Hertle, unpublished).
In summary, these data indicate the possibility of a functional antagonism of E2 and the E3
proteins but the mechanisms underlying these observations are still not clear to date. Two
popular mechanisms have been proposed, one which favors a model where the E3 proteins
destabilize the interaction of the E2-CBF1 complex with DNA (Robertson et al., 1995,
Robertson et al., 1996, Waltzer et al., 1996), and a second, which pictures the E3 proteins to
replace E2 on DNA-bound CBF1 and subsequently recruit co-repressors of transcription
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(Radkov et al., 1999, Touitou et al., 2001, White et al., 2010). However, both might not be
mutually exclusive and it might be possible that both apply for distinct sets of target genes.
1.3 Objectives
In 2011, the year this thesis was initiated, very little was known about the mechanisms by which
E2 and E3 proteins access chromatin and subsequently regulate target gene transcription. CBF1
had been identified as a potential DNA anchor shared by the viral proteins. Most studies had
focused on the viral genome and only selected cellular genomic loci had been studied with
respect to E2 and E3 binding, co-occurring cellular transcription factors, chromatin signatures,
and transcriptional activity. One example, which was extensively investigated in the Kempkes
laboratory, is the CXCL9 and -10 gene locus. Here, E3A was shown to compete with E2 for
chromatin binding to an intergenic enhancer region and to repress transcription by a CBF1
dependent process (Harth-Hertle et al., 2013). In the Kempkes laboratory extensive information
on EBNA target genes was collected and, supported by published data from other laboratories,
formed a picture, where E2 and E3 proteins seem to share a significant subset of counter- and
even co-regulated genes. This suggested that CBF1 might be the common determinant of E2 and
E3 functions. On the other hand, the majority of E2, E3A and E3C target genes are regulated
uniquely by a single viral transcription factor, indicating that additional cellular or viral factors are
critical determinants for E2 and E3 function. These determinants could either influence the
chromatin state of respective target sites or serve as anchors for E2 or E3 proteins to promote
chromatin binding.
 In order to define the specific and unique cellular determinants for E2 and E3 binding to
cellular chromatin, a genome wide screen for E2, E3A, and E3C binding sites was performed by
Chromatin Immunoprecipitation (ChIP) experiments followed by deep sequencing of the
associated DNA fragments (ChIP-seq). The resulting data sets were analyzed in context of
publicly available information on LCLs provided by the Encyclopedia of DNA Elements
(ENCODE) consortium (ENCODE_Consortium, 2012) including ChIP-seq experiments for 84
TFs (by June 2015, start of bioinformatics analysis) and extensive information on the chromatin
state. For this thesis, a novel bioinformatics strategy had to be developed. Based on genome wide
quantitative correlation analyses an unbiased complex picture of the specific composition of the
different subsets of EBNA binding sites needed to be generated.
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2 Material
2.1 Cell lines
Table 1. General and commercially available cell lines
Cell Line Description Reference
721 Human lymphoblastoid cell line, immortalized with EBV type Istrain B95.8 Kavathas et al. (1980)
DG75 Human EBV negative Burkitt’s lymphoma (BL) cell line Ben-Bassat et al. (1977)
HEK293 Human embryonic kidney epithelial cell line, transformed by DNAfragments of adenovirus type 5 Graham et al. (1977)
Raji Human EBV positive BL cell line Pulvertaft (1964)
Table 2. Lymphoblastoid cell lines
Cell Line
Internal DesignationDonor Recombinant EBV Clone
D1
Flag-E3A
1 LG309.1.1
2 LG309.1.2
Flag-E3C
1 LG309.2.1
2 LG309.2.2
wt
1 LG309.3.1
2 LG309.3.2
D2
Flag-E3A
1 LG395.1.1
2 LG395.1.2
Flag-E3C
1 LG395.2.1
2 LG395.2.2
wt
1 LG395.3.1
2 LG395.3.2
D1
Flag-E3A
1 LG396.1.2
2 LG396.1.5
Flag-E3C
1 LG396.2.3
2 LG396.2.6
wt
1 LG396.3.1
2 LG396.3.2
All LCLs listed above were generated in this thesis.
Table 3. HEK293 based EBV producer cell lines
Cell Line Recombinant EBV (BACmid Designation) Internal Designation
HEK293/Flag-E3A* Flag-E3A (pFlag-E3A) LG267 A 5.2
HEK293/Flag-E3C* Flag-E3C (pFlag-E3C) LG267 A 3.1
HEK293/2089 wt (p2089) 2089
HEK293/ΔEBNA2 EBNA2 deletion (pΔEBNA2) KG481-2
 (* generated in this thesis)
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2.2 BAC constructs and plasmids
Table 4. Recombinant EBV BACmids
BACmid Description Internal Designation
pFlag-E3A* Triple Flag-tag integrated in frame and N-terminal ofEBNA3A gene pLG174.1a.1
pFlag-E3C* Triple Flag-tag integrated in frame and N-terminal ofEBNA3C gene pLG191.2.1
pgalk-E3A*
galK integrated in frame and N-terminal of EBNA3A
gene, target site for Flag-tag, intermediate product for
positive/negative selection during Recombineering
pLG154.1a
pgalK-E3C*
galK integrated in frame and N-terminal of EBNA3C
gene, target site for Flag-tag, intermediate product for
positive/negative selection during Recombineering
pLG154.2a
p2089 wt EBV, strain B95.8 (Delecluse et al., 1998) p2089
pΔEBNA2 EBNA2 deletion p2491
(* generated in this thesis)
Table 5. Plasmids
Plasmid Description Reference
Internal
Designation
pgalK
Galactokinase (galK) expression plasmid for
amplification of galK for Recombineering cloning
technique
Warming et al. (2005) -
pBZLF1 Mammalian vector for the constitutiveexpression of Zta/BZLF1 (pCMV backbone) AG Hammerschmidt p509
pBALF4 Mammalian vector for the constitutiveexpression of gp110/BALF4 (pCMV backbone) AG Hammerschmidt p2670
2.3 DNA constructs
Table 6. DNA constructs for Recombineering
Construct Description Sequence
Internal
Designation
E3A/H1-
Flag-H2
Triple Flag-tag flanked
by 150 bp
homologous to region
upstream of E3A
including ATG (H1)
and 150 bp of E3A
gene (H2) 
CCGTGAGATGGATCAGGCTCTGGATGGTGTACTGACACACAAGCAAGG
CTGCCTCCATTGTCTCGGCACCGATTTCTAGGCAGCATCCTCTTTAAT
AGGTACAAGGGGGGTGCGGTGTTGGTGAGTCACACTTTTGTTGCAGAC
AAAATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATC
GACTACAAGGATGACGATGACAAGGACAAGGACAGGCCGGGTCCCCCG
GCCCTGGATGACAACATGGAAGAAGAAGTCCCATCTACCTCGGTTGTG
CAGGAACAGGTATCGGCGGGAGATTGGGAAAATGTCCTCATAGAGTTA
TCAGATAGCAGCTCAGAAAAGGAAGCAGAA
LG177
E3C/H1-
Flag-H2
Triple Flag-tag flanked
by 150 bp
homologous to region
upstream of E3C
including ATG (H1)
and 150 bp of E3C
gene (H2)
TCTGAAACATCGAACGATGAGTGATTTCGCCCATGTAACAAGAACTGG
GATGAACCCTGGGGCAACAGACTGCGGGGAGGAGGGGGGCAGTGATAA
GTCATGACAATTTTAGATGAGGTAGAAATTTTGCATATTTTCAGACCC
ACCATGGACTACAAAGACCATGACGGTGATTATAAAGATCATGACATC
GACTACAAGGATGACGATGACAAGGAATCATTTGAAGGACAGGGGGAC
TCTAGACAGTCACCCGACAATGAGCGGGGAGATAATGTACAGACTACC
GGCGAGCATGATCAGGACCCTGGGCCGGGGCCTCCATCCAGTGGGGCT
TCTGAGAGATTGGTACCAGAAGAGTCATAC
LG178
DNA constructs were ordered at MWG Operon (Ebersberg, Germany), already cloned into pCR2.1, and only used
for amplification via PCR. The Flag-tag encoding sequence is highlighted in bold, primer sites for amplification
(150 bp or 100 bp homology arms possible) are underlined, and the respective start codon is shown in italic,
underlined letters.
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2.4 Bacteria
Table 7. Bacterial strains
E. coli Description Application Reference
DH5α
F– endA1 glnV44 thi-
1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔ
M15 Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ–
Default plasmid
amplification and
cloning
Hanahan (1985)
SW105 DH10B [λc1857 (cro-bioA)<>Tet] gal490(cro-bioA)<>araC-PBADFlpe gal+ ΔgalK Recombineering
Warming et al.
(2005)
2.5 Primers
All primers used in this thesis were ordered at Metabion AG (Martinsried, Germany) and
designed via Primer3 web-based software (http://frodo.wi.mit.edu) and tested negative for
off-target hits by BLAT search (http://genome.ucsc.edu/cgi-bin/hgBlat). Primers used for
transcript quantification were designed to amplify across exon-exon junctions if possible. If
multiple Refseq transcripts (hg19) were assigned for one gene, primers were chosen to cover as
many transcript variants as possible by targeting shared exons. In silico PCR for these primer
pairs were performed to exclude off-target effects in genomic DNA.
Table 8. Primers for amplification of galK flanked by sequence specific homology arms (50 bp) for
Recombineering as overhangs
Primer
Internal
Designation Sequence
Annealing
(°C)
Product
(bp)
E3A/H1(50bp 5’ E3A
+ATG)-galK(first 20bp) Be859 (for)
ACAAGGGGGGTGCGGTGTTGGTGAG
TCACACTTTTGTTGCAGACAAAATG
CCTGTTGACAATTAATCATCGGCA
60
1,331
galK(last 20bp)-E3A/
H2(first 50bp -ATG) LG150 rev
TCTTCTTCCATGTTGTCATCCAGGG
CCGGGGGACCCGGCCTGTCCTTGTC
TCAGCACTGTCCTGCTCCTT
60
E3C/H1(50bp 5’ E3C
+ATG)-galK(first 20bp) Be861 (for)
TGACAATTTTAGATGAGGTAGAAAT
TTTGCATATTTTCAGACCCACCATG
CCTGTTGACAATTAATCATCGGCA
60
1,331
galK(last 20bp)-E3C/
H2(first 50bp -ATG) Be862 (rev)
CGCTCATTGTCGGGTGACTGTCTAG
AGTCCCCCTGTCCTTCAAATGATTC
TCAGCACTGTCCTGCTCCTT
60
Primers were designed to amplify galK from pgalK and generate homology arms (H1 and H2) specific for E3A or
E3C N-terminal integration site by including 50 bp overlaps. GalK specific sequences are highlighted in bold and
start codons are indicated in italic letters.
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Table 9. Primers for amplification of Flag constructs from plasmids
Target
Internal
Designation Sequence
Annealing
(°C)
Product
(bp)
E3A/H1-Flag-
H2/150bp
LG179a for CCGTGAGATGGATCAGGCT 55
366
LG179a rev TTCTGCTTCCTTTTCTGAGCT 55
E3A/H1-Flag-
H2/100bp
LG179b for GCCTCCATTGTCTCGGCA 55
266
LG179b rev CCCAATCTCCCGCCGATA 55
E3C/H1-Flag-
H2/150bp
LG180a for TCTGAAACATCGAACGATGAG 55
366
LG180a rev GTATGACTCTTCTGGTACCAAT 55
E3C/H1-Flag-
H2/100bp
LG180b for TGAACCCTGGGGCAACAGA 55
266
LG180b rev CCGGCCCAGGGTCCTGAT 55
These primers were used to amplify the Flag construct with the specific homology arms from ordered plasmids listed
in Table 6.
Table 10. Primers for diagnostic PCR of Flag constructs in EBV background
Pair Target
Internal
Designation Sequence
Annealing
(°C)
Product
(bp)
A FlankingFlag 5’ E3A
LG179a for CCGTGAGATGGATCAGGCT 55 300(-Flag)
/366(+ Flag)LG179a rev TTCTGCTTCCTTTTCTGAGCT 55
B Only Flag5’ E3A
LG179a for CCGTGAGATGGATCAGGCT 55
212
LG158 rev TCATCGTCATCCTTGTAGTCG 55
C FlankingFlag 5’ E3C
LG180a for TCTGAAACATCGAACGATGAG 55 300(-Flag)
/366(+ Flag)LG180a rev GTATGACTCTTCTGGTACCAAT 55
D Only Flag5’ E3C
LG158.2 for CGGAGGAACTGCTAAACAGG 55
282
LG158 rev TCATCGTCATCCTTGTAGTCG 55
Diagnostic PCR primers were used for verification of EBV genomes in recombinant EBV BACmids (Fig. 7),
HEK293 producer cell lines (Fig. 8), and LCLs (Fig. 9).
Table 11. Primers for transcript quantification
Gene Internal Designation Sequence
Annealing
(°C)
Product
(bp)
E3A
MH277 for GAAACCAAGACCAGAGGTCC
63 276
MH277 rev CCCAGGGCCGGACAATAGG
E3C
LG321 for GACAGTCACCCGACAATGAG
63 344
LG321 rev TTGCAGGTGCGATTGCTTG
BCL2L11
BimEL for GCTGTCTCGATCCTCCAGTG
60 128
BimEL rev GTTAAACTCGTCTCCAATACG
CXCL9
MH2146 for GCATCATCTTGCTGGTTCTG
63 255
MH2146 rev TTTGGCTGACCTGTTTCTCC
CXCL10
MH2145 for TGACTCTAAGTGGCATTCAAGG
63 239
MH2145 rev CCTTTCCTTGCTAACTGCTTTC
GAPDH
BS688 for GAAGGTGAAGGTCGGAGTC
63 152
LG90 rev TGGGTGGAATCATATTGGAAC
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Table 12. Primers for quantification of DNA recovered by ChIP experiments
Target
Internal
Designation Sequence
Annealing
(°C)
Product
(bp)
SDAD1 TSS
MH1729 fw CTCGTGTTTCCGGGTATGAC
63 95
MH1729 rv TGAGGCTTCCGTAGCATAGC
CXCL9 TSS
MH1726 fw AGCTGAGCTAACTAAATTGACCAC
63 81
MH1726 rv ACATGCAGAAATTCCCTTGG
CXCL E1
MH2348.B fw CAGGGACGGTAAGAGCCTTC
63 82
MH2348 rv AAATTCAAACAGGCCTGGAG
CXCL E3
MH2350 fw GTGTTTGCTCAAGGCCCTAC
63 77
MH2350 rv TGCTTGCAGGGAAGGATATAAG
CXCL10 TSS
MH824 fw TCCCTCCCTAATTCTGATTGG
63 138
MH1008 rv AGCAGAGGGAAATTCCGTAAC
CXCL11 TSS
MH1721 fw TGAGTCATGCACCTTTCCTG
63 162
MH1721 rv AAGAAGGCTGGTTACCATCTG
CXCL E4
MH2352 fw AGTTGGTGGCTGGGTATGTG
63 128
MH2352 rv GCCACATGGGAGACATTAAAC
CXCL E5
LG465 fw ACACACAAACACAACAAACCTG
63 117
LG465 rv GCCACAATTCCTGCTGTTTAC
ADAM28 TSS
LG567 fw ATTGTTGCAGGACCACAGC
63 112
LG567 rv TGCCTCCTCTCCAGTGAGAC
ADAM28
+20kb
LG460 fw ACACCTCATCTGTCCCGAAC
63 107
LG460 rv TGGATCAGCACATTTCTTGC
ADAM E1
MH2675 fw CTTCATGGCTACAGACTCTTGG
63 93
MH2675 rv CCTATGTCTCGCTTCCTGCT
ADAMDEC1
TSS
MH2752 fw CCCCAATCTCACACGAAAAG
63 99
MH2752 rv AAGTTGTGGTCTCCCCAGTG
ADAM E2
MH2676 fw GTTTGGCAAGCCTTCTTCTG
63 89
MH2676 rv GAGCCTGTGTCTCAGAGGTG
MED13L TSS
LG587 fw GAAGTGCGACCCAGAATCC
63 129
LG587 rv ATCGTCTCTCTCTCGCCTTG
MED13L -
75kb
LG649 fw CCATTCATGCAACAGTGAGG
63 114
LG649 rv GCAACCTCCAACTTCTGGTC
MED13L E1
LG613 fw GGCTTCTTGACGGTTACTGC
63 108
LG613 rv CATGATGCTCAGCTCTGTGG
MED13L E2
LG614 fw CACTGGCACCTTCCTTTCTC
63 130
LG614 rv CTGGGCTGAGCTAGAAGTGG
cntrl (RPL30)
ST122 fw CTGGTCTGACGCTCCTGACT
63 120
ST122 rv CAGTGCCCAGAATTCCAGAT
CD23 p
ST156 fw TGTGATCGGCCATAGTGGTA
63 101
ST156 rv TTAAGCAGCAAGTTCCCACA
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2.6 Antibodies
Table 13. Primary Antibodies
Specificity
Official
Designation Species Miscellaneous Application Reference
α-BATF B-ATF H-19 Goat Pc IgG, product no.:sc-15280 WB
Santa Cruz
Biotechnology
α-CBF1 RBP-J 7A11 Rat Mc, IgG2b WB E. Kremmer, IMI
α-EBF1 EBF C-8 Mouse Mc, IgG2a, product no.:sc-137065 WB, IP
Santa Cruz
Biotechnology
α-E1 E1B5 1H4-1-4 Rat Mc, IgG2a WB E. Kremmer, IMI
α-E2 1E6 Rat Mc, IgG2a ChIP E. Kremmer, IMI
α-E2 R3 Rat Mc, IgG2a WB, ChIP E. Kremmer, IMI
α-E3A E3AN 4A5-1111 Rat
Mc, IgG2a, epitope within
aas 1-50 WB E. Kremmer, IMI
α-E3B E3B2 6C9-1-1 Rat Mc, IgG2a WB E. Kremmer, IMI
α-E3C A10 P2-583 Mouse Mc, epitope aas 682-686(WAPSV) WB E. Kremmer, IMI
α-Flag M2 F3165 Mouse Mc, IgG1, epitopeDYKDDDDK WB
Sigma-Aldrich
(F3165)
α-GAPDH MAB374 6C9 Mouse Mc, IgG1 WB Millipore, USA(MAB374)
α-GST 6G9 Rat Mc, IgG2a, Isotype control ChIP E. Kremmer, IMI
α-HA 3F10 Rat Mc, IgG1 ChIP E. Kremmer, IMI
α-IRF4 IRF4 H-140 Rabbit Pc IgG, product no.:sc-28696 WB
Santa Cruz
Biotechnology
α-LMP1 S12 Mouse Mc, IgG2a WB E. Kremmer, IMI
Mouse IgG1 Isotype Control Mouse Mc, IgG1 ChIP Invitrogen(MA5-14453)
Mc: Monoclonal antibody, Pc: polyclonal antibody, WB: Western Blot, IP: Immunoprecipitation, ChIP: Chromatin-
Immunoprecipitation, IMI: Institute for molecular Immunology, Helmholtz Zentrum München
Table 14. Secondary Antibodies
Specificity Species Miscellaneous Application Reference
α-mouse IgG goat HRP coupled WB Santa Cruz Biotechnology, USA (sc-2005)
α-rat IgG goat HRP coupled WB Santa Cruz Biotechnology, USA (sc-2006)
HRP: horseradish peroxidase
2.7 Cell culture material
Reagent Distributor/Reference
Dimethyl sulfoxide (DMSO) Merck, Germany
Doxycycline (Dox) Sigma-Aldrich, USA
Fetal Calf Serum (FCS) PAA Laboratories, Austria
Hygromycin B Invitrogen, UK
L-Glutamine GIBCO, UK
OptiMEM Medium GIBCO, UK
Penicillin/Streptomycin GIBCO, UK
Puromycin Merck (Calbiochem), Germany
RPMI 1640-Medium GIBCO, UK
Trypsin GIBCO, UK
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2.8 Bacterial culture material
Reagent Distributor/Reference
Agar BactoTM, BD, USA
Ampicillin Sigma-Aldrich, USA
Chloramphenicol Sigma-Aldrich, USA
D-Biotin Sigma-Aldrich, USA
Galactose Sigma-Aldrich, USA
Glycerol Merck, Germany
L-Leucine Sigma-Aldrich, USA
MacConkey Agar Base Difco, BD, USA
M9 Minimal Salts Sigma-Aldrich, USA
M63 Minimal Salts Sigma-Aldrich, USA
Tryptone BactoTM, BD, USA
Yeast Extract BactoTM, BD, USA
2-Deoxy-galactose (2-DOG) Sigma-Aldrich, USA
2.9 Enzymes and reaction kits
Reagent Distributor/Reference
ECL GE Healthcare (Amersham), UK
High-Capacity cDNA Reverse
Transcription Kit
Applied Biosystems, Thermo Fisher Scientific, USA
LightCycler 480 SYBR Green I Master Roche Diagnostics, Germany
NucleoSpin Plasmid Macherey-Nagel, Germany
peqGold Taq Polymerase, all inclusive PEQLAB, Germany
Phusion® High-Fidelity DNA
Polymerase
New England Biolabs, USA
Proteinase K (PCR grade) Roche Diagnostics, Germany
QIAamp DNA Mini Kit QIAGEN, Germany
QIAquick PCR Purification Kit QIAGEN, Germany
Qubit® dsDNA HS Assay Kit Invitrogen, UK
Restriction Enzymes & Buffers New England Biolabs, USA
RNase A Sigma-Aldrich, USA
RNase-free DNase Set QIAGEN, Germany
RNeasy Mini Kit QIAGEN, Germany
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2.10 Chemicals and reagents
Reagent Distributor/Reference
Acrylamid 30% Roth, Germany
Agarose Invitrogen, UK
APS MP Biomedicals, Germany
BSA MP Biomedicals, Germany
Complete Protease Inhibitor Roche Diagnostics, Germany
Ethidium bromide Merck, Germany
Ficoll-Paque Plus GE Healthcare, UK
Formaldehyde, 37% Merck, Germany
Glycogen Sigma-Aldrich, USA
Isopropanol Roth, Germany
Milk powder AppliChem, Germany
MS2 RNA Roche Diagnostics, Germany
Polyethylenimine (PEI) Sigma-Aldrich, USA
Protein G-Sepharose GE Healthcare, UK
TEMED GE Healthcare, UK
Triton X-100 Sigma-Aldrich, USA
Trypan blue GIBCO, UK
All chemicals which are not listed above were purchased at Merck, MP Biomedicals, Roth, and Sigma-Aldrich.
2.11 Software and databases
Name Reference
CellQuestPro BD Biosciences, USA
Clone Manager 9 Professional Scientific & Educational Software, USA
Ensembl Genome Browser http://www.ensembl.org
LightCycler 480 Software, Version 1.5 Roche Diagnostics GmbH, Germany
Primer3 http://frodo.wi.mit.edu
UCSC Genome Browser http://genome.ucsc.edu
2.12 Bioinformatic Tools
Name Reference
Bowtie2 Langmead and Salzberg (2012)
deepTools package Ramirez et al. (2014a)
FastQC Andrews (2010)
Illumina Demultiplex AG Blum, Gene Center Munich, Germany
MACS2 Zhang et al. (2008)
Trim Galore! Krueger (2012)
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3 Methods
3.1 Mammalian cell culture methods
Cell culture3.1.1
All cell lines were cultivated at 37°C and 6% CO2 in RPMI 1640 Medium supplemented with
100 U/ml Penicillin, 100 µg/ml Streptomycin, 4 mM L-Glutamine, and 10 or 20% FCS
respectively. Cell density was determined by using a Neubauer counting chamber. To this end,
cells were diluted 1:2 with trypan blue, added to the chamber and living unstained cells were
counted under the microscope. The cell density was calculated as follows: cells/ml = mean no.
cells of all four big squares x 2 (dilution factor) x 104.
Suspension cell lines
Cell lines 721, DG75 and DG75 descendant cell lines were cultured with 10% FCS. Additionally,
1 µg/ml Puromycin was added to the medium of DG75 cell lines harboring pRTR vectors for
selection. Cells were maintained at 2-4 x 105 cells/ml and reseeded and supplied with fresh
medium every 3-4 days. Primary B cell preparations infected with recombinant EBV and
established LCLs were supplemented with 20% FCS. Within the first 3-5 weeks after infection in
96 well plates, containing lethally irradiated MRC5 fibroblasts as “feeder cells”, 50% of the
medium was exchanged once a week. Established LCLs were cultured without feeder cells and
medium was exchanged every 3-4 days adjusting the cell density to 2 x 105 cells/ml to ensure
standardized culture conditions. Suspension cells were always centrifuged at 300 g for 10 min at
RT for reseeding purposes or at 500 g for 5 min prior to harvest.
Adherent cell lines
HEK293 cells, stably transfected with recombinant EBV BACmids were cultured in medium
supplemented with 10% FCS and 100 µg/ml Hygromycin B for BACmid selection. MRC5
fibroblasts received 20% FCS supplemented in the medium. To detach adherent cells from the
culture dishes, cells were washed briefly with PBS, subsequently moistened with trypsin and
incubated at 37°C for approx. 3 min, and cell detachment was controlled under the microscope.
Cells were diluted 1:3 – 1:10 with fresh medium and reseeded every 3-4 days.
PBS 137 M NaCl, 2.7 M KCl, 7.3 M Na2HPO4, 1.5 M KH2PO4, pH 7.4
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Long term cell storage3.1.2
To preserve cells for a longer period of time, cells were frozen in liquid nitrogen. To this end,
1 x 107 cells were collected (suspension cells by centrifugation and adherent cells with preceding
trypsin treatment), resuspended in 1.5 ml freezing medium and transferred to 1.8 ml Cryotubes
(NUNC). Using a propanol freezing container cells were slowly cooled to -80°C and stored there
for approx. one day. Subsequently tubes were transferred to liquid nitrogen. To re-cultivate
frozen cells, these were thawed rapidly in a 37°C waterbath, washed with 30 ml medium to
remove DMSO, and resuspended in fresh medium. Required selection additions were added the
day after to the medium.
Freezing medium 40% culture medium, 50% FCS, 10% DMSO
Generation of HEK293 cells stably transfected with recombinant EBV3.1.3
The day before transfection 6 x105 HEK293 cells were plated per well and transfection reaction
of a 6-well plate. For the transfection two reaction batches were pre-mixed: A) 300 µl OptiMEM
with 1 µg of the desired BACmid DNA and B) 300 µl OptiMEM with 4 µg PEI (1 mg/ml).
Subsequently the two reactions were mixed and incubated for 20 min at room temperature (RT).
For transfection the cell culture medium was replaced by 1 ml OptiMEM and the reaction mix
was slowly added to the cells by dropping. Cells were incubated for 4 h at 37 °C and then the
reaction solution was replaced by 3 ml of regular culture medium containing 10% FCS without
selection. The day after the cells were trypsinized and reseeded in a 14 cm diameter culture dish
and supplied with medium containing 100 µg/ml hygromycin B for selection of transfected cells.
Approx. four weeks after GFP expressing clonal colonies are growing out derived from single
transfected cells. These colonies were identified by fluorescence microscope analysis. To pick
colonies the culture medium was removed, the cells were washed were slowly and carefully with
PBS, and small pieces of filter paper, sterilized by autoclaving and pre-incubated in trypsin, were
carefully put on the desired colonies with forceps. After 1 min incubation the filter piece was
removed and immediately placed in a well of a 6-well plate pre-filled with 3 ml of warm medium
supplemented with hygromycin. Clonal HEK cell lines were checked daily by microscope for cell
density and diluted accordingly. After 2-3 weeks the clonal cell lines could be diluted and
reseeded on a regular basis of 2-3 days and could be used for the production of viral particles.
For each recombinant EBV genome several clones were picked and cultivated to check for
differences in virus titers production. Potent clones were maintained and used for further particle
production.
25METHODS
Transfection of HEK293 cells for the production of infectious viral3.1.4
particles
Clonal HEK293 producer cell lines, stably transfected with recombinant EBV genomes and
generated as described above, were transiently transfected with BZLF1 (p509) and BALF4
(p2670) expression plasmids, to induce the lytic cycle of EBV. To this end HEK293 cells were
plated on 10 cm diameter culture dishes with approx. 50-60% confluency the day prior to
transfection. For transfection the culture medium was preplaced by 3 ml of OptiMEM and two
reaction batches prepared as follows: A) (3 µg p509 + 3 µg p2670 + 600 µl OptiMEM)/dish and
B) (24 µl PEI (1 mg/ml) + 600 µl OptiMEM)/dish. Subsequently the two reaction batches were
mixed and incubated for 20 min at RT. Then 1.2 ml reaction was added per dish very carefully by
dropping and the cells subsequently incubated for 4 h at 37 °C, then the supernatant was
removed and replaced by 10 ml of regular RPMI medium supplemented with 10% FCS without
hygromycin. After 3 days of incubation the virus particle containing supernatants were harvested
and filtrated (pore size 0.8 µm) to remove potential cell contaminations and stored at 4 °C.
Quantification of viral titers in cell supernatants3.1.5
 For quantification of viral titers 3 x105 Raji cells in 1 ml reactions were infected with 25, 50, 100,
250, and 500 µl virus containing supernatant, respectively and further cultivated. The day after
infection the culture medium was replaced by fresh one. Four days after infection the cells were
harvested by centrifugation, twice washed in PBS/5% FCS and GFP expressing cells were
quantified by FACS analysis. Viral titers were quantified as green Raji units (GRUs) per ml
supernatant and the mean of all five dilution steps was used as further reference.
Preparation of primary B cells from cord blood3.1.6
Cord blood from anonymized donors was retrieved from the Klinikum der Universität München
(LMU) and lymphocytes were isolated by Ficoll density centrifugation preparation as follows:
20 ml Ficoll-Paque Plus was prepared in 50 ml reaction tubes and carefully overlayed with of 20
ml 1:3 with PBS diluted cord blood (the Ficoll volume was adjusted to match diluted blood
volume but did not exceed 20m; for larger volumes, samples were split in two). The blood was
added very slowly to not disturb the Ficoll layer and two phases were formed. The tubes were
centrifuged at 300 g for 40 min and no brake was applied to stop the centrifuge. After this step
the lymphocytes remain at the interface between plasma (top layer) and Ficoll phase (bottom)
while the red blood cells are pelleted on the tube bottom. Lymphocytes are aspirated carefully
and pooled if blood was split prior to Ficoll centrifugation. The cells were washed twice with
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PBS/Versen (1:5000) and finally resuspended in a small volume of RPMI culture medium
containing 20% FCS, counted, and immediately used for infection experiments or frozen for long
time storage. Prior to infection the rate of B cells in the lymphocyte preparation was quantified
by FACS analysis: To this end 4 reactions à 106 cells were prepared, washed with PBS/5% FCS
and resuspended in 100 µl PBS/5% FCS each and 2 µl of the following FACS specific antibodies
were added: 1) APC Mouse anti-human CD19 (BD Pharmingen, 555415), for the detection of
B cells, 2) Mouse IgG1 negative control:APC (AbD Serotec, MCA928APC), as background
control for 1), 3) PE mouse anti-human CD3 (BD Pharmingen, 555333) specific for T cells, and
4) mouse IgG1 negative control:RPE (AbD Serotec, MCA928PE) as background control for 3).
The reactions were incubated for 40 min at 4 °C in the dark, subsequently washed twice with
PBS/5% FCS and finally resuspended in 500 µl PBS/5% FCS and APC and PE positive cell
percentages quantified via FACS analysis. All samples used for generation of LCLs in this thesis
showed approx. 10% of B cells and 30% T cells within the lymphocyte preparation. Samples with
lower percentages were discarded.
Infection of primary B cells with recombinant EBV for the generation3.1.7
of LCLs
One day prior to the actual infection experiment, MRC5 fibroblast cells were trypsinized,
resuspended in medium, transferred to a 50 ml tube and lethally irradiated using a γ-radiation
source applying 5,000 cGy. Subsequently the cells were washed with medium and reseeded to
approx. 80% confluency in 96-well plates in 200 µl medium. For infection 150 µl of the culture
supernatant per well were removed, and 3 x 105 lymphocytes in 50 µl were added per well. Virus
containing supernatants were added to 5,000 GRUs/well and did not exceed 100 µl/well. For
each recombinant EBV at least half a 96-well plate was infected. After infection the culture
medium containing 20% FCS was exchanged once per week. After 2-3 weeks the cultures were
transferred to new successively larger plates, cultivated without feeder cells, and diluted and
reseeded on a regular basis.
3.2 Bacterial culture methods
Propagation and storage of bacteria3.2.1
Bacteria were cultivated as suspension cultures in LB medium or for separation of colonies
cultured on LB agar plates at 37 °C. All mediums and reagents were autoclaved prior to usage if
not indicated otherwise. Transformed bacteria were selected by addition of antibiotics
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appropriate for the respective resistance gene. Short term storage of bacteria was conducted at 4
°C, while 100 µl DMSO were added to 900 µl freshly overnight grown suspension culture derived
from a single colony and frozen at -80 °C for long term storage.
LB medium 1% Tryptone, 0.5% Yeast Extract, 1% NaCl, pH 7.4
LB agar LB medium supplemented with 1.5% Agar
Antibiotics  100 µg/ml Ampicillin or 20 µg/ml Chloramphenicol, respectively (sterile
filtrated, dissolved in ethanol)
Generation of chemically transformation competent bacteria3.2.2
500 ml LB medium were inoculated with 5 ml overnight culture of E. coli DH5α and incubated
under vigorous shaking at 37 °C until an OD595 of 0.3-0.4 was reached. Subsequently the culture
was divided in precooled 50 ml tubes, incubated on ice for 10 min and pelleted by centrifugation
(1,600 g, 7 min, 4 °C). Each pellet was resuspended in 10 ml ice cold CaCl2 solution, incubated
for 30 min on ice and again pelleted by centrifugation (1,100 g, 5 min, 4 °C). Finally, the cell
pellets were each resuspended in 2 ml ice cold CaCl2 solution, aliquoted in 200 µl per pre-cooled
1.5 ml reaction tube, shock frozen in liquid nitrogen and stored at -80 °C.
CaCl2 solution 60 mM CaCl2, 10 mM PIPES, 15% Glycerol, sterile filtrated (0.22 µm)
Heat shock transformation of E. coli3.2.3
100 µl of chemically competent E. coli were thaw on ice and 50-100 ng of the DNA of interest
were added, mixed, and incubated for 30 min on ice. Then the bacteria were heat shocked for
50 s at 42 °C, shortly incubated on ice, and 900 µl LB medium were added. To enable expression
of the resistance gene, the reaction was incubated 1 h at 37 °C under vigorous shaking prior to
plating various dilutions on LB agar plates containing the appropriate antibiotic.
Recombineering3.2.4
In order generate recombinant EBV genomes in the BACmid background the recombineering
technique (Warming et al., 2005) was applied for cloning strategies. The distinct purpose of this
cloning and the single steps are further explained in chapter 4.1.1, while the technical details are
described in the following section.
Step I – Targeted integration and galK positive selection
E. coli strain SW105 already transformed with wt EBV BACmid p2089 was a gift from W.
Hammerschmidt and cultivated in chloramphenicol containing LB medium or agar. For the first
step of the recombineering protocol 5 ml LB medium containing chloramphenicol were
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inoculated with a single colony and incubated over night at 32 °C under vigorous shaking. The
day after 25 ml LB medium containing chloramphenicol were inoculated with 500 µl of the
overnight culture and further incubated at 32 °C under vigorous shaking until an OD595 of 0.6
was reached. Subsequently 10 ml of the culture were transferred to a new Erlenmeyer flask and
incubated for 15 min in a 42 °C water bath under shaking in order to express the heat sensitive
integrated phage genes exo, bet and, gam, which are needed for mediating homologous
recombination. The remaining culture was kept at 32 °C as not induced negative control. Then
both flasks, induced and not induced cultures, were shortly incubated in iced water and
subsequently the cultures were pelleted by centrifugation using 15 ml round bottom tubes (4,000
rpm, 5 min, 4 °C). The supernatants were aspirated and cell pellets were gently resuspended in
1 ml ice cold H2O by swirling, then 9 ml H2O were added and cells pelleted by centrifugation.
This washing procedure was repeated once and then the supernatant was carefully and
completely aspirated and the bacterial pellets were placed on ice. For the transformation 60 ng of
the desired PCR product, consisting of the galK gene flanked by each 50 bp homologous to the
targeted DNA sequence, were submitted to a BioRad cuvette (0.1 cm). Also 100 ng of pgalK
plasmid DNA were used as positive control for transformation efficiency. Subsequently, 25 µl of
the respective bacteria were added to the DNA and the mixture was electroporated applying
25 µF, 1.75 kV, and 200 Ω using a BioRad Gene Pulser® II device. After electroporation
immediately 1 ml of LB medium was added and the reaction was transferred to a new 15 ml
round bottom tube and incubated for 1 h at 32 °C under shaking. Then the cells were transferred
to a 1.5 ml reaction tube, pelleted by centrifugation (13,200 rpm, 15 s, RT) and resuspended in
1 ml M9 minimal salts (M9) solution. This washing procedure was repeated twice and finally the
pellet was resuspended in 1 ml M9 solution and 1:10 as well as 1:100 dilutions in M9 solution
were made and 100 µl of each dilution was spread on M63 minimal salts (M63) agar plates
containing galactose as the only carbon source. Only bacteria which successfully integrated galK
are now able to process galactose and to grow on these minimal plates (Gal+). The plates were
incubated at 32 °C for approx. 5 days until single colonies were growing out. Colonies were
further checked for successful galK integration by replica plating on fresh M63 plates and
MacConkey base agar plates serving as Gal+ indicator plates (bright red-pink colonies). For each
transformation reaction at least 10 colonies were picked and overnight cultures in 5 ml LB
medium containing chloramphenicol were made. DNA was recovered for integrity check by
restriction enzyme digestion diagnostic PCR as described in 3.2.6.1.
Step II – Exchange of galK and galK negative selection
Bacterial clones which were identified for the correct integration of galK at the destination of
interest were now used for the second step, where galK is exchanged by the sequence of interest,
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here coding for a triple Flag-tag. To this end selected clones were induced to express lambda
encoded, recombination mediating genes and made competent for transformation as described
above. Also the transformation was performed as described above, this time employing 200 ng of
the desired constructs. Here the coding sequence for the Flag-tag including 150 bp homology
arms for the integration sites of interest was amplified from plasmids containing this artificially
synthesized DNA fragment (Table 6) using primers described in Table 9. Both constructs, using
100 or 150 bp homology arms resulted in successful recombination, while usage of a construct
with 50 bp homology arms, as described in the original publication, was not successful. This time
after transfection the bacteria were incubated for 4.5 h at 32 °C under vigorous shaking and
subsequently resuspended and wash with M9 solution as described above. Finally, bacteria were
spread on M63 agar plates containing 2-deoxy-galactose (2-DOG) and glycerol as carbon sources.
Bacteria still harboring galK metabolize 2-DOG to a toxic product thereby galK can now be used
as negative selection marker. Again, at least 10 single colonies were picked and checked correct
insertion of the Flag construct by diagnostic PCR, and also subjected to restriction enzyme
digestion.
M9 minimal salts solution 1x solution (11.3 g 5x salts diluted in 1 l H2O)
M63 minimal salts agar + galactose 1x  M63  salts,  1.5%  agar,  added  after  cool  down:  1mM  MgSo4×7H2O,
2.5 mg Biotin (sterile filtrated), 45 mg Leucine (sterile filtrated),
20 µg/ml Chloramphenicol, 0.2% Galactose
MacConkey base agar 40 g/l MacConkey agar base, 1.5% agar, 20 µg/ml Chloramphenicol,
0.2% Galactose
M63 minimal salts agar + 2-DOG as M63 recipe, but 0.2% 2-DOG and 0.2% Glycerol instead of
Galactose
Plasmid recovery from bacterial cultures3.2.5
To recover plasmid DNA transformed and amplified in E. coli DH5α the NucleoSpin Plasmid kit
was applied according to the manufacturer’s instructions.
BACmid recovery from bacterial cultures3.2.6
3.2.6.1 Small scale preparation for integrity check
For a fast recovery of BACmids from E. coli SW105 in order to check for integrity and success of
recombination, simultaneously checking several clones, 5 ml overnight cultures (which were also
frozen at -80 °C for long time storage until integrity check) were streaked on half a LB agar plate
containing chloramphenicol and incubated at 32 °C overnight. The next day, a small area of
confluent bacteria of approx. 1.5 cm2 was scratched of the plate with the tip of a microliter pipet
and resuspended in 200 µl Binding Buffer. Then 200 µl Lysis Buffer were added and the reaction
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was mixed and bacteria were lysed by carefully inverting the tube 6-8 times and incubation for 5
min on ice. The reaction was neutralized by adding 200 µl Neutralization Buffer to the reaction
and carefully mixed by inverting the tube 6-8 times. The lysate was cleared by centrifugation
(16,000 g, 10 min, 4 °C) and the supernatant was transferred to a new reaction tube. This step
was repeated once to fully clear the lysate. Then 400 µl isopropanol were added and the reaction
was mixed by inverting. The BACmid DNA was precipitated by centrifugation (16,000 g, 10 min,
RT) and the DNA pellet was washed once with 80% ethanol (16,000 g, 10 min, RT). Finally the
supernatant was aspirated completely and the pellet was shortly air dried before it was dissolved
in 20 µl TE Buffer. The complete preparation was used for one diagnostic restriction digest
reaction.
Binding Buffer 50 mM Tris-HCl (pH 8.0), 10 mM EDTA (pH 8.0), 100 µg/ml RNase A
Lysis Buffer 200 mM NaOH, 1% SDS
Neutralization Buffer 3.1 M Potassium acetate (CH3CO2K), pH5.5
TE Buffer 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0
3.2.6.2 High purity large scale BACmid preparation for transfection
In order to obtain high quantities of transfection grade supercoiled BACmid, large volumes of
bacterial culture were harvested and recovered BACmid DNA was subsequently subjected to
CsCl density gradient centrifugation. First 50 ml LB medium containing chloramphenicol were
inoculated with one colony harboring the desired BACmid and incubated at 32 °C under
vigorous shaking overnight. The next day, 6x 400 ml LB medium plus chloramphenicol and
24 ml of 5M NaCl were inoculated with each 1 ml of the overnight culture and again incubated at
32 °C overnight under vigorous shaking. Cells were harvested by centrifugation (4,600 g, 15 min,
4 °C), the supernatant was discarded and the bacterial pellets were (at least) shortly frozen
at -80 °C. Pellets were resuspended in each 10 ml Solution I by pipetting, transferred to 200 ml
conical tubes, and filled up to 45 ml final volume. From now on tubes were constantly kept on
ice. For each tube 10 mg Lysozyme were added, mixed by gently inverting the tube and incubated
on ice for 10 min. Cells were lysed by addition of 58 ml freshly prepared Solution II and
subsequent mixing by gentle 5-6 times inversion of the tube. Then the tubes were incubated for 5
min on ice. The reaction was neutralized by addition of 70 ml Solution III and mixed by gentle
inversions of the tube until the lysate was cleared and kept of at least 30 min on ice. Then the
non-soluble fraction was pelleted by centrifugation (4,600 rpm, 45 min, 4 °C). The supernatants
were cleared by filtration trough filter paper and transferred and distributed into new conical
200 ml tubes with a maximal volume of 130 ml. BACmid DNA was precipitated by addition of
0.75x volume of isopropanol, mixed by inversions, and incubated for 30 min at RT. The DNA
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was pelleted by centrifugation (4,600 rpm, 60 min, RT), the supernatant was discarded, and each
pellet washed with 50 ml 80% ethanol. After centrifugation for 20 min, the supernatant
discarded, the pellets were air dried and resuspended in a total of 40 ml TE Buffer. DNA pellets
were not pipetted but dissolved by gentle rocking overnight. After complete resuspension of the
DNA, all tubes were combined and 400 µg RNase A was added and incubated at 37 °C for
15 min. Then 6 mg Proteinase K were added and the reaction incubated at 50 °C for 45 min. The
reaction volume was split into two 50 ml tubes, the net weight was determined and the same
quantity of CsCl salt in g (+ 1 g to compensate for the 1 ml ethidium bromide (EtBr) to be
added) was slowly added to each tube in several portions and warmed to 50 °C in between for
better dissolving. When the CsCl was completely dissolved, 1 ml EtBr was added to each tube.
Each reaction was transferred in one 35 ml Sorvall ultracentrifugation tube (#03989) and the
tubes were completely filled with 1.55 g/ml CsCl solution, carefully balanced against each other,
and sealed. The tubes were subjected to ultracentrifugation at 38,000 rpm, for three days at RT
without applying a brake to stop the rotor. DNA was shortly visualized under UV light (312 nm)
and the lower DNA band (supercoiled DNA) was slowly and carefully aspirated using a 14 gauge
needle and syringe. Prior to aspiration of the DNA a second needle was carefully put through the
upper part of the tube to ensure pressure compensation upon volume reduction in the tube. The
DNA containing solutions were combined, filled up to 11.5 ml with 1.55 g/ml CsCl solution, and
again subjected to density gradient centrifugation at 38,000 rpm, for three days at RT, without
brake applied. Supercoiled DNA was aspirated as described above. Subsequently EtBr was
completely removed by Isobutanol solvent extraction and CsCl was removed by dialysis with 2x
2 l TE Buffer. Recovered BACmid DNA was checked for integrity by restriction enzyme digest,
diagnostic PCR, and was subjected to sequencing for critical regions e.g. the inserted regions.
Solution I 50 mM Glucose, 25 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 8.0,
100 µg/ml RNase A
Solution II 200 mM NaOH, 0.4% SDS
Solution III 3 M Potassium acetate (CH3CO2K), pH5.5
3.3 RNA related techniques
All RNA involving assays and experiments required the usage of filter tips, RNase free reaction
tubes and reagents, and were conducted on ice.
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Isolation of RNA from mammalian cells3.3.1
RNA was isolated from 5 x 106 to 107 cells using RNeasy mini extraction kit (Qiagen) according
to the manufacturers’ instructions. For lysis β-Mercaptoethanol (β-ME) was added to buffer RLT
(134 mM final) and cells were lysed applying 700 µl RLT+ β-ME. For complete disruption of
cells QIAshredder columns were used according to the manufacturers’ instructions. Additionally,
RNase-free DNase set (Qiagen) was applied according to the manufacturers’ instructions to
eliminate residual genomic DNA in the preparation. Finally, RNA was eluted in 50 µl H2O and
RNA concentration and purity was determined using a nanodrop device.
RNA agarose gel electrophoresis3.3.2
RNA preparations were subjected to denaturing RNA agarose gel electrophoresis to assess RNA
quality. High RNA quality is associated with sharp 28 and 18S rRNA bands visible under UV
light, while degraded RNA produces rather smeared bands. To this end 1.2% agarose was melted
in autoclaved water and after cooling to approx. 60 °C, formaldehyde and MOPS were added to a
final concentration of 2.2 M and 1 x, respectively. For each sample 5 µg RNA were subjected to
electrophoresis. The reaction was prepared on ice, where 2 µl 5 x MOPs, 3.5 µl 37%
formaldehyde, 10 µl deionizing 100% formamide, and 0.08 µl EtBr were added to each sample,
mixed by pipetting and denatured at 56 °C for 15 min. Subsequently samples were shortly
incubated on ice, 2 µl of RNA sample Buffer were added and samples were subjected to
electrophoresis. 1 x MOPS was applied as running buffer and electrophoresis was conducted at
1-2 V/cm.
10 x MOPS 0.4 M MOPS, pH 7.0, 0.1 M Na-Acetate, 0.01 M EDTA, pH 8.0
RNA sample Buffer 50% Glycerol, 1 mM EDTA, pH 8.0, 0.4% Bromophenol blue
Reverse transcription of RNA3.3.3
RNA was reverse transcribed (RT) to obtain cDNA as target for PCR analyses (RT-PCR and
RT-qPCR). To this end the High-Capacity cDNA Reverse Transcription Kit was applied
according to the manufacturers’ instructions using 2 µg RNA as input. As a standard procedure
for each analyzed sample, two reactions were set up, one containing reverse transcriptase and the
second without enzyme, serving as negative control for genomic DNA contamination. For qPCR
analysis, 1/80 or 1/40 of the cDNA reaction (corresponding to 25 or 50 ng input RNA,
respectively) was used as template for quantification of GAPDH and the other analyzed
transcripts, respectively.
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3.4 DNA related techniques
Preparation of genomic DNA from mammalian cells3.4.1
For the preparation of complete genomic DNA QIAamp DNA Mini Kit was applied according
to the manufacturers’ instructions using 5 x 106 cells as input material. Finally, DNA was eluted in
100 µl H2O and concentration and purity was determined using a nanodrop device.
Restriction enzyme digestion of DNA3.4.2
Plasmid or BACmid DNA was controlled for integrity and cloning success by restriction enzyme
digestion according to the manufacturers’ instructions of the respective enzyme. To this end
0.5-1 µg purified DNA or the complete BACmid mini preparation was used as template.
DNA Gel electrophoresis3.4.3
DNA fragments were separated on agarose gels with the appropriate agarose concentrations
(0.8-1.5%) which contained 0.01% (v/v) EtBr and 1 x TAE Buffer was used as gel and running
buffer. The DNA samples were mixed with 1/6 final volume of DNA Loading Buffer and
electrophoresis was conducted applying 5-8 V/cm. Finally, gels were analyzed under UV light
and captured for documentation.
TAE 40 mM Tris-Acetate, 1 mM EDTA, pH 8.0
6x DNA Loading Buffer 15% Glycerol, 0.25% Bromophenol blue, 0.25% Xylene cyanol
Sequencing of DNA3.4.4
Sequencing of DNA was conducted at MWG Operon, Ebersberg, Germany and analyzed using
the Chromas Lite software.
Conventional PCR3.4.5
Diagnostic PCR analysis for confirming Flag insertions was conducted applying peqGold Taq
Polymerase all-inclusive kit according to the manufacturers’ instructions using 100 ng DNA as
template.
Quantification of cDNA and DNA by quantitative PCR (qPCR)3.4.6
cDNA obtained from reverse transcribed RNA and DNA recovered from chromatin-
immunoprecipitation (ChIP) experiments was quantified using a Roche LightCycler 480 II
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instrument and LightCycler 480 SYBR Green I Master (Roche) reagent according to the
manufacturers’ instructions. In particular qPCR was performed using 96 well plates in 10 µl
reaction volume. A mastermix consisting of 5 µl LightCycler 480 SYBR I Green, 1 µl 5 µM
Forward Primer, 1 µl 5 µM Reverse Primer, and 1 µl H2O per well was prepared and pipetted in
the wells and 2 µl sample was added last in the appropriate wells and mixed by pipetting. Sample
volume did not exceed 2 µl and was adjusted to 2 µl in cases of lower volume. Cycle conditions
are listed in Table 15.
Table 15. Cycle conditions for qPCR at the LightCycler 480 II device
Analysis
Mode Cycles Segment
Temperature
(°C)
Ramp Rate
(°C/s) Time*
Acquisition
Mode
None 1 Pre-Incubation 95 4.4 10 min None
Quantification 45
Denaturation 95 4.4 3 s None
Annealing 60-63 2.2 10 s None
Extension 72 4.4 20 s Single
Melting Curves 1
Denaturation 95 4.4 5 s None
Annealing 65 2.2 1 min None
Melting 97 0.1 - Continuous
None 1 Cooling 40 1.5 10 s None
* time hold after reaching the indicated temperature
Standard curves using dilutions defined amounts of the respective PCR product as templates
were made to account for differences in primer efficiencies. To this end at least two “standard”
samples of defined PCR product particles per primer pair were applied for each run and used for
absolute particle quantification and normalization between runs. For analysis of ChIP samples
this absolute quantification analysis was performed and % input was calculated as described in
chapter 3.5.4. Relative expression levels were calculated by normalization of transcripts of interest
to GAPDH applying the relative quantification mode of the LightCycler 480 software (based on
the ΔCt method but using the measured primer efficiency instead of 2 as default).
Library preparation for deep-sequencing of ChIP associated DNA3.4.7
fragments
DNA fragments recovered from chromatin immunoprecipitation (ChIP) experiments were
subjected to next generation sequencing to gain genome wide information on TF binding sites.
To this end recovered DNA, and also an input sample as negative control, were quantified with a
Qubit® dsDNA HS (high sensitivity) Assay Kit using a Qubit® Fluorometer (Invitrogen). Samples
were further processed in Dr. Blums laboratory at the Gene Center of the LMU Munich. A
maximum of 100 ng ChIP as well as the same amount of input DNA were subjected to library
preparation using NEBNext Ultra DNA Library Prep Kit (New England Biolabs) according to
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the manufacturers’ instructions. Up to eight samples per lane were sequenced separated by
different barcodes. Sequencing was conducted using an Illumina HiSeq 1500 device producing 50
bp single-end reads.
3.5 Protein biochemistry related techniques
Generation of whole mammalian cell lysates3.5.1
For the generation of whole cell lysates 107 cells were harvested by centrifugation, washed once
with PBS, and resuspended and lysed in 100-200 µl NP-40 Lysis Buffer. The reaction was
incubated for 1 h one ice and subsequently sonicated 3 x for 10 s applying 10% amplitude (3 mm
conical microtip, Branson Sonifier). Cell debris was pelleted by centrifugation (20,000 g, 15 min,
4 °C),the supernatant was transferred to a new 1.5 ml reaction tube and stored at -80 °C. The
protein content of lysates was quantified by Bradford method using a defined serial dilution (1-10
µg) of BSA as reference. To this end 5x Bradford Solution was diluted 1:5 with H2O just prior to
usage and 1-2 µl of the lysates were added and mixed by inversion of the cuvette. Adsorption of
the mixtures was measured at 595 nm using a spectral photometer and applying 1x Bradford
Solution without protein as blank value.
NP-40 Lysis Buffer 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 1x Proteinase Inhibitor
Cocktail (Roche)
5x Bradford Solution 100 mg Coomassie Brilliant Blue G-250, 47% Methanol, 42.5% Phosphoric acid
SDS Polyacrylamide gel electrophoresis3.5.2
To separate proteins by electrophoresis reducing SDS containing polyacrylamide gels were
applied. Separation gels contained 8, 10, or 15% and stacking gels 5% polyacrylamide,
respectively, using a 30% (w/v) acrylamide (Sambrook and Gething, 1989). The appropriate
amount of whole cell protein lysate (1.5-30 µg, depending on protein of interest) was mixed with
2x or 5x Lämmli Buffer, boiled at 95 °C for 5 min, and loaded on a gel next to a protein
molecular weight standard (Prestained Protein Ladder, MBI Fermentas, Germany). Separation
was conducted applying 25 mA per gel for approx. 1 h.
2x Lämmli Buffer 4% SDS, 20% Glycerin, 5% β-Mercaptoethanol, 120 mM Tris-HCl, pH6.8, 1
spatula tip Bromophenol blue
5x Bradford Solution 10% SDS, 50% Glycerin, 12.5% β-Mercaptoethanol, 300 mM Tris-HCl, pH6.8,
1 spatula tip Bromophenol blue
Running Buffer 25 mM Tris Base, 0.2 M Glycine, 0.1% SDS
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Western Blot3.5.3
SDS-PAGE separated proteins were transferred to PVDF membranes for specific protein
detection by antibodies. First, membranes were activated by incubation in 100% methanol for
5 min and subsequently equilibrated, together with Whatman blotting (WB) paper, and sponges,
in Transfer Buffer. The blotting sandwich was set up, starting on the cathode side, as follows:
One sponge, two layers WB paper, the running gel, PVDF membrane, two layers WB paper, and
another sponge. The transfer was conducted at 400 mA for 1 h. Membranes were rinsed with
PBS and incubated for 30-60 min at 4 °C under rolling in Blocking Buffer for protein saturation.
Then membranes were incubated with primary antibodies diluted in Blocking Buffer for 1 h at
RT or overnight at 4 °C. After several washing steps with PBS/Tween and a final wash step with
PBS, membranes were incubated with the appropriate horseradish peroxidase (HRP) coupled
secondary antibodies, specific for the used primary antibody, diluted in Blocking Buffer. Again,
membranes were washed several times with PBS/Tween and once with PBS before bound
antibodies were detected using an Enhanced Chemiluminescence (ECL) system (GE Healthcare)
according to the manufacturers’ instructions. The emitted light, resulting from the HRP mediated
oxidation of luminol, was detected by applying Hyperfilm ECL films (Amersham, GE
Healthcare).
Transfer Buffer 25 mM Tris Base, 192 mM Glycine, 0.1% SDS, 20% Methanol
Blocking Buffer 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5% non-fat milkpowder
PBS/Tween PBS plus 0.05% Tween
Chromatin Immunoprecipitation (ChIP)3.5.4
3.5.4.1 ChIP in LCLs
The basis of this approach forms a protocol commonly used in our laboratory (Ciccone et al.,
2004) with minor modifications as indicated below. In brief, 2 x 107 cells were harvested and
washed twice in ice cold PBS, resuspended in 20 ml RPMI 1640 and cross-linked first with
disuccinimidyl glutarate (DSG, 2 mM final) for 23 min at RT and then formaldehyde (1% final)
was added for additional 7 min. The reaction was stopped by addition of glycine (125 mM final)
and gentle shaking for 5 min at RT. Cells were pelleted and washed twice in ice cold PBS. Nuclei
were isolated by washing the cells 3x with 10 ml of ice cold Lysis Buffer and subsequent
centrifugation (300 g for 10 min at 4 °C). Nuclei were resuspended in 1 ml Sonication Buffer I
and incubated on ice for 10 min. Chromatin was sheared to an average size of 300 bp by four
(qPCR analysis as final readout) or five (samples designated for deep sequencing, resulting in
fragments with average 200 bp in size) rounds of sonication for 10 min (30 sec pulse, 30 sec
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pause) using a Bioruptor® device (Biogenode). Cell debris was separated by centrifugation at
maximum speed for 10 min at 4 °C and chromatin containing supernatants were stored at -80 °C
or directly used for IP. For preparation of input DNA 25 µl aliquots (1/10 of the amount used
per IP) were saved at -80 °C. For IPs 250 µl  chromatin (equals 5 x 106 cells) were diluted 1:4
with IP Dilution Buffer I and incubated with 5 µg of antibody or 100 µl of hybridoma
supernatant on a rotating platform at 4 °C overnight. Antibodies used for ChIP are listed in
Table 13. Protein G sepharose (GE Healthcare) was equilibrated with IP Dilution Buffer I,
added to the lysate and incubated at 4 °C for 4 h with constant rotation. Beads were extensively
washed with 2x Wash Buffer I, 1x Wash Buffer II, and 1x Wash Buffer III for 5 min under
rotation. Then washed 2x with TE for 1 min. Protein-DNA complexes were eluted with 2x 150
µl Elution Buffer at 65 °C for 15 min. Input samples were adjusted to 300 µl with Elution
Buffer. Eluates and input samples were incubated with Proteinase K (1.5 µg/µl final, Roche) for
1 h at 42 °C. Cross-linking was reversed by incubation at 65 °C overnight. DNA was recovered
using QIAquick PCR purification kit (Qiagen) according to the manufacturers’ instructions. For
sequencing purposes four ChIP samples for the same protein of interest were pooled using one
QIAquick column.
The DNA amount in input samples and after IP with specific antibody or an unspecific
isotype-matched IgG control was quantified by qPCR using primers listed in Table 12. To
account for differences in amplification efficiencies a standard curve was generated for each
primer pair using serial dilutions of fragmented DNA (input) as template. DNA quantities
detected in input samples were adjusted to the amount of chromatin used per IP by
multiplication with 10. Enrichment was indicated as percentage of input and calculated as (DNA
from specific IP corrected for IgG control background/ DNA input) x 100.
DSG Pierce #20593, using freshly prepared 0.5 M stock solution in DMSO
Lysis Buffer 10 mM Tris-HCl, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.5% NP-40, 1x proteinase
inhibitor cocktail (PIC, Roche)
Sonication Buffer I1 50 mM Tris-HCl, pH 8.0, 5 mM EDTA, pH 8.0, 0.5% SDS, 0.5% Triton X-100,
0.05% sodium deoxycholate, 1x PIC
Dilution Buffer I 12.5 mM Tri-HCl, pH 8.0, 187.5 mM NaCl, 1.25 mM EDTA, pH 8.0,
1.125% Triton X-100, 1 x PIC
Wash Buffer I 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0, 1% Triton X-100, 150 mM NaCl,
0.1% SDS, 1 x PIC
Wash Buffer II 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0, 1% Triton X-100, 500 mM NaCl,
0.1% SDS, 1 x PIC
Wash Buffer III 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0, 250 mM LiCl, 1% NP-40,
1% sodium deoxycholate, 1 x PIC
Elution Buffer 25 mM Tris-HCl, pH 7.5, 10 mM EDTA, pH 8.0, 0.5% SDS
1 Adopted composition from an commercially available buffer (SDS lysis buffer, upstate, EZ ChIP protocol, catalog
#17-371) and the sonication buffer used by Kouskouti et al. (2004).
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3.5.4.2 ChIP in DG75 cell line
The ChIP protocol for DG75 cells is based on the ChIP protocol for LCLs described above with
minor modifications. Cross-linking of cells was achieved by only using formaldehyde (1% final, 7
min incubation). Nuclei were resuspended in 1 ml Sonication Buffer II and incubated on ice for
10 min. Chromatin was sheared to an average size of 200-300 bp by four rounds of sonication
for 10 min (30 sec pulse, 30 sec pause) using a Bioruptor® device (Biogenode) for all down-
stream applications. Here, Dilution Buffer II was used instead of Dilution Buffer I.
Sonication Buffer II 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, pH 8.0, 0.5% SDS, 1x PIC
Dilution Buffer II 12.5 mM Tris-HCl, pH 8.0, 1.25% Triton X-100, 212.5 mM NaCl, 1x PIC
3.6 Bioinformatic methods
All bioinformatic analyses steps were conducted independently, using the Galaxy platform hosted
at the Bioinformatics Department of the University of Freiburg, if not indicated otherwise.
Generated workflows were downloaded from the Galaxy server for documentation and are
accessible at the HMGU server accessible via the following link:
https://hmgubox.helmholtz-muenchen.de:8001/d/2dcf3ec670/
The directories of the single files are described in the following sections.
Peak calling and generation of normalized ChIP-seq signals3.6.1
TF ChIP-seq data
The main procedure of processing ChIP-seq data and purpose of each step is explained in
chapter 4.2.1.2 (summarized in Fig. 13). The initial step of demultiplexing the obtained data
according to applied barcodes was conducted at the Galaxy of the sequencing facility of the Blum
laboratory using an in-house script. The subsequent quality control by FastQC (Andrews, 2010),
read trimming applying TrimGalore (Krueger, 2012), mapping to hg19 applying Bowtie2
(Langmead and Salzberg, 2012), peak calling applying MAC2 (Zhang et al., 2008) and subsequent
filter steps, and the generation of input normalized signal tracks applying bamCompare of the
deepTools package (Ramirez et al., 2014a) are documented in the following workflow:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-peak_calling_and_signal_track_LG
For E2, E3A, and E3C ChIP-seq in LCL the analyzed data for called peaks and signals are also
available via the HMGU server under the following directories:
Dissertation_LG/EBNA_ChIP-seq_LCLs/hg19_peaks
Dissertation_LG/EBNA_ChIP-seq_LCLs/hg19_input_norm_signals
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For analysis of binding to the EBV genome, reads which did not map to hg19 were extracted and
mapped to the EBV genome (HHV-4 type I, NC_007605.1). The workflow for peak calling and
normalized signal generation can be found in the following workflow:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-peak_calling_and_signal_track_EBV_LG
Analyzed LCL derived data for EBV can be found at:
Dissertation_LG/EBNA_ChIP-seq_LCLs/HHV4_peaks
Dissertation_LG/EBNA_ChIP-seq_LCLs/HHV4_input_norm_signals
The E2 ChIP performed in DG75 was analyzed applying the same workflows and analyzed data
can be found at:
Dissertation_LG/E2_ChIP-seq_DG75/E2_DG75_peaks
Dissertation_LG/E2_ChIP-seq_DG75/E2_DG75_input_norm_signals
Histone modification ChIP-seq data
Histone modifications are known to produce rather broad peaks than sequence specific TF,
therefore the workflow for peak calling had to be adapted and is available at:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-peak_calling_and_signal_histone_mods_LG
To this end, mapped reads (bam) as published by the ENCODE project (for discrete files see
Table S1) or other studies (Table S2) were downloaded and the appropriate replicate ChIP-seq or
input files were merged, independent of the absolute number of bam files (between 1-5), prior to
peak calling.
DNase-seq data
DNaseI hypersensitive sites (HS) in LCL and DG75 were analyzed as well (file list, see Table S2)
applying a separate workflow due to the absence of input sample, which can be found at:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-peak_calling_and_signal_DNaseI_HS_LG
Generation of anchor plots for comparison of signals at different peak3.6.2
sets
To compare a distinct normalized signal between two sets of peaks, anchor plots were generated
for visualization and the underlying data was used for statistical analyses. To this end
computeMatrix and profiler tools of the deepTools package (Ramirez et al., 2014a) were applied.
Depending on the question 2 (TF peaks), 5 (DNaseI HS), 10 or 20 kb (most histone modification
analyses) in each direction of the peak center were analyzed. An example workflow for three peak
sets and 2 kb extension from the peak center in both directions is available for download:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-Achor_plots_LG
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Generation of heatmaps for comparison of different signals at the3.6.3
same peak set
In order to visualize different signals at the same peak set heatmaps were generated applying
computeMatrix and heatmapper tools of the deepTools package (Ramirez et al., 2014a). To this
end, as for the anchor plot generation, distinct regions of 2 kb in each direction from the peak
centers were analyzed. In some cases (Fig. 20) the analyzed peak set was sorted by the mean
signal of each peak in a descending manner, and subsequently this sorted peak list was used as
reference for other ChIP-seq signals without changing the order of the peaks this time. An
example workflow was deposited at:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-Heatmaps_LG
Correlation analyses3.6.4
For correlation analyses and matrix generation bamCorrelate of the deepTools package was
applied (Ramirez et al., 2014a) using Spearman correlation method. An example workflow with
only three input data sets to compare was stored at the HMGU data deposit for demonstration of
parameters:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-bamCorrelate_LG
In order to investigate and correlate two signals at one distinct peak set (as in Fig. 23), a different
approach was chosen where for each peak the mean signal was calculated by computeMatrix and
the resulting data was plotted applying an R script. The workflow and R script can be found at:
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-Correlation_peak_set_LG
Dissertation_LG/Galaxy_Workflows/R_script_correlation_peak_set
Peak cluster analyses3.6.5
To investigate the occurrence of preselected TFs at distinct peak sets cluster analyses were
performed applying either Jaccard index or k means based clustering. Jaccard clustering was
conducted by Björn Grüning (Universität Freiburg) while k means cluster was performed using
Galaxy tool Numeric Clustering (Pedregosa et al., 2011).
Dissertation_LG/Galaxy_Workflows/Galaxy-Workflow-k_means_clustering_LG
Analyzed data of the E2 and E3 cluster can be found at:
Dissertation_LG/Cluster_Analyses/E2_cluster
Dissertation_LG/Cluster_Analyses/E3_cluster
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4 Results
The results of this thesis are structured into three main parts:
In the first part (chapter 4.1), the generation of LCLs expressing epitope tagged E3 proteins is
described and the cell lines are confirmed and characterized.
The establishment of the ChIP-assay for E3 proteins, the reliability of this assay, the
bioinformatic analyses, the actual identification of EBNA binding sites in the viral and human
genome, the further characterization of those sites in the human genome and pattern formation
as well as the identification of associated TFs are depicted and explained in the second part
(chapter 4.2).
In the last results part (chapter 4.3) the dependency of E2 chromatin accession on CBF1 is
further examined in studies using knock-out cell lines and a potential novel adaptor is identified
and characterized.
4.1 Introducing a new experimental system: LCLs infected with
recombinant EBV encoding epitope tagged E3A or E3C
protein
To investigate the chromatin binding properties of E3A and E3C proteins, a robust and reliable
ChIP assay displays the basis for all further experiments and analyses. One crucial step of this
assay, as for all immunological experiments, is the choice and specificity of the respective
antibody. For the E3 proteins several commercially available antibodies, as well as such from Dr.
Elisabeth Kremmer’s laboratory at the HMGU, have been tested in the Kempkes’ laboratory and
failed to reach ChIP assay standards in enrichment and specificity (data not shown). Therefore an
epitope tag was fused to either E3A or -3C ORF in the viral genome to gain LCLs which express
the recombinant proteins at an endogenous level. Furthermore this epitope tag ensures a highly
efficient immunoprecipitation.
The process of infection and immortalization of primary B cells by EBV and the
subsequent outgrowth of LCLs is well described in literature (Delecluse et al., 1998, Delecluse et
al., 2008, Feederle et al., 2010) and also established in our laboratory. The different steps of this
procedure are depicted in Figure 5.
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Figure 5. Generating LCLs by infection of primary B cells with recombinant EBV. Flow scheme depicting the
multistep process to generate LCLs starting from recombinant EBV genomes.
Starting with transfection of the desired EBV genome (as described in 4.1.1) in HEK293 cells
and subsequent hygromycin selection, EBV positive clones can be selected and further cultivated
to become stable so called “EBV producer cell lines”. The lytic cycle of EBV and consequently
the production of infectious particles can be induced by the lytic switch protein BZLF1.
Infection efficiency of virus containing supernatants can be measured by infecting Raji B cells
and monitoring eGFP expression via FACS (Delecluse et al., 1998) (see 4.1.2). Viral titers can be
calculated and potent supernatants can be used for infection of primary B cells derived from
lymphoid tissue or as in this case cord blood which is free of endogenous virus.
The single steps and results of this work are described in the following chapters with the
details for the experiments outlined in the methods section (chapter 3.2.4).
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Generation and characterization of recombinant EBV genomes via4.1.1
“Recombineering”
The overall idea was to insert an epitope tag N-terminally and in frame fused to E3A or E3C
respectively in the EBV genome using the EBV BACmid (p2089) (Delecluse et al., 1998) as
wildtype reference. Originally in this publication, the EBV genome was extracted from B95.8 cell
line and hygromycin phosphotransferase (hpt) resistance gene for selection in eukaryotic cells,
chloramphenicol acetyltransferase (cat) resistance gene for selection in bacteria, enhanced green
fluorescent protein (eGFP) as a reporter and an origin of replication (ori, derived from F-plasmid)
for propagation in bacteria were inserted.
For the epitope a Flag-tag consisting of a triple repetition of the Flag peptide was chosen,
since many ChIP assay compatible antibodies are commercially available specific for this
construct.
Since the assay for cloning in the viral genome, which was already established in the
laboratory, includes the permanent introduction of a reporter/selection gene (Cherepanov and
Wackernagel, 1995), a different protocol was chosen: “Recombineering” makes it possible to
insert or to delete sequences and also to introduce mutations in bacterial artificial chromosomes
(BACs) without leaving any other sequences in the vector of interest (Warming et al., 2005). In
brief, a special bacterial strain (here E coli SW105) deficient for the galK gene, which encodes
galactokinase one of the enzymes crucial for metabolizing galactose, and the usage of different
minimal media makes it possible to use galK in a two-step procedure as both, positive and
negative selection marker. Additionally E. coli SW105 harbors an integrated defective lambda
prophage whose expression is temperature sensitive and which is coding for three proteins (exo,
bet, and gam) mediating homologous recombination. First a PCR construct consisting of galK
flanked by two homologous arms of the region of interest is transformed into the bacteria and
subsequently expression of the lambda genes and thereby recombination is induced (Fig. 6). Here
two different constructs were used, ensuring the integration 3’ of the start codon of E3A or E3C
respectively. Using minimal media with galactose as the only carbon source, selection of clones
with an integrated galK gene was ensured. This intermediate product was also checked via
restriction digest and gel electrophoresis for genomic integrity (Fig. 6, plasmid no. 2). In a second
step, a PCR product of the described Flag-tag flanked by the same homology arms as used before
was transformed, lambda expression induced and the bacteria plated on minimal media
containing 2-deoxy-galactose (2-DOG), allowing galK to be used for negative selection this time.
Bacteria still harboring galK metabolize 2-DOG to a toxic product while galK deficient ones can
use it as carbon source. The resulting products were two EBV BACs with a Flag-E3A or -E3C
fusion gene.
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Figure 6. Generation of two recombinant EBV genome BACmids harboring Flag-E3A and -E3C fusion
genes. Schematic overview of the two-step cloning procedure to generate N-terminal Flag-tag insertions for E3A
and E3C in the EBV genome applying the recombineering protocol (middle panel). Wildtype EBV BACmid (1,
p2089) which encodes chloramphenicol acetyltransferase (cat), the origin of replication from an F-plasmid (ori), eGFP
as a reporter and hygromycin phosphotransferase (hpt) was used as starting point. After transformation of galK
flanked by homologous regions H1 and H2 for E3A or E3C (E3A/C), induction of recombination and positive
selection for galK the intermediate product (2, pgalK-E3A or -E3C) was obtained. In the second step a construct of
the Flag-tag flanked by homologous regions was transformed in the bacteria, recombination was induced and after
galK negative selection the final EBV BACmid with the respective desired fusion gene were produced (3, pFlag-E3A
or -E3C). Gel electrophoretic separation of BglII restriction digest for all three plasmid steps as performed for E3A
(left panel) and E3C targeting (right panel) is shown and expected fragment sizes are indicated. The arrows highlight
restrictions fragments of particular interest, since they shift in size upon galK or Flag insertion.
The integrity of the recombinant EBV genomes was monitored by restriction digest and gel
electrophoresis (Fig. 6, plasmid no. 3) and a diagnostic PCR was established to quickly check for
correct Flag insertion (Fig. 7). This PCR assay was also used at various steps of this work to
verify the identity of recombinant EBV genomes in different cell lines.
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Figure 7. Diagnostic PCR confirming the correct insertion of Flag-tag 5’ of E3A or E3C in the EBV
BACmid genome. Schematic representation of the genomic background of the constructed recombinant EBV
BACmid genomes (upper panel) and the positions and product sizes for four PCR primer combinations (A-D). The
depiction of exons and primers is not in scale. In the lower panel gel electrophoretic separation and UV light
detection of the obtained PCR products are shown.
Furthermore the critical regions where the insertion took place were sequenced (chapter 3.4.4) to
further ensure genome accuracy. Finally correct recombinant EBV BACmids were used to
generate cell lines.
Generation and characterization of HEK293 EBV producer cell lines4.1.2
In a second step the novel recombinant EBV BACmids were transfected into HEK293 cells and
outgrowth of EBV positive clones was ensured using hygromycin selection. Single clone colonies
were selected and separately cultivated until stable cell lines were growing out. Those cell lines
could now be used as a tool to generate infectious virions. Upon transient transfection of
expression plasmids for EBV proteins BZLF1, the lytic switch protein which induces the lytic
cycle (Countryman et al., 1987), and BALF4, the viral glycoprotein gp110 which enhances
packaging and thereby infection efficiency (Neuhierl et al., 2002), viral particles were produced
and released into the cell culture medium. To determine viral titers and infection efficiency of
different producer cell line clones and supernatant batches, the EBV positive B cell line Raji is
incubated with those supernatants and eGFP expression from recombinant EBV is monitored by
FACS analysis.
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For the purpose of this work several HEK293 EBV producer cell lines with the two different
recombinant EBV genomes encoding Flag-E3A and -E3C respectively, could be generated and
characterized to be efficient producers of infectious EBV particles. Also at this point the
diagnostic PCR, as described in chapter 4.1.1, was used to determine the integrity of the EBV
genome of the different clones (Fig. 8A).
Virus titer determination via FACS analysis allowed the identification of efficient EBV
producer cell lines (Fig. 8B). Therefore different dilutions of the virus particle containing
supernatants were incubated with Raji cells, the mean percentage of eGFP positive cells was
calculated and the virus titer defined as green raji units (GRUs) was determined.
Figure 8. Stable HEK293 producer cell lines efficiently generate infectious recombinant EBV particles with
Flag-E3A and  E3C fusion genes. (A) Diagnostic PCR verifying the recombinant EBV genome of different
established producer cell lines. Only after PCR confirmation cell lines were used for virus production. The parental
HEK293 cell line is used as negative control (293) and p29089 is used for wt EBV reference. For each recombinant
EBV genome two different HEK293 producer clones were analyzed. (B) FACS analysis showing the percentage of
eGFP positive Raji cells after 24 h incubation with EBV producer cell line supernatants containing infectious
particles. Here the readouts of one representative supernatant sample per recombinant EBV using 1:2 dilutions are
shown. Virus titers (GRUs) were determined using the mean of 5 dilution steps and the most potent supernatants
were used in further experiments.
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Generation and characterization of LCLs expressing Flag-E3A4.1.3
or -E3C fusion proteins
The recombinant EBV particles could now be used to infect primary B cells derived from cord
blood and stable LCLs expressing Flag-E3A and -E3C respectively were generated for three
different donors. For each donor an LCL infected with wt EBV (p2089) was generated in parallel
as phenotype reference, since the introduction of the Flag-tag should not impair the EBV
variants in infection efficiency, the LCL in viability and proliferation or the respective E3 in
target gene regulation and interaction behavior. When using B cells collected from tonsils
which might be derived from an EBV positive donor, it is possible that some cells, infected with
endogenous virus, spontaneously grow out and give rise to LCLs. Thus, as a negative control,
primary B cells were infected with a recombinant EBV harboring an EBNA2 deletion, since
EBNA2 is an important EBV encoded transactivator and essential for immortalization. This
control is actually not necessary when using cord blood as B cells source, since EBV cannot pass
through the placenta and infection shortly after birth is very unlikely. However, using EBNA2
deletion mutant as negative control for infection displays standard procedure in our laboratory
and was applied as standard procedure in infection assays.
During infection experiments, at least 48 wells with 3 x 105 B cells were infected with wt,
Flag-E3A, Flag-E3C, and E2 deletion EBV and no impairment of the Flag-E3 EBVs in
comparison to wt could be observed (data not shown). Infection with EBNA2 deletion virus did
not result in immortalization in all cases; the cells did not enter cell cycle and underwent
apoptosis after approximately 2 weeks.
As expected, all of the established LCLs passed the diagnostic PCR analyses verifying the
particular EBV genome (Fig. 9A/B). RT-qPCR analyses for E3 expression levels showed no
significant differences between LCLs with different recombinant EBV genomes (Fig. 9C).
Western Blot analyses (Fig. 9D) confirmed the expression of Flag-E3A and -E3C fusion genes in
the respective cell lines and also showed no aberrant expression level of other EBV latent
proteins due to Flag insertion. Thus the expression levels of the Flag fusion genes are comparable
to the respective wildtype E3 protein. Also full-length proteins are expressed since the apparent
protein sizes in SDS-PAGE are comparable to the respective wildtype E3, but show a small shift
to a higher molecular weight due to the 22 aa Flag-tag. Shorter variants could not be observed by
Western Blot analyses.
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Figure 9. Established LCLs expressing Flag-tagged E3A or E3C show wildtype levels of EBV latent protein
expression. Characterization of LCLs derived from three different donors. Schematic representation (A) and results
(B) of diagnostic PCRs confirming the genomic background of recombinant EBVs used for infection. RT-qPCR (C)
demonstrating E3 expression levels for LCLs with different EBV genome background. Cell lines derived from three
different B cell donors (D1-D3) and for each donor two clones (1 and 2) were examined. Means and standard
deviations (SD) from two independent experiments consisting of technical duplicates are shown. cDNA levels were
normalized to GAPDH expression levels. Western Blot analysis (D) showing expression levels of six EBV latent
proteins. An anti-Flag antibody was used to confirm the expression of recombinant E3 proteins. Equal amounts of
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total protein lysates were loaded and GAPDH served as internal loading control. For both analyses the established
wt LCL (721) was used as positive control while the EBV negative Burkitt’s lymphoma cell line DG75 served as
negative control.
Proliferation rates of the Flag-E3A and -E3C LCLs were comparable to wt LCLs. Also, viability
was determined using MTT-assays and did not show disadvantage of Flag-E3 LCLs compared to
wt LCL derived from the same donor as control (data not shown).
To assess the protein-protein interaction capabilities of the Flag-E3 LCLs the well described
interaction with CBF1, a cellular DNA binding
protein, was examined. CBF1 is known to physically
interact with E2 (Henkel et al., 1994) as well as with
E3A and E3C (Robertson et al., 1995, Robertson et
al., 1996) and to mediate their recruitment to DNA
(reviewed in (Kempkes and Ling, 2015, Allday et al.,
2015). In immunoprecipitation (IP) experiments
(Fig. 10) the interaction of both Flag-tagged E3
proteins with CBF1 could be verified and also a
heterodimer of E3A and E3C could be detected.
Interestingly this experiment revealed that E3B can
form a heterodimer with E3A as well, but failed to
interact with E3C. This finding was not reported
before and might be an interesting interaction to be
further studied since it could also have an impact on
E3 functions. However, this interaction was not further analyzed in this work. The transcriptional
repressor function of the Flag-E3 proteins was also reviewed with special attention to the
introduced Flag-tag. To this end expression levels of three well described target genes were
monitored. BCL2L11 (or Bim), a proapoptotic tumor suppressor, is repressed by E3A and E3C
in a cooperative fashion (Anderton et al., 2008) and CXCL9 and  -10, encoding chemokines,
which are both repressed by E3A (Hertle et al., 2009) and E3C (our data, not published and for
CXCL10 (McClellan et al., 2012)). Expression levels for all three target genes did moderately
fluctuate between samples, but no impact of the Flag-tag on gene expression could be observed
(Fig. 11).
Figure 10. Flag-E3 proteins do interact with
the DNA adaptor CBF1 in recombinant
LCLs. IP analyses using a Flag specific antibody
in Flag-E3A, -E3C  and  wt  LCLs.  Total  cell
lysates (L) display 5% of the cells used for IP
samples. One representative experiment is shown
(n=3).
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Therefore the Flag-E3 expressing LCLs developed and described in this work are an excellent
tool to investigate chromatin binding mechanisms of the E3 proteins, which is the main focus of
part II of this thesis. In addition these cell lines represent a versatile tool for different applications
involving IP steps for the E3 proteins in a wt EBV and latency III expression background.
4.2 EBNA transcription factors – Exploiting enhancer elements
In the following chapter the process of how to get from ChIP-seq data to a better understanding
of chromatin accession of EBNA proteins and eventually target gene regulation is pictured. It
starts with the establishment of the necessary ChIP protocol, then the bioinformatic analysis
pipeline is explained. Finally, upon comparison with data on TF binding, information on histone
modifications and functional elements derived from the ENCODE project, conclusions on
chromatin accession of EBNA proteins and contributing factors will be drawn.
Figure 11. Flag-tag does not impair E3 target gene
regulation. Expression levels of E3 target genes were
quantified using RT-qPCR. Cell lines derived from three
different B cell donors (D1-D3) and for each donor two
clones (1 and 2) were examined. Shown are means and
SD from two independent experiments consisting of
technical duplicates. cDNA levels were normalized to
GAPDH expression levels.
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Identification of E2, E3A, and E3C binding sites by ChIP-seq4.2.1
This section of the thesis is divided into two different parts: One is the biochemical experimental
part, which required several steps of adaption to the specific question as well as to the deep
sequencing readout. The second part, which is very important as well, demands many control and
optimization steps and careful evaluation of the results: the bioinformatic analyses of the
obtained data. Since this part was performed independently, using the Galaxy Platform (Giardine
et al., 2005) hosted and maintained by the Bioinformatics Department of the University of
Freiburg, and very specific thresholds and parameters were used, a very detailed description is
provided here in the results section. The details for each tool that was used and specific
parameters are listed in the methods section (chapter 3.6).
4.2.1.1 Biochemistry
Optimization of the ChIP-assay – Cross-link
To elucidate subsets of EBNA binding sites and their characteristic TF occupancies a robust and
reliable ChIP-assay had to be established. Here different protocols were combined to achieve the
best results for the specific case of TFs which access DNA in an indirect manner. The basis of
this approach forms a protocol commonly used in our laboratory (Ciccone et al., 2004) with
some adaptions as described in the methods sections (chapter 3.5.4).
The most crucial adaption displays the optimization of the crosslinking process since
formaldehyde only bridges a distance of 2 Å between two amino (or imido) groups, such as side
chains of lysine and arginine by a covalent but reversible bond (Jackson, 1999). The E3 proteins
but probably also E2 are expected to act in bigger protein complexes and to be recruited to DNA
by cellular proteins. Therefore it is important for this specific assay to cover protein-protein as
well as DNA-protein interactions.
It has been described that the usage of different cross-linking agents such as bifunctional
imidoesters (Fujita and Wade, 2004) or N-hydroxysuccinimide (NHS)-esters (Nowak et al., 2005)
could significantly improve the DNA recovery in ChIP assays, especially for proteins which form
complexes on DNA. Those two different classes of reagents have a longer effective bridging
distance between functional groups (approx. 8-16 Å) in common and are thereby thought to
cross-link especially protein-protein interactions, which are not covered by formaldehyde only.
Imidoesters show a higher reactivity for alkyl amines (as in lysine) than for aromatic amines (as in
DNA bases), therefore favoring the cross-link of protein-protein over DNA-protein interactions
(Fujita and Wade, 2004). Furthermore, both reagent classes are soluble in DMSO and can freely
permeate cell membranes making them convenient for ChIP.
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In this study the imidoester dimethyl 3, 30-dithiobispropionimidate (DTBP) and the two NHS-
esters disuccinimidyl glutarate (DSG) and ethylene glycol bis(succinimidylsuccinate) (EGS) were
tested for their ability to improve cross-linking efficiency. ChIP was performed for E2 and Flag-
E3A in Flag-E3A LCLs and known E2 binding sites (Zhao et al., 2011b) in the well-studied E3A
and E3C controlled region encompassing CXCL9 and -10 (Harth-Hertle et al., 2013) genes were
analyzed (Fig. 12). In this publication from our laboratory the competitive binding of E2 and
E3A for enhancers in this region could be shown. Therefore this locus displays an optimal
example for ChIP assay improvement.
Figure 12. The impact of dual cross-linking on specific E2 and Flag-E3C ChIP enrichment. Three different
cross-linking agents in addition to formaldehyde (FA) treatment were analyzed for their effect on specific DNA
enrichment in E2 and Flag-E3A ChIP assays in the Flag-E3A LCL: the imidoester dimethyl 3, 30-
dithiobispropionimidate (DTBP) and the two NHS-ester disuccinimidyl glutarate (DSG) and ethylene glycol
bis(succinimidylsuccinate) (EGS). (A) Schematic view of a genomic region on chromosome 4 (hg19 coordinates)
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encompassing CXCL9 and -10 genes, which are repressed by E3A and E3C while induced by E2. E2 and CBF1
ChIP signals and peaks are shown. The raw data derived from another study (Zhao et al., 2011b) but was processed
with own bioinformatics pipeline. DNaseI HS, histone modification marks and chromatin state segmentation (css)
for GM12878 cell line (LCL) from ENCODE are shown. All signals were normalized to input sample and RPKM
but DNaseI HS only to coverage. 25x the mean signal at respective peaks was set as maximum for visualization.
Positions of primers used for ChIP-qPCR are indicated and are located at strong (orange) or weak (yellow) enhancer
regions as determined by ENCODE css. ChIP-qPCR for (B) E2 and (C) Flag-E3A using different cross-linking
strategies. Cells were treated with 1.5 mM EGS for 20 min, 2 mM DTBP or 2 mM DSG for 30 min prior to FA
cross-link for 7 min or with FA only for 7 min. Isotype matched antibody controls (IgG control) were used in both
ChIP assays as negative controls. Three regions with known E2 binding (E1-E3) were chosen for investigation along
a negative control locus (cntrl) were no E2 or CBF1 binding could be observed as well as the CD23 promoter
(CD23 p), a well described E2 binding site as positive control for effective E2 ChIP intensity. Means of biological
and technical duplicates with SD are shown. Significances of differences of means were assessed applying an
unpaired two-tailed t-test (* p<0.05, *** p<0.0005).
The regular ChIP protocol was already successful in detecting E2 and Flag-E3A at the three
investigated and described (Harth-Hertle et al., 2013) binding sites. Only the application of DSG
prior to FA cross-linking could increase ChIP-qPCR signals for E2 and Flag-E3A at known
binding sites E1, E2 and E3 (Harth-Hertle et al., 2013) while unspecific DNA recovery at a
negative control region or using an isotype matched antibody as control did not increase
(Fig. 12B and C). Thereby a 1.5 to 3.1 fold increase for E2 and 2.2 to 4.8 fold increase for Flag-
E3A could be detected. E2 detection could also be enriched at the CD23 promoter region, a well
described E2 binding site (Wang et al., 1991, Ling et al., 1994, Zhao et al., 2011b), while E3A was
not significantly enriched here. This observation was expected since CD23 is only a described
target gene for E2 (reviewed in Kempkes and Robertson, 2015) but not E3A or E3C.
Application of EGS or DTBP did rather decrease DNA recovery than enrich the output.
Especially EGS seems to work not as reliable as the other reagents since in one experiment very
high DNA recoveries for the Flag-E3A ChIP could be detected in a very unspecific way (data not
shown). The evaluation of the single experiment using EGS, which did not result in those huge
enrichments, showed no significant improvement over sole FA cross-link. Thus a combination of
DSG and FA was chosen for cross-link in all further ChIP-assays.
Optimization of the ChIP-assay for subsequent sequencing (ChIP-seq) - general protocol
But not only the cross-link displays a crucial point for possible optimization of the ChIP-assay.
Especially ChIP samples which are intended for sequencing purposes need to pass certain criteria
which have been carefully assessed and evaluated by the ENCODE consortium (Landt et al.,
2012) and the ChIP-seq experiments conducted in this work vastly rely on those criteria.
One benchmark is of course the choice of the specific antibody, which should pass at
least two different characterization assays. By using an epitope tag with commercially available
well characterized antibodies, as described in this work, this step can be circumvented. As
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described in chapter 4.1.3 the successful detection of Flag-E3A and -E3C in immunoblot assays
(Fig. 9) as well as in IP experiments (Fig. 10) using a Flag specific antibody was possible.
In contrast to ChIP-assays with qPCR as readout (ChIP-qPCR), for ChIP-seq the size of
DNA fragments after chromatin fragmentation is very crucial to the outcome of the experiment.
Since only the two ends of a fragment are being sequenced (single-end sequencing) the absolute
length of the DNA fragments ultimately limits the possible resolution for ChIP-seq. Hence,
average fragment sizes of 100-300 bp are recommended for sequencing purposes. Since the
application of DSG prior to FA cross-link results in stronger overall cross-linking in the cell the
sonication process was analyzed and optimized carefully. Finally five rounds of sonication were
applied to obtain fragment sizes desired for sequencing, while four rounds were enough for
subsequent qPCR analyses (data not shown).
Furthermore, it was shown that more than two biological replicates did not significantly
improve binding site discovery (Rozowsky et al., 2009) but sequencing depth has  a  great
positive impact on site detection (ENCODE_Consortium, 2011). Especially low density peaks
indicating weak or indirect DNA interactions and therefore display interesting data as well are
only detected with higher sequencing depth. The ENCODE consortium therefore advises a
minimum depth of 20 million reads for point-source TFs, which was exceeded in all experiments
of this work (see Table 16).
Reproducibility and binding site detection are also depended on the complexity of the
ChIP-seq library as defined by the nonredundant fraction of mapped reads (Landt et al., 2012).
Calculation of the nonredunadant fraction as described by ENCODE was not performed here
but all sequencing experiments conducted in this work showed percentages uniquely mapping
reads of 62-72 % (with alignment rates of 94-99 %), which is described in detail in chapter
4.2.1.2.
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4.2.1.2 Bioinformatic experimental design – from reads to peaks
There are many ways to get information on TF binding sites from ChIP-seq data using diverse
bioinformatic tools and several guidelines for analyses were published, for instance by the
ENCODE consortium (Landt et al., 2012). Having access to the Galaxy Server, hosted and
maintained by the Bioinformatics Department of the University of Freiburg under the
supervision of and kindly provided by Prof. Dr. Rolf Backofen, an independent analysis of the
ChIP-seq data obtained in this thesis was possible. Galaxy per se is a publically accessible
platform developed and hosted by researchers at Penn State University and John Hopkins
University (galaxyproject.org) (Giardine et al., 2005). The Galaxy Platform does not only give
access to diverse bioinformatic tools, they are also presented in a very comprehensible way and
most notably workflows can be saved and shared with other users thereby making the whole
process reproducible.
In the following the strategy for identifying binding sites for E2, E3A, and E3C is
explained briefly with focus on the choice and importance of each step (Fig. 13), while the details
are listed in the methods section (chapter 3.6.1).
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Figure 13. Schematic workflow of peak detection from ChIP-seq raw data. Each step of the analysis is
explained briefly. The purpose of each task (grey boxes) is described and the respective used bioinformatic tools
(blue boxes) are indicated.
For each protein of interest two independent biological replicates, consisting of the ChIP and a
chromatin input control sample, were prepared and single-end sequencing libraries were prepared
and subjected to next generation sequencing using an Illumina HiSeq 1500 machine, set to
produce 50 bp reads as output, at Dr. Helmut Blums laboratory at the Gene Center of the LMU
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Munich. ChIP samples were prepared by myself, while library preparation and sequencing
process were conducted by Dr. Blums laboratory.
The obtained raw data was provided at their own Galaxy instance alongside an in-house
developed Demultiplexing tool. Since samples were barcoded (for distinct identification) and
then pooled, up to 8 samples per flow cell lane, the raw data displays a composite of all reads
from one flow cell lane. For each flow cell lane one fastqsanger file, containing the actual reads
plus their identifiers and one index file, containing the identifiers plus the detected barcode, are
generated. Upon demultiplexing the data is split in separate files according to the designated
barcodes which are then ready for further processing.
Table 16. Obtained reads from ChIP-seq after demultiplexing
ChIP
Replicate –
Sample Type Read Count
Overrepresented
Sequences (%)
Internal
Designation
E2
E2-I-ChIP 21,451,466 0.37 LG562.2_E2
E2-I-input* 35,575,701 - LG562.2_input
E2-II-ChIP 26,478,900 0.79 LG568.1_E2
E2-II-input 29,618,835 - LG568.1_input
Flag-E3A
E3A-I-ChIP 30,675,192 - LG470_Flag-E3A
E3A-I-input 37,311,996 0.40 LG470_input
E3A-II-ChIP 26,637,528 1.14 LG562.1_Flag-E3A
E3A-II-input 28,509,282 - LG562.1_input
Flag-E3C
E3C-I-ChIP 82,905,413 - LG478_Flag-E3C
E3C-I-input 38,575,786 0.89 LG478_input
E3C-II-ChIP 45,447,840 1.81 LG562.2_Flag-E3C
E3C-II-input* 35,575,701 - LG562.2_input
For each protein of interest two independent biological replicates (I and II), each consisting of the actual ChIP
sample and an input control, were generated and subjected to deep sequencing. Reads were demultiplexed according
to the designated barcode using a tool from the Gene Center specific for this purpose and a single fastqsanger file
was written for each sample. The absolute number of reads for each sample is listed here alongside the percentage of
overrepresented sequences as calculated by FastQC. * E2-I-input and E3C-II-input are actually the same sample
since E2 and Flag-E3C ChIPs were performed using the same chromatin preparation.
In a first Quality Control step the obtained reads for each sample were analyzed for their basic
features as per base sequence quality, per tile sequence quality, per sequence quality, per base
sequence content, per sequence GC content, per base N content, sequence length distribution,
sequence duplication levels, overrepresented sequences, adapter content, and Kmer content.
Thereby the FastQC tool (Andrews, 2010) rates each quality control step in three categories
(good, intermediate and failed) and all assessed samples rated intermediate at worst for all criteria.
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Nevertheless it was noticeable that some samples showed an elevated percentage of
overrepresented sequences (Table 16), which appeared to be derived from adaptor
contamination and therefore a trimming step was included prior to mapping the reads. For the
Read Trimming TrimGalore (Krueger, 2012) was applied and set to remove Illumina adaptor
sequences if found and to trim the reads from the 3’ end if low quality is detected. If reads
became shorter than 20 nt after adapter and quality trimming they were discarded.
In a second Quality Control step applying FastQC the trimmed reads were checked and
showed no overrepresented sequences at all, indicating the Illumina adaptor has been responsible
for those. Just a very small fraction of reads for each sample was discarded due bad quality or
length after quality trimming (Table 17, column 4).
Next the reads were mapped to the human genome (hg19) using the Bowtie2 software
(Langmead and Salzberg, 2012). This algorithm identifies the most probable location on the
assigned genome for each read, which can be one distinct location (uniquely mappable read) or
several locations which display different assigned probabilities. My ChIP-seq data reached 93.8 -
98.8% of reads Mapping to the human genome, including around 70% of uniquely mapping
reads, reflecting good sample qualities (Table 17). Reads not mapping to the human genome were
written in a separate output file and were subsequently used for mapping against the EBV
genome (HHV-4 type I, NC_007605.1) as depicted in Table 18.
Table 17. Reads after different workflow steps and mapping to the human genome
ChIP
Replicate -
Sample Type
Read count
Demultiplex Trimming (% of
Demultiplexed)
Mappable Reads
(% of Trimmed)
Uniquely Mappable
Reads (% of Trimmed)
E2
E2-I-ChIP 21,451,466 21,321,357 (99.4) 95.8 71.3
E2-I-input* 35,575,701 35,502,629 (99.8) 98.8 70.1
E2-II-ChIP 26,478,900 26,212,962 (99.0) 96.5 70.0
E2-II-input 29,618,835 29,558,726 (99.8) 98.8 72.0
Flag-
E3A
E3A-I-ChIP 30,675,192 30,331,627 (99.9) 97.0 71.2
E3A-I-input 37,311,996 36,668,892 (98.3) 97.9 71.3
E3A-II-ChIP 26,637,528 26,234,960 (98.5) 97.5 71.3
E3A-II-input 28,509,282 28,434,767 (99.7) 98.7 69.8
Flag-
E3C
E3C-I-ChIP 82,905,413 82,871,787 (99.96) 97.9 72.5
E3C-I-input 38,575,786 38,409,666 (99.6) 95.8 61.7
E3C-II-ChIP 45,447,840 44,451,409 (97.8) 93.8 70.0
E3C-II-input* 35,575,701 35,502,629 (99.8) 98.8 70.1
Reads obtained after demultiplexing were subjected to trimming (percentages of remaining reads are indicated) and
subsequently to Bowtie2 for mapping to the human genome (hg19). * E2-I-input and E3C-II-input are actually the
same sample since E2 and Flag-E3C ChIPs were performed using the same chromatin preparation.
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Table 18. Reads mapping to the EBV genome
ChIP
Replicate -
Sample Type
Read Count
Not Mapping
to hg19
Mapping to EBV
(HHV-4)
Uniquely
Mappable (%)
E2
E2-I-ChIP 895,965 7,791 6,809 (87.4)
E2-I-input* 424,267 13,358 10,649 (79.7)
E2-II-ChIP 906,486 32,365 29,007 (89.6)
E2-II-input 351,825 10,233 8,444 (82.5)
Flag-
E3A
E3A-I-ChIP 905,260 15,347 12,855 (83.8)
E3A-I-input 761,709 33,599 25,974 (77.3)
E3A-II-ChIP 644,486 6,588 5,478 (83.1)
E3A-II-input 359,120 11,162 9,229 (82.7)
Flag-
E3C
E3C-I-ChIP 1,728,003 60,067 47,693 (79.4)
E3C-I-input 1,609,662 142,042 108,330 (76.3)
E3C-II-ChIP 2,745,597 8,305 6,864 (82.6)
E3C-II-input* 424,267 13,358 10,649 (79.7)
Reads from ChIP-seq experiments conducted in LCLs which did not map to the human genome were mapped to
the EBV genome (HHV-4 type I, NC_007605.1). * E2-I-input and E3C-II-input are actually the same sample since
E2 and Flag-E3C ChIPs were performed using the same chromatin preparation.
E2, E3A, and E3C ChIP-seq experiments were performed as independent duplicates, each time
an input sample was sequenced as well. There is no standard procedure of dealing with duplicates
in ChIP-seq experiments. Some researchers call peaks for the individual replicates and then make
an intersection and only further analyze those peaks. This kind of analysis tends to focus on
peaks with high enrichment rates but smaller peaks, which are present in only one experiment get
lost. Since not only the peak positions but also enrichment for quantitative analyzes was of
interest for this thesis, duplicates were merged prior to peak calling. Peaks with low enrichment
and significances deriving from only one replicate, most likely due to noise, are “flattened” out by
this kind of analysis. Low enrichment peaks due to indirect DNA interaction or weak TF binding
but present in both replicates are expected to be be included in the output.
For Peak Calling MACS2 (Zhang et al., 2008) was applied using merged ChIP and input
files. The specific settings had to be adjusted for each experiment (e.g. due to different fragment
lengths) (see MM chapter 3.6.1). In Table 19 absolute numbers of called peaks on the human
genome are listed while those on the EBV genome are listed in Table 20.
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Table 19. Peaks identified in the human genome using MACS2
ChIP
Subjected to
MACS2
Read Count Allowed
Duplicate
Tags
Redundancy
Rate (%) Peaks
Merged
Mapped Reads
Filtered
E2
E2-ChIP 45,731,868 44,783,737 2 2.1
23,314
E2-input 64,285,263 63,034,015 2 1.9
Flag-
E3A
E3A-ChIP 55,016,841 53,573,894 2 2.6
14,858
E3A-input 63,982,830 62,781,693 2 1.9
Flag-
E3C
E3C-ChIP 122,849,596 120,155,588 3 2.2
12,504
E3C-input 71,878,366 70,492,793 3 1.9
Mapped reads of replicates were merged and subjected to MACS2 peak calling algorithm. Here reads were filtered
for allowed duplicate tags, which represent maximum permitted reads mapping to the exact same position. This
value is calculated by MACS2 in accordance with absolute read count and genome coverage. The redundancy rate is
indicating the percentage of duplicate reads not allowed and displays a measurement for library complexity.
Table 20. Peaks identified in the EBV genome using MACS2
ChIP
Subjected to
MACS2
Read Count Allowed
Duplicate
Tags
Redundancy
Rate (%) Peaks
Merged
Mapped Reads
Filtered
E2
E2-ChIP 40,156 31,347 4 22.0
7
E2-input 23,591 23,591 4 0.0
Flag-
E3A
E3A-ChIP 21,935 21,864 4 0.3
10
E3A-input 44,761 44,756 4 0.0
Flag-
E3C
E3C-ChIP 68,372 68,327 5 0.1
15
E3C-input 155,400 155,279 5 0.1
Mapped reads of replicates were merged and subjected to MACS2 peak calling algorithm. Here reads were filtered
for allowed duplicate tags, which represent maximum permitted reads mapping to the exact same position. This
value is calculated by MACS2 in accordance with absolute read count and genome coverage. The redundancy rate is
indicating the percentage of duplicate reads not allowed and displays a measurement for library complexity.
In the peak calling process the files containing the merged duplicates of already mapped reads
were filtered for duplicate reads at the same position. MACS2 calculates the number of maximum
allowed duplicates at the exact same position including the information on sample and genome
size. Using large input datasets as in this example, MACS2 rates two or even three reads at the
same position in hg19 to be due to sample size rather than to low library complexity and PCR
artefacts. Redundancy rates are calculated based on this assumption and exceeding duplicate
reads are excluded from peak calling. Peak calling for human and EBV genome differs noticeably:
Less reads could be aligned to the EBV genome but more duplicate reads at the exact same
position are allowed due to the significantly smaller EBV genome (180 kb) were the overall read
coverage is higher than for the human genome (data not shown).
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Besides peak calling also the quantification and visualization of ChIP-seq results in read coverage
density displays an important analysis step. Many laboratories, also the ENCODE project, are
providing such Signal Tracks but in most cases the ChIP-seq signal here is only normalized to
genome coverage and the input sample is treated and shown in parallel for comparison. Here, in
this thesis, one further normalization step was included by using bamCompare, a tool from the
deepTools package (Ramirez et al., 2014a), where the input was subtracted from the actual ChIP
sample in addition to normalization to fragments (reads) per kb per million (RPKM) to account
for genome coverage. By normalization to the input file, not only for the peak calling but also the
signal track generation, the resulting visualization is more informative and regions with high
enrichment for both, specific ChIP and input, e.g. small repeats are not showing signal
enrichment anymore. This procedure was used as standard procedure in this work, unless
indicated otherwise when e.g. using data derived from other laboratories with no respective
control sample available bamCoverage (of deepTools) was used to generate signal tracks
normalized to coverage only.
During this bioinformatic analysis and constant monitoring of the obtained results in
genome browsers the observation was made that in some cases a peak was called for a certain
position but the signal track was not matching, but in fact showed negative amplitude. This event
could be observed in particular at pericentromeric or -telomeric regions, which are enriched in
repetitive elements and are harder to map. Therefore one further step was established to filter
peaks called by MACS2 for “negative peaks” and such falling in “unmappable regions”: Peaks
were sorted according to their mean signal (using bamCompare signals and normalized to peak
length) and discarded if below 1.5 (to get rid of negative peaks and marginal cases). Then peaks
which were located on black-listed regions, as assigned by ENCODE DAC and Duke to account
for unmappable regions (Derrien et al., 2012), were excluded, resulting in fewer but high
confidence peaks (Table 21). Since the data should be comparable with those from ENCODE
for GM12878 LCL, peaks located on unknown chromosomal locations (e.g. chrUn) and the Y
chromosome, since GM12878 derived from a female and the LCL used here from a male donor,
were excluded as well.
Table 21. Signal and mappability corrected peaks in the human genome
ChIP
Identified by
MACS2
Signal
corrected
Blacklist
corrected
GM12878
compatible
% of MACS2
peaks
E2 23,314 22,857 22,715 22,500 96.5
Flag-E3A 14,858 14,553 13,579 13,490 90.8
Flag-E3C 12,504 11,134 8,898 8,733 69.8
Peaks identified by MACS2 were further filtered to exclude peaks which display a negative amplitude, fall on
blacklisted regions or a chromosome not compatible with GM12878, the LCL used by ENCODE.
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This evaluation could not be applied to the peaks identified by MACS2 in the EBV genome, but
due to the small genome size and few peak numbers, the genome wide peak assessment is here
more feasible than for the human genome. None of the detected peaks shows a negative
amplitude and or is located at the known repetitive EBV regions and therefore could be used for
further investigation as provided by MACS2.
Later in this part of the results, the data obtained during this work is compared to other NGS
data, mostly ENCODE data. Here the self-designed standard procedure was applied and for
signal tracks, replicates (if available) were merged (for ChIP sample and input) and ChIP
normalized to input and genome coverage as explained above. Also for peak calling (if applied)
the merged replicates were used. For both analyses, peak calling and generation of signal tracks,
already mapped reads (conducted by the respective laboratories) were used. If peak files were
available e.g. from the ENCODE project, they were subjected for further analyses. In some
indicated cases peak calling was conducted by myself e.g. when comparing data derived from
different laboratories.
One exception displays the data on E2 and CBF1 DNA binding by Zhao et al., which was
only provided as reads mapped to hg18. In this special case fastqsanger files were used and
processed applying the self-designed workflow.
Characterization of E2, E3A, and E3C binding sites in the EBV4.2.2
genome
Potential binding of E2, E3A, and E3C to the EBV genome should be investigated in this thesis
as well, since regulation of EBV genes by the EBNA proteins has been described and
characterized intensively in the past. E2 is known to induce expression of viral genes LMP1,
LMP2A/B as well as such derived from the C promoter (Cp), which gives rise to a polycistronic
RNA coding for all six EBNA proteins (reviewed in Kempkes and Ling, 2015).
The E3 proteins were also described to interfere with EBV transcription but the complete
picture is still not clear to date. On one hand the E3 proteins, E3A, E3B, and E3C, were
described to repress the E2 mediated activation of the LMP1 promoter (Le Roux et al., 1994),
but E3C was also found to CBF1 independently activate the LMP1 promoter in cooperation with
E2 (Lin et al., 2002). Furthermore, E3C could be located at the LMP1 promoter (Jimenez-
Ramirez et al., 2006) as the only E3 protein so far. In reporter assays E3C, as well as E3A, were
described to repress Cp derived transcription (Radkov et al., 1997, Waltzer et al., 1996), which
could not be verified in an EBV positive B cell line with inducible E3C expression (Jimenez-
Ramirez et al., 2006).
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Analyzing the ChIP-seq data derived from LCLs in this thesis, 7 E2, 10 E3A, and 15 E3C
binding sites could be identified (Table 20) and were further investigated for their locations
within the EBV genome. Due to its relatively small size it is possible to depict the whole EBV
genome in one map for an overview of EBNA binding behavior (Fig. S1). Here, E2, E3A, and
E3C data from this work were compared with published data on E2 and CBF1 (Zhao et al.,
2011b), the best described DNA adaptor for the EBNAs. To this end the publicly provided raw
data was used to generate signal tracks and peaks applying standards described above leading to
the identification of 3 E2 and 4 CBF1 binding sites (Fig. 14). The analysis of those published
ChIP-seq data revealed significantly less reads mapping to the EBV genome than was discovered
in the experiments conducted in this thesis (approx. 10% of total read count, data not shown).
Accordingly, genome read coverage was much lower and peak calling is also influenced by this
circumstance.
Two of the identified E2 binding sites showed a very prominent enrichment at the
bidirectional LMP1/LMP2B promoter site and the LMP2A promoter 3 kb further upstream
(Fig. 14, red columns). E2 could be identified at the same positions using the data from Zhao et
al. supporting the significance of those binding sites. Interestingly, the signal enrichment at the
LMP1/LMP2B promoter is higher in this study compared to Zhao et al., which could be due to
better read coverage. Also CBF1 could be located at both sites, showing the same enrichment
pattern as E2 derived from Zhao et al. Both sides are also positive for E3A and E3C, with
significant peaks at the LMP1/LMP2B promoter but only for E3C at the LMP2A promoter.
Figure 14. Identification of E2, E3A, and E3C binding sites in the EBV genome. Schematic map depicting two details of the EBV genome (HHV-4 type I, NC_007605.1, map
provided by the EBV portal (Arvey et al., 2012)). Genes expressed during the lytic cycle are depicted in black and genes expressed during latency are highlighted in color. Also marked is
the EBNA regulated Cp, which gives rise to different (polycistronic) splice variants coding for all EBNAs, including proteins of interest E2, E3A, and E3C. The light grey box to the
right encompasses a region, which is deleted in the B95.8 EBV genome used for EBV BACmid generation compared to HHV-4 type I reference genome. Genes affected by the B95.8
deletion are highlighted in blue and green. Thus it is not possible that reads from ChIP-seq analysis derive from this genomic region. EBNA regulated LMP1, LMP2A, and LMP2B
genes are shown in red, with the bidirectional promoter controlling LMP1 and LMP2B expression as well as the LMP2A promoter highlighted with light red columns. In the upper
panels ChIP-seq signal  profiles and underneath peaks called by MACS2 for E2, E3A, and E3C are shown. (*)  Additionally published data for E2 and CBF1 (Zhao et al.,  2011b) is
shown for comparison. All signal tracks were set to show maximal intensities of the respective ChIP-seq.
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Another region of interest displays the C promoter (Fig. 14, blue column), which harbors an E2
but also E3A and E3C binding sites, which do not overlap precisely. This E2 binding site could
not be identified using the data from Zhao et al. and also no CBF1 enrichment was detected
here. Furthermore the E3 proteins, especially E3C, show a very broad stretch of ChIP-seq signal
enrichment a region spanning oriP, the EBERs, and up to the last exon of LMP2A/B. This
behavior is not typical for TF factors and is more common among histone modification marks or
histone variants.
Strikingly, the Cp and LMP1/LMP2B promoter show alternate binding behavior for E2
and E3 signal enrichment. Both regions harbor significant binding sites for all proteins but the
relative enrichment is inverted, with high E2 signals at the LMP1/LMP2B and LMP2A promoter
and high E3C signal at the C promoter and upstream region. Thereby E2 and CBF1 show a very
similar binding pattern with one additional, low enrichment CBF1 peak within the BART region.
Also the E3 proteins demonstrate a very similar enrichment profile, with a few more called peaks
for E3C mainly at the oriP region but also at the terminal repeats (TR) and exons 2 and 3 of
LMP2A/B.
Also all four investigated TFs could be identified to bind at the promoter of the full length
transcript of RPMS1 (Fig. 14, turquoise), a putative ORF whose translation to a protein could not
be confirmed to date but gives rise to BART ncRNAs and BART miRNAs.
The contribution of cellular TFs on EBNA binding to the EBV genome was not assessed
in this study, since the major focus was on interaction with the cellular genome and TFs in this
context. Nevertheless, the findings on EBNA binding to the EBV genome display a new piece of
information which could contribute to further characterizations of gene regulation in the viral
background.
Preferential targeting of enhancer modules in the human genome by4.2.3
E2, E3A, and E3C
The main focus of this study is on the interaction of EBNA proteins with the cellular genome in
order to regulate target gene transcription. As described in the introduction, several laboratories
published datasets on target genes for EBNA proteins and for some distinct examples the
regulation processes were characterized in detail: E2 induces viral the expression of Cp derived
transcripts and LMP1 by targeting promoters (reviewed in Kempkes and Ling, 2015). A genome
wide analysis of E2 and CBF1 binding sites revealed the conjointly targeting of regulatory
elements such as enhancers rather than promoters (Zhao et al., 2011b). Within the CXCL9
and -10 genomic locus the direct reciprocal targeting of intergenic enhancers by E2 and E3A
could be shown for the first time (Harth-Hertle et al., 2013). Also a genome wide search for E3
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binding sites revealed that E3 proteins primarily target promoter distal elements (McClellan et al.,
2012). Although one has to mention that in this particular study all three E3 proteins were
precipitated together in one ChIP-seq experiment and no genome wide conclusion for single E3
binding behavior can be drawn. Furthermore, this experiment was performed in Mutu III cell
line, which derived from an EBV positive Burkitt’s lymphoma but showing latency III type
expression of viral genes, and not in an LCL background.
To investigate which functional elements are targeted by the single EBNA proteins within
the human genome, the chromatin state segmentation (css) dataset from ENCODE was used
(Ernst et al., 2011). Here, 9 histone modifications associated with distinct functional regions,
binding sites for CTCF a sequence specific chromatin insulator protein, PolII and histone variant
H2A.Z associated with nucleosome free regions derived from 9 different cell lines commonly
used by ENCODE, including the LCL GM12878, were used to generate chromatin state maps of
the human genome consisting of 15 distinct states. Those are divided in active, weak and poised
promoters, strong and weak enhancers, putative insulators, transcribed regions, polycomb
repressed regions, and heterochromatin.
Comparison of detected binding sites with css shows that all three EBNAs and the adaptor
protein CBF1 (data from Zhao et al. 2011) primarily target enhancer regions in the human
genome (Fig. 15A). Interestingly, the percentage of targeted enhancer regions is higher for both
E3 proteins compared to E2 and CBF1. The second most targeted functional elements by all
EBNAs are promoter regions. Here, E2 and CBF1 show more binding sites at promoter regions
than both E3 proteins.
The segmentation of the human genome into functional elements by css is exclusively
based on histone modification marks and PolII occurrence, including the determination of
promoter positions without referring to the genomic positions of annotated genes. Besides, it was
described that active enhancers are frequently transcribed (reviewed in Plank and Dean, 2014,
and Kulic et al., 2015) which makes it possible that those transcribed enhancers get annotated as
promoters by css. Such incidents could be observed when visualizing the obtained ChIP-seq data
in a genome browser (data not shown).
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Figure 15. EBNA proteins target enhancer elements rather than promoter regions. Locations of CBF1, E2,
E3A, and E3C peaks were analyzed in respect to functional DNA elements using the peak center as decisive position
criterion. (A) Chromatin state segmentation (css) performed by the ENCODE consortium (Ernst et al., 2011) in
GM12878 cell line was used as information for the location of functional DNA elements. Here histone
modifications and polymerase occupation were used to identify the different states. Absolute number of peaks and
percentages located on enhancer elements are indicated below. (B) Peaks which are located on one of the three
promoter states from css (22.4, 16.6, 12.9, and 11.9% for CBF1, E2, E3A, and E3C respectively) were further
analyzed for their location relative to annotated Refseq genes. To this end the regions of 1 kb upstream of each
Refseq gene in hg19 were considered as Refseq promoters. Peaks which were previously described to be located on
promoter elements by css but do not fall on a Refseq promoter are designated as peaks on css only promoters.
Percentages of peaks located on those subsets are indicated below.
In order to investigate this phenomenon, the promoter associated peaks were further analyzed
for the presence of annotated genes by Refseq (Pruitt et al., 2005) (Fig. 15B). Interestingly, only
8.4% of CBF1 and 4.7% of E2 binding sites were located at promoters as defined 1 kb upstream
of Refseq TSS (RefSeq promoters) when the genome wide css prediction identified 22.4 and 16.6%
peaks at promoters for CBF1 and E2, respectively. This effect was even more prominent for E3
binding sites. When further dissecting E3A and E3C peaks located at promoter regions (12.9 and
11.9% respectively) only 1.4 and 0.9% respectively were found at Refseq promoters. These
findings imply that part of the regions targeted by EBNA proteins and declared as promoters by
css are actually promoters of enhancers which give rise to non-coding RNAs which are not yet
included in the Refseq genes catalogue. Thus the percentage of targeted enhancers is even higher
than anticipated in the initial analysis and reveals a picture where E3 proteins are almost
exclusively targeting enhancers but almost no promoter regions. And also the percentage of E2
and CBF1 bound promoters is lower than estimated first but still accounts for a subset not to be
ignored.
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To further characterize the regions bound by EBNA proteins, histone modifications H3K4me1
and H3K4me3, characteristic for enhancers, as well as H3K27ac, typical for active enhancer
elements, derived from ChIP-seq experiments in GM12878 by ENCODE were used to generate
anchor plots depicting signal distribution at the different binding sites (Fig. 16).
Figure 16. E2 binding sites show stronger enrichment for enhancer marks than E3 binding sites. Signal
intensities for histone modification marks H3K4me1, H3K4me3, and H3K27ac as well as PolII derived from
ENCODE ChIP-seq and were normalized for input and genome coverage (RPKM). (A) Anchor plots were
generated showing signal distributions at regions flanking 20 or 10 kb (PolII) in each direction of EBNA peak
centers. (B) The data underlying (A) were used to generate boxplots depicting distributions of signal intensities. For
internal comparison of the different signal intensities peaks of each histone modification or PolII were used as
positive control. Fold changes of signal intensities between E2 and E3 peaks are indicated and all comparisons are
statistically significant with p<0.0001 applying two-tailed t-test with Welch’s correction. Boxplot whiskers extend to
1.5x interquartile range.
Interestingly, all enhancer marks as well as PolII showed higher signal enrichments at E2 peaks
compared to E3 peaks. The phenomenon was most distinctive for PolII followed by H3K27ac,
indicating that E2 can be found more frequently at activated enhancers than E3. The E3 proteins
are even targeting more enhancers percentage wise than E2 in the css analysis (Fig. 15A), which
indicates that E2 is binding to strong enhancers more frequently than E3.
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However, subsets of E2, E3A, and E3C peaks are located at RefSeq promoters, as described
above (Fig. 15B). In order to investigate the relationship between the positions of EBNA binding
sites and their regulated genes, a relative distance analysis was performed (Fig. 17). To this end
different data sets from the Kempkes laboratory on EBNA target genes were used: The
information on E2 target genes derived from an inducible system in BL41 (Maier et al., 2006),
E3A target genes were analyzed in LCL, comparing E3A ko and wt cells (Hertle et al., 2009), and
E3C targets were also investigated by comparison of E3C ko and wt cells (diploma thesis Agnes
Nowak).
Figure 17. Subsets of E2, E3A, and E3C target genes are directly bound by the regulating EBNA. Relative
distance analysis showing the relationship between E2, E3A, and E3C peaks and their regulated genes. The distance
of each peak was to the nearest gene within the analyzed data set was assessed and relativized by diving this distance
through the distance between the two genes the peak is located between. The relative distance measure ranges
between 0, which displays a perfect hit of the peak on the nearest gene, to 0.5, which displays the perfect center
between to genes. The percentage of peaks showing distinct relative distance values (from 0 to 0.5) is indicated.
Therefore, if no spatial correlation between peaks and the analyzed gene set exists an uniform distribution of relative
distance values from 0 to 0.5 is expected but if they are closer than expected by chance, a shift towards small values
of relative distance are expected. The upper panel shows the whole range of relative distances for EBNA peaks and
their target genes, the middle panel displays a zoom-in to relative distance values 0-0.15, and in the bottom panel the
top 25% peaks, sorted by mean signal are assessed for their relative distance to different gene sets.
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This relative distance analysis revealed that E2 peaks showed an elevation of peaks showing very
low relative distance towards E2 induced genes, including 6.6% of E2 peaks located directly at an
induced gene, while this could not be observed towards E2 repressed genes (Fig. 17, top and
middle panel). This effect was even more pronounced when focusing only on the top 25% of E2
peaks, defined by E2 signal enrichment, even reaching 8.6% peaks directly located at an induced
gene. Interestingly, this phenomenon could not be observed for E3A or E3C peaks towards their
regulated genes. Only when the top 25% of E3A or E3C peaks were used for this analysis, an
elevation of E3A and E3C peaks with very low relative distances towards E3A or E3C repressed
genes, respectively, could be observed (Fig. 17, bottom panels). For all analyses the distribution
of EBNA peaks towards the whole RefSeq gene set was used as a negative control which resulted
in a random distribution of relative distances each time.
Enhancer signature is a prerequisite for accession of E2 to chromatin4.2.4
and is enriched upon E2 expression
The finding that EBNA proteins primarily target enhancer elements and especially that E2
associates with stronger enhancer signatures than identified for E3 proteins raised the question if
this strong enhancer signature is a prerequisite for E2 accession to chromatin or a result of E2
chromatin binding and subsequent recruitment of e.g. histone acetyltransferases which mediate
active marks.
Another study already showed H3K4me1, the histone modification most prominent at
enhancer elements, to be present not only at E2 binding sites in LCL but also at the same
genomic positions in CD19+ primary B cells, which are EBV negative and model the situation
before infection (Zhao et al., 2011b). It was concluded that E2 is binding to enhancer elements
already existing in primary B cells, with overall lower H3K4me1 intensities. However, this
analysis did compare absolute values of normalized H3K4me1 signals at E2 binding sites derived
from two different experiments, conducted by two different research groups (CD19+ cells by
Roadmap Epigenomics (Bernstein et al., 2010) and LCL by ENCODE (ENCODE_Consortium,
2012) with two different antibodies being used for ChIP-seq.
Due to the inconsistencies listed above, it seems hard to draw profound conclusions from
comparison of absolute numbers, which do not include the relative value of a signal within a
dataset with an unknown signal distribution and pattern across the genome. To account for the
differences between the two experiments, a different approach was chosen here to investigate E2
chromatin accession. To this end not only H3K4me1 but also H3K4me3, enhancer and
promoter mark, H3K27ac, active enhancer mark, and DNaseI hypersensitive sites (DNaseI HS),
typical for open chromatin, derived from CD19+ primary B cells, conducted by Roadmaps
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Epigenomics project (Bernstein et al., 2010) and from LCL GM12878 (ENCODE_Consortium,
2012) were used for comparison applying one further normalization step. For each ChIP-seq or
DNase-seq experiment peaks were called applying the self-generated workflow (see chapter 3.6)
and signal distributions at histone modification or DNaseI HS peaks were used as reference for a
positive signal. This step allowed a relative comparison to signal intensities at positive sites and
therefore a comparison between the two experiments is now possible (Fig. 18).
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Figure 18. E2 binding sites already exhibit enhancer specific histone modifications in EBV negative B cells
(CD19+) which increase in the presence of E2. ChIP-seq experiments for histone modifications and DNaseI HS
performed in CD19+ primary B cells (Roadmap Epigenomics,(Bernstein et al., 2010)) and the LCL GM12878
(ENCODE_Consortium, 2012) were used to compare chromatin signature changes upon EBV infection and E2
expression. To this end raw data (already mapped reads) were analyzed applying own standard workflows using
Galaxy platform and tools. (A) Anchor plots depicting the respective histone modification or DNaseI HS signal at
E2 binding sites in CD19+ cells (upper panel) and LCL (lower panel). For comparison each time the peaks of the
respective histone modification or DNaseI HS are shown as well, so average signal strength at peaks can be used as
indirect reference. Regions of 20 kb, or 5kb for DNaseI HS, in each direction from peak center were analyzed. ChIP-
seq signals of histone modifications were normalized to input and coverage, DNaseI HS signal only to coverage.
(B) Analysis of mean ChIP-seq signal strength at E2 binding sites in CD19+ cells compared to LCL. Again the
regions of 20 kb, or 5 kb for DNaseI HS sites, in both directions from peak centers were used. The mean signals at
E2 binding sites were normalized to the mean signal at the respective histone modification or DNaseI HS peaks so
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E2 signal derived from two different cells and experiments can be compared. Box plots whiskers extend to 1.5x the
interquartile range and p-values were calculated using unpaired two-tailed t-test (all comparisons between average
signal at positive sites and E2 binding sites and all comparisons of E2 peaks in different cell background: p<0.0001).
The fold changes of the mean relative signals at E2 binding sites in LCL compared to CD19+ cells are shown. (C)
Graphic representation of histone modification and DNaseI HS signals at the E2 binding site in proximity to
CDK5R1 target gene. The position on hg19 is indicated on top. Called peaks for E2 are shown as yellow bars below
the signal track. For all histone modification and DNaseI HS tracks the maximum of the scale is set to 50x the mean
signal at called peaks for the respective signal. This allows the comparison of tracks derived from different cell lines.
This analysis showed that E2 binding sites in CD19+ primary B cells do indeed display
H3K4me1 enrichment, also in comparison to mean H3K4me1 enrichment at H3K4me1 peaks.
Relative comparison to data from LCL revealed even a very small decrease in H3K4me1
enrichment at E2 sites. Analysis of H3K4me3, H3K27ac, and DNaseI HS showed signal
enrichment for all three marks at E2 binding sites in CD19+ cells and also a relative enrichment
of all three marks compared to LCL. Since H3K4me3 is a histone modification associated with
active transcription, H3K27ac is associated with activated enhancers, and DNaseI HS is
associated with accessible chromatin, these findings imply that E2 is binding to preexisting
enhancers in CD19+, which subsequently get activated. In summary, E2 is not introducing
enhancer signatures upon chromatin binding, rather targets existing enhancers for an initial
accession to chromatin and in turn activates them.
Distinct combinations of cellular TFs characterize E2 versus E34.2.5
predominated chromatin regions
As described in the introduction, a significant overlap of E2 and E3 target genes as well as E3A
and E3C target genes could be observed comparing expression array data from our laboratory,
which could indicate a competition for CBF1 binding to achieve chromatin accession and
thereby operating the same target genes. Nevertheless, the majority of EBNA target genes are
uniquely regulated by one EBNA protein and also studies from other laboratories tend to show a
separate mode of action for E2 and E3 proteins.
4.2.5.1 Comparing genomic positions of significant EBNA binding sites revealed
only moderate overlaps
Comparing the different EBNA binding sites identified in this study, including published CBF1
ChIP-seq data, for their positions in the human genome also shows moderate overlaps (Fig. 19).
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Figure 19. Binding site intersections for EBNA proteins and CBF1. Called peaks  were  extended by 50 bp in
each direction before performing intersection analyses. Absolute numbers of called peaks are indicated as well as
percentages for important subsets.
The intersection analyses revealed two important pieces of information. First, on the one hand,
significant overlaps can be observed between E2 and both E3 peak sets (Fig. 19A) as well as
between E3A and E3C (Fig. 19B), supporting the CBF1 competition model. Nevertheless, the
majority of identified peaks are unique for one EBNA protein. Second, when looking at CBF1
co-occupation, E2 displays a far bigger overlap with CBF1 sites than both E3 proteins do
(Fig. 19C and D), displaying a first hint for a more important role of CBF1 in recruitment of E2
to DNA than for E3 proteins.
4.2.5.2 Quantitative analysis of signal intensities at EBNA binding sites reveals
significant positive correlation patterns
In this very simple comparison of binding site occupation, one important piece of information
from ChIP-seq experiments is missing: A quantitative examination of binding sites. To achieve a
more complete overview on E2 and E3 binding sites in the human genome, a different approach,
including quantitative values was introduced. To this end EBNA binding sites were ordered by
their own signal intensities and compared to the ChIP signals from other TFs (Fig. 20A-C). Here,
a more complex picture emerged: E2 does not only show a larger overlap with CBF1 binding
sites in comparison to E3, but also displays a correlation in CBF1 signal enrichment at E2
binding sites (Fig. 20A, column 2). However, CBF1 signal at E3 binding sites does not display
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this kind of positive correlation but seems rather to be distributed randomly (Fig. 20B and C,
columns 3). Interestingly, E3A and E3C exhibit a very prominent positive correlation of signal
intensities at both, E3A and E3C peaks, indicating a more intense cooperation on DNA binding
level than assumed by intersection analyses only. Also E2 and the E3s do not show a significant
correlation of signal intensities at E2 (Fig. 20A, columns 3 and 4) or E3 binding sites (data not
shown). So despite a moderate overlap in significant binding sites no correlation in signal
intensities could be observed.
This phenomenon could be detected at various genomic regions when visualizing ChIP-seq
data in a genome browser, e.g. at the well described genomic region encompassing CXCL9 and -
10 (Fig. 20D), confirmed by ChIP-qPCR analysis (Fig. 20E). E2 and CBF1 show a very similar
ChIP signal distribution at this region as well as E3A and E3C do. As already demonstrated on a
genome wide scale by histone modification analysis at different EBNA peaks (Fig. 16), also the
E2 enriched enhancer “E1” in this example exhibits higher H3K27ac signals as the E3 dominant
enhancer regions “E4” and “E5”. In fact, E2 and the two E3 proteins show reciprocal signal
enrichment at bound enhancer regions within this analyzed region.
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Figure 20. CBF1 signal positively correlates with E2 signal at E2 binding sites but not with E3 signals at E3
sites. (A) E2, (B) E3A, and (C) E3C peaks were sorted in a descending order according to their own mean
normalized signal (first lane of each panel) and then compared to signal intensities of other TFs, listed on top,
without changing order. (D) Graphic representation of E2, CBF1 (* raw data from Zhao et al., 2011), E3A, and E3C
signals at a genomic region encompassing E2, E3A, and E3C target genes CXCL9 and -10. The position on hg19 is
indicated on top. Primers used for ChIP-qPCR are shown as turquois bars below the signal tracks and primers at
enhancer regions are labeled. Annotated RefSeq genes are shown below. For all histone modification tracks the
maximum of the scale is set to 10x the mean signal at called peaks for the respective signal. (E) ChIP-qPCR analysis
using primers highlighted in (D). A Flag-ChIP was performed in Flag-E3A and -E3C LCLs as well as in the wt LCL
derived from the same donor as a negative control. The E2-ChIP was performed in the wt LCL, derived from the
same donor as used for the Flag-ChIP. Here, an isotype matched antibody was used as negative control. Means and
SEM of two independent ChIP experiments with technical duplicates are shown.
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4.2.5.3 A genome wide correlation analysis of transcription factor binding
patterns reveals distinct sets of E2 and E3 associated factors
In this study a hypothesis was formed, which pictures subsets of EBNA regulated genes and a
definition of those by the TF occupancies of their regulatory elements. In this picture CBF1 is
not sufficient for subset determination rather than co-occurring factors and their combinations,
which define such subsets. To include information on further TF binding in the most unbiased
fashion, all TF ChIP-seq experiments performed in GM12878 by ENCODE at the time when
this analysis was performed (chapter 3.6.4) were included in a genome wide approach to identify
potential TFs important for EBNA accession of (specific) DNA elements.
To this end a genome wide correlation analysis was performed applying bamCorrelate,
which is part of the deepTools package (Ramirez et al., 2014a), and signal distributions over the
whole genome for all three EBNAs, CBF1, and 84 ENCODE TFs were included. BamCorrelate
performs a one to one comparison for all possible combinations of submitted samples, where the
genome is split in bins of distinct size and reads for each bin and sample are counted. Comparing
reads/distinct bin for two samples a regression curve and correlation coefficient (here Spearman
correlation, rs) can be calculated indicating the degree of “similarity”. An rs of 1 displays perfect
positive correlation, 0 no correlation at all, and -1 indicates perfect anti-correlation. A detailed
information on this tool can be found at the developers github page (Ramirez et al., 2014b).
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Figure 21. Genome wide correlation analysis reveals distinct clusters for E2 and E3 proteins. All 84 TFs
ChIP-seq experiments available in GM12878 to date (ENCODE_Consortium, 2012) and the CBF1 ChIP-seq were
compared with E2 and E3 proteins for their genome wide overall “similarity” in signal enrichment applying
bamCorrelate. To this end the human genome (hg19) was split in 100 bp bins, reads of each sample for each bin
were counted, one to one comparison of all samples looking at reads/distinct bin were performed, and then a
correlation coefficient, applying Spearman correlation, for each possible sample pair combination was calculated.
The matrix shows relations between single TFs as predicted by hierarchical clustering by bamCorrelate. The color
intensities representing correlation coefficients are depicted below the matrix as color bar. E2 and E3 associated TF
subsets are highlighted by colored frames; investigated EBNAs are highlighted by red arrows. The red frame
highlights the correlation values between E2 and E3 subsets.
The resulting data matrix (Fig. 21) provides a huge amount of information on TFs clusters and
specific combinations in LCL, which were not fully analyzed in this thesis. Here, the focus is
mainly on TFs factors displaying a high positive correlation with the single EBNAs. Taking a first
79RESULTS
look at the results, one feature attracts attention immediately: E2 and the two E3 proteins are
located in two separate clusters, each associated with specific TFs.
Here, E2 was found in one cluster together with the described DNA adaptor CBF1, EBF1,
PU.1, BCL3, BATF, and in a more distant branch of this cluster RUNX3, MEF2A, and MEF2C
with assigned rs in comparison to E2 of 0.50, 0.42, 0.17, 0.32, 0.20, 0.25, 0.16, and 0.16
respectively (Fig. 21, orange box). Taking a closer look at the single rs values revealed that not all
of the TFs show a high correlation to E2 but rather show a similar pattern in the genome wide
comparison to the investigated TFs. The characteristics and quality of E2 and CBF1 binding on
DNA was characterized in detail above (Fig. 20), where a strong positive correlation at identified
E2 binding sites could be shown, indicating that an rs of 0.50 in a genome wide comparison
displays a solid positive correlation. Only the comparison to EBF1 reached a similar rs of 0.42
within the E2 cluster.
E3A and E3C were placed in a different subset by bamCorrelate, which includes 16 further
TFs besides the E3s (Fig. 21, blue box). Interestingly, the comparison of E3A and E3C shows a
very high rs of 0.70, the highest rs each E3 reaches in comparison to all investigated TFs.
Members of the cohesion complex SMC3 and RAD21, which are known to be recruited to DNA
together, reached an rs of 0.71 and are clustered together with CTCF, which interacts with
cohesion on DNA to link regulatory elements with their targets (reviewed in Merkenschlager and
Odom, 2013). Also TFs, which are known to act in heterodimers, such as BATF/IRF4 (Ravasi et
al., 2010, Glasmacher et al., 2012) and MEF2A/MEF2C (Li et al., 2015) combinations, score rs
values in the range of E3A with E3C (0.60 and 0.78 respectively). This finding implies that E3A
and E3C act very closely together on DNA and might even operate as a heterodimer. It has to be
mentioned though, that some TF combinations, which are known to act as heterodimers, like
AP-1 factors Jun and Fos only show a low rs (0.06) in this genome wide correlation analysis.
Several reasons could contribute to this finding: some heterodimer combinations are cell type
specific and often distinct combinations only access a certain subset of binding sites detectable
for the single components of such a heterodimer, which would result in lower rs values on a
genome wide level.
Both E3 proteins exhibit rs values of at least 0.3 for all TFs within the E3 cluster, with
TF12 as one exception (rs of 0.26 and 0.25 for E3A and E3C respectively). In general, the E3
cluster forms the most prominent cluster within the genome wide matrix, where all factors
display high rs values to each other. This phenomenon indicates the existence of an LCL specific
TF network which is exploited by E3 proteins for chromatin accession.
The E2 cluster in contrast does not exhibit high rs values for all TFs included but is rather
formed by pattern similarities in the overall comparison. Interestingly, looking at the relationship
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of the E2 and the E3 clusters to each other, a slight but noticeable positive correlation is
detectable (Fig. 21, red frame) pointing out a relationship between the two clusters.
A drawback of the matrix and the hierarchical clustering is the formation of branches and
clusters by pattern similarities, which sometimes results in separation of factors which display
high rs values per se but fall into patterns of different hierarchies. Of course this approach is very
useful for identifying patterns also in big datasets, but in this special case the TFs with significant
positive correlation to the EBNAs were of particular interest, more than the cluster of higher
magnitude they are fitting in.
Thus the next analysis step only focused on TFs, which might by relevant for chromatin
accession of the EBNA proteins. To this end TFs identified by the genome wide correlation
analysis, which scored a high positive correlation (rs > 0 35) with at least one of the investigated
EBNA proteins were included in a second genome wide correlation analysis. Here, the same
parameters were applied and already calculated rs values did not chance, but the pattern discovery
differed from the previous one, including all TFs examined by ENCODE. In this new matrix,
only including preselected TFs (by rs threshold) as slightly different pattern emerges (Fig. 22).
Again two separate clusters for E2 and E3
proteins could be identified, which are
associated with distinct sets TFs of a very
similar composition as in the first analysis.
E2 still clusters with CBF1 and EBF1, but
newly emerged CUX1, which was previously
added in a branch together with IKZF1 and
p300. The comparison with the E3 cluster
shows that CBF1 and EBF1 signals are
exclusively correlating with E2 and CUX and
exhibit almost no cross interaction with the
E3 cluster.
The E3 cluster now consists of 16 TFs
forming five subsets consisting of (i) STAT5,
NFATC1, CEBPB, MTA3, and TCF3, (ii)
E3A and E3C, (iii) ATF2, FOXM1, and
NFIC, (iv) TAF1, PML, POU2F2, EGR1,
and REST, as well as (v) IRF4, BCL11A, and
BATF. Subclusters (i), (ii), (iii), and (v) show
Figure 22. Genome wide correlation analysis of
preselected TFs reveal two separate clusters for E2 and
E3 proteins associated with distinct TFs. TFs with a
genome wide rs > 0.35 in comparison to at least one
investigated EBNA protein were used to generate a new
matrix. BamCorrelate was used to calculate rs and perform
hierarchical clustering applying the same standards as in
Fig. 21. The color intensities representing correlation
coefficients are depicted below the matrix as color bar. E2
and E3s are highlighted by colored frames.
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very strong signal correlations, while subcluster (iv) displays weaker correlations.
The TFs now identified in a very unbiased genome wide approach to positively correlate
with EBNA ChIP-seq signal intensities displayed a starting point for further characterization of
the TF composition of specific subsets of binding sites and associated chromatin accession.
4.2.5.4 Anti-correlation of E2 and E3 signal intensities at combined binding sites
The correlation analysis described above gave a great overview on a genome wide interaction
network of distinct TF sets associated with the EBNA proteins. To refine the resolution of this
kind of analysis and to further concentrate on TFs associated with EBNA proteins only, a second
more specific correlation analysis was performed. To this end, not the whole genome but only
regions which are binding sites for at least one of the investigated EBNA proteins (EBNA peaks)
were considered as reference regions and the TFs identified in the genome wide correlation
analysis, which showed a good positive correlation were reanalyzed (Fig. 23).
Figure 23. Correlation analysis of TF signal intensities at EBNA binding sites only revealed anti-correlation
of E2 and E3 proteins and largely confirmed associated TF clusters. Correlation analysis for EBNA proteins,
CBF1, and the 19 TFs identified in 4.2.5.3 was repeated (as performed in 4.2.5.3), but restricted to genomic sites
bound by at least one EBNA protein (EBNA peaks). (A) Schematic representation of EBNA peak file generation.
Called E2, E3A, and E3C peaks were merged (32,671 resulting regions) and subsequently used as reference regions
for correlation analysis applying Spearman correlation. Scatter plots (plotted by Simone Rieger) depicting E2 versus
CBF1, E3A, or E3C signals at EBNA peaks. Each dot represents one EBNA peak. Correlation coefficients rs are
indicated. (B) Preselected TFs which displayed an rs > 0.3 in comparison to at least one investigated EBNA protein
were used to generate a new matrix. The color intensities representing rs values are depicted next to the matrix as
color bar.
This analysis, restricted to the EBNA peaks confirmed the presence and composition of the two
distinct clusters of TFs, one for E2, which is again strongly associated with CBF1 (rs = 0.55) and
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EBF1 (rs = 0.49), and another cluster for E3A and E3C, which again show a very strong positive
correlation (rs = 0.62) to each other. TFs POU2F2, REST, EGR1, TCF3, and TAF1, which were
identified in the genome wide approach, were not included in the generation of the new EBNA
peak restricted correlation matrix, since they scored rs values below the set threshold to all three
investigated EBNA proteins. This could be due to a general presence of those TFs at EBNA
peaks which is recognized as a significant correlation in the genome wide point of view (Fig. 21
and 22), but the signals do not positively correlate with either E2 or the E3 signals at the peak
restricted analysis.
In general, on a genome wide scale, a inter-correlation between E2 and E3 clusters can be
observed, since all TFs involved mainly bind to enhancer elements which only represent a very
small fraction of the entire genome. In this broad context, the interconnection between the E2
and E3 cluster is quite significant (Fig. 21, red frame). But when the picture was narrowed down
on only the fragments of interest, which are actually occupied by the EBNA proteins (EBNA
peaks), a more specific picture emerges. Here, E2 and E3 proteins display an anti-correlation
relationship which characterized by two distinct sets of TFs. The described E2 and E3 specific
associated TF compositions could be observed frequently when visualizing the signal tracks in a
genome browser and the E2 and E3 anti-correlation in signal intensities could be verified by
ChIP-qPCR for several loci. For illustration two well described gene loci were chosen and the
signals for TFs identified above were used for comparison (Fig. 24). ADAM28 and
ADAMDEC1 are two described target genes known to be repressed by E3A and E3C (Hertle et
al., 2009, McClellan et al., 2012, our unpublished data from E3C ko LCL gene expression array)
and induced by E2 action (unpublished data by Sybille Thumann from gene expression array and
conditional expression of E2 in DG75 B cell line). Here, the two described correlation trends are
visible: CBF1, EBF1, and CUX signal distribution is very similar to E2 signal intensities, while
the TFs derived from the E3 cluster follow the E3 signal intensity distribution at inter- and
intragenic enhancers E1 and E2. E3A and E3C, as well as their correlating TFs, each show the
higher signal at E1 and a lower enrichment at E2. For E2 and its associated TFs it is the other
round; E2 is the enhancer with the higher signal enrichment (Fig. 24A). This phenomenon could
also be observed at enhancers in proximity to E2 and E3 target genes CXCL9 and -10 (described
above in more detail): E2 and associated TFs show high enrichments at enhancer E1, but only
low enrichment at enhancers E4 and E5, which are significant E2 binding sites as well. E3
proteins and the TFs from the E3 cluster showed more prominent enrichment at the distal
enhancers E4 and E5 over intergenic E1 (Fig. 24D).
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Figure 24. E2 and E3 specific associated TF sets identified in correlation analyses show reciprocal binding
patterns at EBNA peaks at two model loci. (A, D) Graphic representation of E2, CBF1 (* raw data from Zhao et
al., 2011), E3A, and E3C signals as well as signals of the 13 TFs identified in 4.2.5.4 at two genomic model loci. The
position on hg19 is indicated on top. Primers used for ChIP-qPCR are shown as turquois bars below the signal
tracks and primers at enhancer regions are labeled. Annotated RefSeq genes are shown below. For all ChIP-seq
tracks the scale was set to the local maximum of the depicted regions. (B, E) Flag and (C, F) E2 ChIP-qPCR analysis
using primers highlighted in (D). The Flag-ChIP was performed in Flag-E3A and -E3C LCLs as well as in the wt
LCL derived from the same donor as a negative control. The E2-ChIP was performed in the wt LCL, derived from
the same donor as the LCL applied for the Flag-ChIPs. Here, an isotype matched antibody was used as negative
control. Means and SEM of two independent ChIP experiments with technical duplicates are shown.
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4.2.5.5 Characterization of EBNA binding sites by cluster analyses including
preselected TFs
The performed correlation analyses described above revealed TFs which are positively correlating
in signal intensities with the investigated EBNA proteins and therefore might be contributing to
recognition and specificity of EBNA binding site subsets. In order to stress the idea that subsets
exist, which are defined by their TF composition, clusters of TF combinations were searched at
EBNA binding sites. Together with Björn Grüning (University of Freiburg), intersection analyses
of called peaks of TFs, identified in the correlation analysis 4.2.5.3, at the EBNA peaks were
performed and Jaccard similarity coefficients were calculated to compare similarity and diversity
of the included sample sets. Hence, a cluster analysis was performed describing the relationship
of the selected TFs at EBNA peaks, but also the EBNA peaks were sorted according to the
identified clusters (Fig. 25). This analysis does not include quantitative measurements like the
correlation analysis, where signal intensities were used, but is only based on called peaks and
therefore is able to sort the EBNA peaks according to their TF occupancies and identified
clusters.
Figure 25. Cluster analysis at EBNA peaks identified hierarchies of associated TFs at EBNA peaks. TFs
identified to positively correlate (rs > 0.35) with at least one EBNA protein in the genome wide correlation analysis
comparing TF signal intensities were included in a new cluster analysis in order to sort EBNA peaks according to
compositions of associated TFs. To this end, the EBNA peaks were used as reference regions for an intersection
analysis creating a matrix which depicts hits for each selected TFs (using peaks identified by ENCODE, see
Table S1) at every EBNA peak. The resulting matrix was used as template for cluster search applying Jaccard
similarity correlation index (performed by Björn Grüning). The resulting identified relations between the investigated
TFs are depicted in the dendrogram in the upper panel. The EBNA peaks were sorted according to the identified TF
clusters, and heatmaps for each TF were generated. Sorted EBNA peaks were centered and genomic regions of 2 kb
in each direction from peak center are show. The scale of each heatmap was set to depict the whole range of
detected signal at the investigated EBNA peaks.
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Here, the 19 TFs which were already identified in the genome wide correlation analysis were used
to generate this cluster analysis, where not only TFs are clustered according to their relation at
EBNA peaks but also the respective EBNA peaks were sorted.
Interestingly, TFs REST, EGR1, and TAF1 were placed at the very outer level of
relationship towards the other factors including the EBNA proteins, which could indicate that
they play a more general role at EBNA binding sites, rather than defining E2 or E3 binding site
subsets. TCF3 and POU2F2 hierarchically fall into the E2 sub-branch, but are located to the
outer level there.
The E3 sub-branch includes TFs BATF, FOXM1, ATF2, NFIC, BCL11A, and IRF4, while
the other TFs which were previously sorted in the E3 cluster, now are predicted to have a more
close relationship to E2.
E2 builds the strongest cluster with CBF1, EBF1, and CUX1. This E2 core-branch is
identical with the TF composition of the E2 cluster in the genome wide signal correlation
analysis, as well as with the one from the EBNA peak restricted correlation analysis. Since both
approaches, signal correlation and plain peak intersection analysis, identify the same TFs to be
strongly associated with E2, they were chosen for further investigations.
The heatmaps generated for the sorted EBNA peaks and the investigated TF signals show
a prominent pattern, shared by factors within one sub-branch, but no sharp clusters of peaks
defined by TF occupation could be identified. This finding is probably due to the relatively large
set of investigated TFs, including some, which show rather an overall EBNA peak binding than
preference for distinct subsets. To get a better understanding of the TF composition of E2
versus E3 binding sites, both peak sets were investigated separately using the TFs identified in
this approach.
4.2.5.5.1 Cluster analyses for E2 binding sites reveal subsets defined by combinatorial
TF sets
The TFs identified in the cluster analysis of TFs present at EBNA peaks (Fig. 25) to be closely
related to E2, were now used to cluster E2 peaks according to their TF compositions. Again an
intersection analysis was performed, this time using E2 peaks as reference regions, where each
region was evaluated for intersection with CBF1, EBF1, and CUX1. The resulting matrix was
used as template for cluster search and eight (out of 16 possible) distinct clusters of E2 peaks
could be identified which are characterized by specific combinations of the investigated TFs
(Fig. 26A). The identified clusters of E2 peaks do not only show distinct compositions of the
investigated TFs, but also show different signal intensities for those within each cluster
(Fig. 26B).
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Figure 26. Cluster analysis for E2 peaks identified eight distinct clusters of TF combinations which are
associated with different histone modifications. TFs identified to cluster with E2 in the EBNA peak wide TF
cluster analysis described in 4.2.5.5 were used to generate a new cluster analysis in order to sort E2 peaks according
to compositions of associated TFs. To this end, the E2 peaks were used as reference regions for an intersection
analysis creating a matrix which depicts hits for each selected TFs (using peaks identified by ENCODE, see
Table S1) at every E2 peak. The resulting matrix was used as template for cluster search applying Jaccard similarity
correlation index (performed by Björn Grüning). (A) The E2 peaks were sorted according to the eight identified TF
clusters and heatmaps for each TF were generated. Sorted E2 peaks were centered and genomic regions of 2 kb in
each direction from peak center are show. The scale of each heatmap was set to the maximum signal detected at an
E2 peak. Anchor plots depicting mean signal distributions of (B) E2 and the three cluster determining TFs as well as
(C) histone modifications and PolII at the different E2 peak clusters. As in (A) a region of 2 kb in each direction of
the peak center was analyzed. ChIP-seq signals from ENCODE were normalized to their respective input samples
and RPKM (see chapter 3.6.1). (D) E2 peaks of the eight different clusters were analyzed for their location on
functional chromatin elements as determined by ENCODE css. Centers of E2 peaks were used to assign chromatin
states.
Cluster I displays by far the highest signal intensities for E2 and all three defining TFs. The
remaining clusters are either positive or negative for each defining TF, but the mean signal
intensities for those do not differ to the extent observed for cluster I. Interestingly, the clusters
do not only differ in their TF composition, but also they show different chromatin signatures as
defined by histone modifications (Fig. 26C and Fig. S2). Three clusters emerge to be of special
interest for further studies of functionality:
Cluster I, positive for all three investigated TFs, shows the strongest enrichment for
H3K4me1 as well as for H3K27ac, indicating an association of these binding sites with active
enhancers. Consistent with this finding, the majority of E2 peaks from this cluster are located at
strong enhancers (66.7%) according to css by ENCODE in GM12878 (Fig. 26D). Hence, this
cluster shows the strongest enrichment of strong enhancer associated peaks of all identified
clusters.
Cluster VII, characterized by co-occupation of E2 binding sites with CBF1 and CUX1 but
no EBF1 binding, exhibits the highest enrichment for H3K4me3 and PolII signals, which are
associated with transcribed promoters. Also the css analysis of E2 peaks within this cluster shows
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an overrepresentation of promoter regions of 27.3% (Fig. 26D) of which 10.3% are located
within 1 kb upstream of a Refseq gene (data not shown).  This subset of E2 peaks could
therefore display a TF composition which determines E2 accessible promoter regions.
Furthermore, E2 binding sites of this cluster are also enriched for H2AFZ, a histone variant
associated with active or poised promoters (Ku et al., 2012) and H3K79me2, a histone
modification associated with active transcription as well as DNA repair (reviewed in Nguyen and
Zhang, 2011) supporting the connection to active promoter regions (Fig. S2).
Cluster V, which is comprised of E2 binding sites with no significant peaks for CBF1,
EBF1, nor CUX1, shows the lowest E2 signal as well as the lowest enrichment of all investigated
histone modifications associated with transcriptional or positive regulatory activity out of all
clusters. However, cluster V displays the weakest depletion for H3K27me3, a histone
modification associated with repression of transcription by polycomb group proteins (PcG)
(Fig. 26C) and also H3K9me, associated with repression of transcription, is not as much locally
depleted as for the other clusters. All other investigated histone modifications show the lowest
enrichment for this very E2 peak cluster (Fig. S2).
The majority of the remaining TFs investigated by ENCODE, not included in this cluster
formation, show the strongest signal enrichments at E2 peaks of cluster I or VII compared to the
other E2 peak clusters (Fig. S3 and S4). No TF emerged to be as strongly enriched for one of the
other clusters. Strikingly, the vast majority of TFs showed the lowest signals for cluster V and IV.
A de novo motif search for E2 binding sites of the eight different clusters was performed
as well, to scan for further factors which might contribute to their specificity and to identify
probable determining DNA sequences (Fig. 27). Interestingly, EBF1 showed up as the most
significantly enriched motif of E2 peaks derived from cluster I to IV, all four clusters out of eight
which are actually positive for EBF1 binding in ChIP-seq (Fig. 26A). CBF1 on the other hand,
which only displays significant binding at E2 sites of cluster I, II, VII and VIII, can be found as
an enriched motif for all eight clusters.
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Figure 27. Cluster of E2 binding sites are characterized by specific compositions of enriched DNA motifs.
The DNA sequences of E2 binding sites (500 bp in each direction from peak center) for the eight different clusters
of TF composition (as identified in 4.2.5.5.1) were subjected to de novo motif search using MEME-ChIP analysis
tool (Machanick and Bailey, 2011). Depicted are the top five enriched de novo identified motifs (E-values for
significance of enrichment within input dataset are shown in brackets). The TF (or TF family) most likely to
recognize the identified motifs are indicated and were predicted by TOMTOM motif comparison tool (Gupta et al.,
2007) (scanning hocomoco v9 database). EBF1 and CBF1 motifs are highlighted by blue and pink frames,
respectively.
However, the E-value for significance of enrichment and the ranking of CBF1 motifs varies
between the different clusters, while EBF1 motif, if enriched, displays the top candidate for
clusters I to IV. For clusters V to VIII, lacking EBF1 binding and motif enrichment, CBF1 motif
takes up top ranking positions.
For all eight clusters similar motifs show up in this de novo motif enrichment search,
highlighting the importance for TFs of e.g. the AP-1, ETS, NFκB, RUNX, and IRF families to
chromatin accessibility and determination of E2 binding. Yet, the respective motifs emerge in
different combinations and rankings for the different clusters and some patterns can be
recognized.
E2 binding sites of clusters I to IV, characterized by EBF binding and motif enrichment,
are enriched for the NFkB motif as well, while the EBF1 negative clusters do not show this
characteristic, pointing at a potential role for TFs of the NFkB family in E2 binding at those sites.
The sequence motif recognized by members of the interferon regulatory factors (IRFs)
family could be discovered within peaks of clusters I, V, VI, and VII and even displays the most
significantly enriched motif for cluster VI. Also the recognition motifs for TFs of the ETS family
could be identified in all clusters but I and II.
Interestingly, the ETS and ISRE composition motif (EICE) was also enriched for binding
sites of clusters I and VII, the strong enhancer and promoter clusters respectively. EICEs are
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recognition sites for ETS factors as PU.1 and SpiB, both being expressed in B cells, which recruit
IRF4 or IRF8 to DNA and are very well described (Brass et al., 1996, Brass et al., 1999, Eisenbeis
et al., 1995).
Also the consensus recognition motif for TFs of the AP-1 family could be observed in all
clusters but clusters I and VI in the motif enrichment analysis. This superfamily includes TFs of
the c-Fos, c-Jun, ATF, and JDP families of TFs and many of them are included in the E3 cluster
of TFs as identified by genome wide signal pattern correlation analyses (Fig. 21). Here, the E2
cluster showed a slight positive correlation towards the E3 cluster (Fig. 21, red frame). But, the
AP-1 and ISRE composition motif (AICE), which can be recognized by AP-1/IRF complexes
(Glasmacher et al., 2012) is enriched for E2 binding sites of cluster VI, leaving cluster I the only
E2 peak cluster without top enriched AP-1 motifs. Since cluster I represents the E2 peaks with
the highest signal intensities, it is most likely that AP-1 TFs are not necessary are prerequisite for
E2 accession to chromatin, but could facilitate binding in scenarios missing one or more
important factors, like CBF1 or EBF1.
Furthermore, consensus motifs for TFs SP1 (cluster VI), RUNX family (cluster II, V, and
VIII), and MYOG (cluster VII) could be observed among to the top enriched motifs.
Noticeably, the consensus motif of CUX1 could not be observed to be enriched in any of
the analyzed E2 binding site clusters. As a control analysis CUX1 binding sites, as determined by
ENCODE (experiment: ENCSR000DYR, peaks: ENCFF001VDY, peak count: 40,246), were
subjected to de novo motif search using MEME-ChIP applying the same parameters as for E2
peak analyses (data not shown). Here, the CUX1 consensus motif (vbRvndATYRRTbb,
TRANSFAC20112:136) was not among the top 5 enriched motifs as well but only identified as
the sixth most enriched motif (E-value: 1.0e-70), while ETS (8.7e-388), RUNX (1.6e-158), ISRE
(2.1e-151), and MEF (5.9e-101) motifs were more significantly enriched. In Summary, eight
clusters of E2 binding sites characterized by distinct TF binding events and motif occurrences
and associated with different chromatin marks could be identified. These clusters can now
contribute to further elucidate the determining prerequisites for E2 accession to chromatin.
4.2.5.5.2 Cluster analyses for E3 binding sites reveal subsets defined by combinatorial
TF sets
The combinatorial approach as performed for E2 binding sites was applied to E3A and E3C
peaks as well. To this end, TFs which could be identified in the cluster analysis of TFs present at
EBNA peaks (Fig. 25) and were clustered within the “E3 sub-branch”, were now used to cluster
E3A and E3C peaks according to their TF compositions. Also in this setting an intersection
analysis was performed, this time using E3 peaks (merge of E3A and E3C peaks) as reference
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regions, where each region was evaluated for intersection with BATF, ATF2, BCL11A, FOXM1,
NFIC and IRF4. The resulting matrix was used as template for cluster search which could
identify eight clusters (out of 256 possible) of E3 peaks with different TF combinations (Fig. 28).
Figure 28. Cluster analysis for E3 peaks identified several sub-clusters of TF combinations which are
associated with different histone modifications. TFs identified to cluster with E3A and E3C in the EBNA peak
wide TF cluster analysis described in 4.2.5.5 (Fig. 25) were used to generate a new cluster analysis in order to sort E3
peaks (merge of E3A and E3C peaks) according to compositions of associated TFs. To this end, the E3 peaks were
used as reference regions for an intersection analysis creating a matrix which depicts hits for each selected TFs (using
peaks identified by ENCODE, see Table S1) at every E3 peak. The resulting matrix was used as template for k-
means clustering. (A) The E3 peaks were sorted according to the eight identified TF clusters, and heatmaps for each
TF were generated. Sorted E3 peaks were centered and genomic regions of 2 kb in each direction from peak center
are show. The scale of each heatmap was set to the maximum signal detected at an E3 peak. Anchor plots depicting
mean signal distributions of (B) E3A, E3C, and the six cluster determining TFs as well as (C) histone modifications
and  PolII  at  the  different  E3  peak  clusters.  As  in  (A)  a  region  of  2  kb  in  each  direction  of  the  peak  center  was
analyzed. ChIP-seq signals from ENCODE were normalized to their respective input samples and RPKM.
E3 peak cluster I is positive for both, E3A and E3C, as well as all six investigated TFs, which
show the highest enrichment for this cluster. Cluster III depicts E3A and E3C shared binding
sites, with higher E3A enrichment, and associated TFs BATF and IRF4. Clusters V, to VIII
appear to be very similar but display distinct combinations of E3A and E3C associated factors:
Cluster V is depleted for IRF4 signal, cluster VI shows significant enrichment for BATF and
IRF4 but shows random occurrence of the other TFs, cluster VII shows at depletion for BATF
and IRF4, and cluster VIII is depleted for FOXM1 signal. Also an E3A specific cluster, with only
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very low E3C enrichment and depletion for all investigated TFs (cluster II) as well as an E3C
specific cluster, with no other associated factors (cluster IV) could be detected.
Cluster I represents the strongest enhancers in this analysis, since it shows the highest
enrichment for active enhancer associated chromatin marks H3K4me1, H3K27ac, and even
PolII. Cluster V and VII are very similar to cluster I in the presence of enhancer specific histone
modifications, but less enriched. However, it has to be pointed out that the absolute signal
enrichment for PolII at these three clusters is much less pronounced than for E2 cluster VII and
is more comparable to the slight enrichment at the other E2 clusters. Clusters VI and VIII
display enhancer signatures as well, but not as highly enriched and without strong H3K27ac or
PolII marks characteristic for weak enhancers. Clusters II and III exhibit the lowest enrichment
of all investigated histone modifications but repressive H3K27me3, which is representative for
PcG mediated repression, while cluster IV is almost devoid of any histone modifications, which
is distinctive for heterochromatin.
Therefore, the eight identified clusters of E3 peaks reveal a combinatorial TF co-
occupation of E3A and E3C binding sites, characterized by different histone modification
patterns, and display a great basis for further functional analyses.
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4.3 CBF1 as a determining factor for E2 access to chromatin?
The interaction of E2 and CBF1 has been studied extensively and the interaction of CBF1 and
E2 together with DNA could be demonstrated in different approaches (Grossman et al., 1994,
Henkel et al., 1994, reviewed in Hayward et al., 2006). A more recent study could show that also
on a genome wide level E2 and CBF1 binding sites are significantly overlapping (Zhao et al.,
2011b) and also the findings presented in this thesis show a strong positive correlation of E2 and
CBF1, not only in binding site occupation but also in signal intensity.
Furthermore, in the context of viral gene regulation, another cellular factor, PU.1 (or Spi-1)
was described to be important for E2 driven activation of the LMP1 promoter (Laux et al.,
1994b, Laux et al., 1994a, Johannsen et al., 1995). Nevertheless, the interaction of E2 and PU.1
was only reported once (Yue et al., 2004) in a co-immunoprecipitation (Co-IP) experiment
applying whole cell lysates which allows no conclusion on a direct interaction. Also the different
correlation analyses of TF binding intensities performed in this thesis did not identify PU.1 to
correlate with E2 binding patterns.
The dependency of E2 on CBF1 in its function as transcriptional activator has long been
subject to studies in our laboratory. To assess the whole extend of CBF1s contribution to E2
mediated gene regulation on a genome wide level, Sybille Thumann of our group, performed
gene expression analyses, using GeneChip® Human Gene 2.0 ST (Affymetrix) chip arrays,
comparing CBF1 wt and ko cell lines (manuscript in preparation). The utilized DG75 cell lines,
with CBF1 wt or ko genetic background, expressing E2 fused to the hormone binding domain of
the Estrogen receptor (ER) (in the following ER/E2) have been published (Maier et al., 2005).
Here, E2 activity can be induced by addition of Estrogen to the cell culture media. This study
revealed a total of 136 at least 4-fold (p<0.001) E2 regulated transcripts in the DG75ER/E2/CBF1
wt cell line. Interestingly, also in the CBF1 ko situation 21 E2 regulated (≥ 4x, p<0.001)
transcripts could be identified. The majority of CBF1 independently regulated transcripts are
regulated by E2 in the wt background as well.
These findings were leading to the questions of how E2 mediates gene regulation and how
it gains access to chromatin in the absence of the cellular anchor protein CBF1. To this end,
further ChIP-seq studies for E2 binding in DG75 cell lines, with CBF1 wt and ko background,
were performed as part of this work.
DG75 cell lines inducibly expressing HA-tagged E2 as a model system4.3.1
In pursuance of studying E2 binding to DNA in the absence of CBF1 expression, the DG75 cell
line harboring a somatic knock-out for CBF1 constructed in our laboratory (Maier et al., 2005)
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was again the system of choice. Since the precipitation of E2 in the DG75 cellular background
was rather inefficient using standard antibodies (Master thesis Jasmin Schwarz, 2014 and
experiments by Sybille Thumann) an HA-tagged E2 was introduced in the pRTR vector
(Fig. 29A) which was subsequently transfected in DG75/CBF1 wt and ko parental cell lines
respectively (conducted by Cornelia Kuklik-Roos). E2 inducibility of the obtained cell lines was
monitored by FACS analysis and cell line integrity was confirmed by western blot experiments
(Fig. 29B and C).
Figure 29. Stable DG75 EBV negative B cell lines proficient or deficient for CBF1 conditionally express
HA-E2. (A) Simplified schematic map of the pRTRdoxHA-E2 vector used to generate stable DG75 cell lines. The
coding sequence for E2 fused to a N-terminal HA-tag (HA-E2) with a preceding intron of the beta-globin gene for
enhanced expression was cloned into the pRTR vector (Jackstadt et al., 2013, Bornkamm et al., 2005) using SfiI
restriction sites. The bidirectional promoter (Ptetbi-1) simultaneously drives the expression of HA-E2 in one and the
bicistronic reporter construct of a truncated nerve growth factor receptor gene (tNGFR) and enhanced green
fluorescent protein (eGFP) gene in the other direction upon doxycycline induction. A truncated CD2 gene from rat
which is constitutively expressed from SV40 promoter allows further selection of transfected cells. (B) Expression of
HA-E2 was induced with 1 µg/ml doxycycline for 24 h and monitored by quantifying eGFP expression via flow
cytometry and scored at least 89% with a maximum of 5% difference between DG75/CBF1 wt and ko. Data from
one representative experiment (n=3) and percentages of induced cells are shown. (C) Western Blot analysis
confirming the expression of HA-E2 in DG75doxHA-E2 cell lines upon 24 h induction with 1 µg/ml doxycycline and
the absence of CBF1 expression in DG75doxHA-E2/CBF1 ko cell line. GAPDH was used as internal loading control.
EBV positive LCL 721 lysate serves as a positive control for protein expression levels. Same amount of total protein
lysate was loaded for each sample but for the E2 blot. Here a 1:10 dilution of DG75 lysates compared to 721 was
loaded due to high E2 expression levels.
E2 expression could only be detected upon addition of doxycycline, in FACS analyses
monitoring the surrogate marker GFP as well as in western blot experiments, confirming a
reliable expression system. E2 expression levels did not noticeably differ between
DG75doxHA-E2/CBF1 wt or ko lines but were approx. ten-fold elevated over LCL (721) levels. To
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confirm the correct parental DG75 cell lines, CBF1 expression status was evaluated as well.
Furthermore, the expression levels of TFs IRF4, BATF, and EBF1, which were identified in this
work to correlate with E2 or E3 binding patterns, were assessed. IRF4 could not be detected at
all and BATF was reduced compared to LCL, while EBF1 expression was comparable to LCL
levels (Fig 29C).
Next, the ChIP protocol had to be optimized for the application in DG75 cells as well as
for the used antibodies (see chapter 3.5.4.2). The combination of an HA-tag specific antibody
and two different antibodies directed against E2 were the most efficient approach for ChIP in
this case (data not shown). The success of the E2 ChIP in DG75doxHA-E2 in  CBF1  wt  and  ko
background was determined by ChIP-qPCR evaluating regions which were identified as E2
binding sites in the E2 ChIP-seq in LCL (Fig. 30).
Figure 30. Successful detection of specific HA-E2 chromatin interactions by ChIP-qPCR in the inducible
DG75 cell system. E2 ChIP was performed in DG75doxHA-E2/CBF1 wt and ko respectively upon induction of E2
expression as described in chapter 3.5.4.2. Recovered DNA was analyzed for enriched regions by qPCR applying
primers specific for known E2 binding sites (underlined, detected in LCL, chapter 4.2). As negative control for
unspecific DNA enrichment, the E2 ChIP was performed using uninduced cells for chromatin preparation as well.
Percent input values for each genomic region were calculated and these background values were subtracted from
values of induced samples respectively. Relative ChIP enrichment over negative control regions (*) with no known
TF binding site in LCL were calculated. One representative experiment is shown (n=2). Binding sites in (A)
proximity to ADAM28 and ADAMDEC1 as well as (B) CXCL9 and -10 have been described (chapter 4.2.5.4,
Fig. 24). (C) Schematic representation of the genomic region of approx. 300 kb upstream of MED13L including two
significant E2 binding sites in LCL (E1 and E2). Signal intensities of E2, CBF1 (Zhao et al., 2011b), E3A, and E3C
are shown with the scale set to 3x the mean value of each track. Positions of ChIP-qPCR primers are indicated and
RefSeq genes are shown. (D) E2 ChIP-qPCR analysis of the genomic region depicted in (C).
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Here, E2 could be detected at the intergenic enhancer (E1) between ADAM28 and
ADAMDEC1 and at the ADAMDEC1 intragenic enhancer (E2) in DG75doxHA-E2/CBF1 wt cell
line and binding was severely impaired in the CBF1 ko but still above unspecific background
levels (Fig. 30A). Interestingly, at the intergenic enhancer E1 within the genomic region
encompassing CXCL9 and CXCL10, a significant E2 binding site in LCL, no E2 binding in
neither DG75doxHA-E2/CBF1 wt nor ko cell line could be detected (Fig. 30B). At a third genomic
region, upstream of E3A and E3C target gene MED13L (Hertle et al., 2009, and our unpublished
results from E3C ko LCLs), two E2 binding sites were identified in LCL and could now also be
detected in DG75doxHA-E2/CBF1 wt cell line (Fig. 30C). E2 binding in DG75doxHA-E2/CBF1 ko at
E1 and E2 upstream of MED13L could not be detected any more.
These selective E2 ChIP-qPCR analyses did show a successful and specific precipitation of
E2 in the DG75doxHA-E2/CBF1 wt and even some enrichment in the CBF1 ko background, at least
at one genomic locus. Therefore, the same samples analyzed by qPCR were subjected to deep-
sequencing (ChIP-seq) for a genome wide analysis of CBF1 dependent E2 chromatin binding.
Identification of E2 binding sites in DG75 cell lines proficient or4.3.2
deficient for CBF1
The data obtained from E2 ChIP-seq experiments in DG75doxHA-E2/CBF1 wt and ko cell lines
was subjected to the same bioinformatic pipeline as described in chapter 4.2.1.4 (schematic
depiction in Fig. 13) to identify binding sites in the human genome and to generate signal tracks.
However, in this case overrepresented sequences were rarely detectable and the overall quality of
the obtained reads as assessed by FastQC quality control tool was very good (data not shown), so
demultiplexed reads were directly subjected to mapping to the human genome (hg19) without a
prior trimming step.  An overview of the sequenced samples and data obtained directly from
sequencing and mapping is shown below (Table 22).
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Table 22. E2 ChIP-seq in DG75 cell lines - Perceived reads after different workflow steps and mapping to
the human genome
DG75
Cell
Line
Replicate -
Sample
Type
Read Count
Internal
Designation
Demultiplexed
Mappable
(% of
Demultiplxed)
Uniquely Mappable
(% of
Demultiplexed)
CBF1
wt
E2-I-ChIP 17,455,101 94.81 69.06 LG620_wt_E2
E2-I-input 19,901,128 97.69 70.21 LG620_wt_input
E2-II-ChIP 34,613,332 94.78 68.89 LG625_wt_E2
E2-II-input 27,927,224 97.93 70.56 LG625_wt_input
CBF1
ko
E2-I-ChIP 17,320,583 97.15 69.82 LG620_ko_E2
E2-I-input 20,294,961 97.48 69.64 LG620_ko_input
E2-II-ChIP 25,601,620 97.21 70.81 LG625_ko_E2
E2-II-input 29,324,523 97.66 70.28 LG625_ko_input
Reads obtained after demultiplexing were directly subjected to Bowtie2 software for mapping to the human genome
(hg19).
Significant E2 binding sites could well be detected in both DG75doxHA-E2/CBF1 wt and ko cell
lines (Table 23) applying the pipeline described in chapter 4.2.1.2 where biological ChIP-seq
replicates were merged.
Table 23. E2 ChIP-seq in DG75 cell lines - Peaks identified in the human genome using MACS2
DG75
Cell
LIne
Subjected to
MACS2
Read Count Allowed
Duplicate
Tags
Redundancy
Rate (%) E2 Peaks
Merged
Mapped Reads
Filtered
CBF1
wt
E2-ChIP 49,354,861 48,526,538 2 1.68
1,937
E2-input 46,790,793 45,788,697 2 2.14
CBF1
ko
E2-ChIP 41,714,810 41,006,646 2 1.70
429
E2-input 48,423,478 47,262,377 2 2.40
Mapped reads of replicates were merged and subjected to MACS2 peak calling algorithm. Here reads were filtered
for allowed duplicate tags, which represent maximum permitted reads mapping to the exact same position. This
value is calculated by MACS2 in accordance with absolute read count and genome coverage. The redundancy rate is
indicating the percentage of duplicate reads not allowed and displays a measurement for library complexity.
Also in this case identified peaks were submitted to further quality control steps (described in
4.2.1.2) before gaining a final peak list (Table 24) which then could be subjected to further
bioinformatic analyses.
Table 24. E2 ChIP-seq in DG75 cell lines - Signal and mappability corrected peaks in the human genome
DG75 Cell
Line
Identified by
MACS2
Signal
corrected
Blacklist
corrected
GM12878
compatible
% of MACS2
peaks
CBF1 wt 1,937 1,818 1,793 1,789 92.4
CBF1 ko 429 286 271 271 63.2
Peaks identified by MACS2 were further filtered to exclude peaks which display a negative amplitude, fall on
blacklisted regions or a chromosome not compatible with GM12878, the LCL used by ENCODE.
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E2 binding sites in DG75 cell line differ from those identified in LCLs4.3.3
due to cell line specific enhancer signatures
Comparing the total of 1,789 detected E2 peaks in DG75doxHA-E2/CBF1 wt with the 22,500
identified peaks in LCL described in chapter 4.2, a relevant difference in absolute numbers
becomes evident. Several reasons could contribute to this finding. Low library complexity and
poor read qualities could be excluded by FastQC quality control. Poor enrichment in the
immunoprecipitation is not very like as predicted by qPCR analyses.
DG75 is an EBV negative Burkitt’s lymphoma cell line harboring a t(8:14)(q24;q32)
translocation bringing MYC under the control of the IGH gene locus and therefore driving
proliferation (Ben-Bassat et al., 1977). In LCLs on the other hand EBV, with E2 as one of the
most important factors, is the driving cause and indispensable for proliferation and
immortalization. During immortalization the B cell changes its phenotype and becomes more
similar to a activated B cell (reviewed in Thorley-Lawson, 2001). This process is accompanied by
changes gene expression patterns and therefore also in the chromatin landscape, partly directly
mediated by E3 proteins. This could be shown for several exemplary genomic regions (reviewed
in Allday et al., 2015).
However, the DG75 cell line displays a completely different cellular system than LCL
which is not in need of external pro proliferative signals and therefore very likely also exhibits a
different chromatin landscape than LCL. Recently, a study on methylome analyses in different
lymphomas, including information on important genome wide histone modifications in DG75,
was published and sequencing data is now publically available (Kretzmer et al., 2015).
Comparing enhancer defining chromatin modifications at E2 binding sites in
DG75doxHA-E2/CBF1 wt with those in LCLs an interesting picture emerged where DG75 and LCL
indeed differ significantly in their chromatin signatures (Fig. 31). To this end the available raw
ChIP-seq data on histone modifications in DG75 and LCL was processed applying the self-
generated bioinformatics pipeline for the identification of peaks and generation of signal tracks as
described in chapter 3.6.1.
The majority of E2 binding sites in DG75doxHA-E2/CBF1 wt is also present in LCL (1,325
LCL/DG75 shared sites = 74.1%) but both cell lines exhibit specific E2 binding sites (Fig. 31A).
The E2 signal in LCLs was the highest at the LCL/DG75 shared binding sites, while E2 signal
did only slightly differ between these shared and DG75 unique sites in DG75 (Fig. 31B).
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Figure 31. E2 binding sites in DG75 differ from those in LCL but are also located at cell line specific
enhancers. (A) Intersection of E2 binding sites identified in LCLs and DG75doxHA-E2/CBF1 wt. Anchor plots
showing (B) E2 signals or (C) signals of histone modifications associated with active chromatin and enhancer state at
E2 binding sites in LCL (ENCODE_Consortium, 2012) and DG75 (Kretzmer et al., 2015) cell line. Here, the mean
normalized signal for each signal and peak subset was calculated for the region spanning 20 kb in each direction of
E2 peak centers. Absolute numbers for signal intensities for the same histone modification cannot be compared
between the two cell lines since the experiments were conducted at different laboratories also using different
antibodies. Generation of the signal tracks for this analysis was performed applying the same data processing
workflow for both data sets.
Investigating the three subgroups of E2 peaks, LCL/DG75 shared, LCL unique, and DG75
unique, separately for present histone modifications in the two different cell lines respectively, the
LCL/DG75 shared E2 sites stand out as the subsets with the most prominent enrichment for all
three investigated histone modifications (H3K4me1, H3K4me3, and H33K27ac) associated with
active enhancers (Fig. 31C). Furthermore, it could be shown that the DG75 unique E2 binding
sites display the lowest enrichment for all three investigated histone modifications in LCL, while
the LCL unique E2 sites show the poorest enrichment in DG75.
Another point to be mentioned apart from different patterns of chromatin landscape
between LCL and DG75 is the difference in expression of TFs. The DG75 cell lines used in the
experiments conducted in this thesis are not expressing IRF4 and BATF only to a reduced extend
(Fig. 29C). Evaluation of transcript levels detected by gene expression arrays in DG75,
performed (by Sybille Thumann) to gain insights on E2 target genes, revealed several TFs which
are only expressed at very low levels, while E2 associated factors EBF1 and CUX1 are
transcribed at much higher levels (Fig. 32A). Among the TFs of the ENCODE ChIP-seq panel 7
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factors, including IRF4 and BATF, were transcribed at very low levels with unsure protein
expression status. MTA3 could be identified as part of the E3 cluster of positively correlating
TFs on a genome wide level (Fig. 22). Since E2 and E3 clusters show also inter-connection, the
depletion of MTA3 could also have a moderate impact on E2 binding in DG75. The other 4 TFs
could not be identified to correlate with E2 signals in any of the conducted approaches and
therefore are very unlikely to have an impact on E2 accession to chromatin in DG75 cell line.
Figure 32. TFs expressed at very low levels in DG75 parental cell lines are enriched at LCL unique E2
binding sites. (A) RMA expression levels as received from gene expression analysis (GeneChIP® Human Gene 2.0
ST, PhD thesis Sybille Thuman) applying cDNA from parental DG75 cell lines, proficient and deficient for CBF1.
An RMA value of 100 displays an approximate threshold for reliable detection of transcription. Only TFs of the
ENCODE ChIP-seq panel were included in analyses for expression levels in DG75. (B and C) Anchorplots
depicting TF signals at the three subsets of cell line specific E2 peaks. A region of 2 kb in each direction from peaks
centers  was  analyzed.  (B)  TFs  identified  to  be  correlating  with  E2  signal  in  LCL  and  (C)  TFs  not  or  very  low
expressed in DG75 were included.
Information on TF enrichment, derived from LCL, at E2 binding sites was assessed as well and
first a pattern very similar to the ones for histone modifications emerged for E2 associated TFs
(Fig. 32B) but also for many other TFs (data not shown). Interestingly, BATF and IRF which are
not expressed or only at very low levels in DG75 were showing very high enrichments at the
LCL unique E2 binding sites indicating a role for those two TFs for E2 accession to these very
binding sites.
In summary, chromatin landscape and TF expression in DG75 parental cell lines differ
considerably from those present in LCL and therefore change accessibility of certain E2 binding
sites. The E2 peaks which can be detected in both cell lines therefore display strong B cell
enhancers which are most likely generally important for B cell identity.
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E2 binding to chromatin is strongly but not exclusively dependent on4.3.4
CBF1
Within the DG75 cell system 271 E2 binding sites could be detected in the CBF1 ko situation
accounting for 15.1% of the peaks in CBF1 wt (Fig. 33A). More specifically, 243 CBF1
independent E2 peaks could be identified which are present in both cell lines independent of
CBF1 expression (CBF1 independent). 1,546 E2 sites could only be detected in the
DG75doxHA-E2/CBF1 wt cell line and therefore are CBF1 dependent E2 peaks. A small subset of 28
peaks could only be identified in DG75doxHA-E2/CBF1 ko designated as ko unique E2 peaks.
Figure 33. Chromatin binding of EBNA2 is mainly but not exclusively dependent on CBF1. Comparison of
E2 binding sites detected in DG75doxHA-E2/CBF1 wt and ko cell lines. (A) E2 peaks in DG75 cell line with CBF1 wt
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or ko background were identified using MACS2. Peaks were subdivided according to their dependence on CBF1
expression. (B) Comparison of mean normalized ChIP-seq signal for E2 in DG75doxHA-E2/CBF1 wt and ko
background. (Here signal intensities are comparable since the same antibodies for the HA-E2 construct could be
used in both cell lines and the expression levels are comparable). (C) The scatter plot shows the distribution of signal
intensities and the mean with a 95% confidence interval of the mean normalized signal for E2 peaks in DG75/CBF1
wt or ko for a region flanking the peak center for 2 kb in each direction (Data underlying panel B). Signal means and
SEMs are indicated below. (D) Anchorplots depicting signal intensities at CBF1 independent or dependent and ko
unique EBNA2 peak subsets as defined in A. (E) Signal distribution of data underlying panel D, means and 95%
confidence intervals are indicated. Statistical significance for differences of all means were assessed applying unpaired
two-tailed t-test for log values with Welch’s correction (**** p<0.0001); absolute means and SEMs are indicated
below.
The mean E2 signal distribution and enrichment at E2 peaks in DG75doxHA-E2/CBF1 wt is very
similar to the one observed at E2 peaks in the CBF1 ko situation (Fig. 33B). However, taking a
closer look at the mean signal distribution over all peaks it becomes evident that E2 signal is 1.4
fold higher in DG75doxHA-E2/CBF1 wt than in the ko situation (Fig. 33C). Importantly, E2 signal
intensities of the two different ChIP-seq experiments can be directly compared in this case, since
the same protein, expressed in similar quantities, using the same antibodies was precipitated
under the same experimental conditions and ChIP-seq data was analyzed and normalized
applying the same pipeline.
Even more dramatic becomes this effect when observing E2 signal intensities at the three
E2 peaks subsets, CBF1 independent, dependent, and ko unique, separately. E2 signal is most
enriched at CBF1 independent E2 binding sites, in DG75doxHA-E2/CBF1 wt as well as in CBF1 ko
cell line but the total signal is the highest in the CBF1 wt situation (Fig. 33D and E). Hence, the
strongest E2 binding sites in DG75 cell line are the ones that can still be detected in the CBF1 ko
situation. Interestingly, the E2 binding sites detected in DG75 display a similar E2 signal
distribution pattern in LCL as in the CBF1 wt situation. Here, CBF1 independent E2 peaks,
detected in DG75, display the highest E2 enrichment as well, followed by CBF1 dependent and
then ko unique peaks.
Taken together, significant E2 binding sites could be detected even in the absence of
CBF1, but display a lower mean E2 enrichment and the strongest binding sites in the CBF1 wt
situation. It seems to be very likely that other TFs contribute to the high enrichment of E2 at
CBF1 independent peaks which allow accession to chromatin even in the absence of CBF1.
E2 targets strong enhancer in DG75 independent of CBF1 expression4.3.5
status
The identified CBF1 independent E2 peaks in DG75 cell line exhibit very high E2 signal
intensities suggesting a potential involvement of strong enhancers as a prerequisite for high E2
signal intensities. To stress this idea CBF1 independent and dependent E2 peaks detected in
DG75 were now analyzed for the prevalent histone modifications at those regions. To this end
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ChIP-seq data on H3K4me1, H3K4me3, and H3K27ac (Kretzmer et al., 2015), characteristic for
active enhancer elements were analyzed for their abundance at the different E2 peak subsets
(Fig. 34).
Figure 34. CBF1 independent and dependent E2 binding sites in DG75 display almost identical histone
modification patterns defining enhancer activity. CBF1 dependent and independent E2 binding sites identified
in DG75 were analyzed for enhancer associated histone modifications. The normalized ChIP signals for the regions
spanning 20 kb in each direction from peak center were used. (A) Anchor plots showing the histone modification
signal profiles at E2 peak subsets. Peaks for each analyzed modification were used as references for average positive
signals and model profiles. In (B) the data underlying panel (A) were used to generate boxplots depicting the signal
distributions over the whole regions of 40 kb. Significances of differences of means were assessed applying unpaired
two-tailed t-tests with Welch’s correction (**** p<0.0001, *** p<0.001). The differences of means for CBF1
independent and dependent E2 peaks were not statistically significant (p= 0.706, 0.7595, and 0.1396 respectively).
Boxplot whiskers extend to 1.5x interquartile range. (C) Table depicting means and SEMs of histone modification
signals at peaks described in (A) and (B).
As a matter of fact, all three investigated enhancer defining histone modifications did not
significantly differ in their signal intensities at CBF1 independent and dependent E2 peaks in
DG75. Noticeably, H3K4me1 was 2.9x higher at both E2 peak subsets than at the average
H3K4me1 peak in DG75 (Fig. 34A and B, left panels) indicating targeting of strong enhancers.
Therefore a strong enhancer signature is not the defining feature of a CBF1 independent E2
binding site but rather as implicated in previous chapter, most likely the co-occurrence of specific
TFs besides CBF1.
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EBF1 as a potential chromatin anchor for E2 in the absence of CBF14.3.6
4.3.6.1 EBF1 is enriched at CBF1 independent E2 binding sites in LCL
In order to investigate how E2 accesses chromatin in the absence of CBF1 a de novo TF DNA
sequence motifs search was performed to get a first idea about possible enriched motifs since no
TF ChIP-seq experiments in DG75 were available. Applying MEME-ChIP (Machanick and
Bailey, 2011) on CBF1 independent and 243 randomly selected CBF1 dependent E2 peaks, to
account for the big differences in sample size, only two motifs could be discovered which match
described TF sequence motifs: While both, the CBF1 and the EBF1 motif, could be discovered
at CBF1 dependent E2 peaks, only the EBF1 motif was significantly enriched at CBF1
dependent E2 sites (Fig. 35A).
Figure 35. EBF1 is significantly enriched at CBF1 independent E2 peaks in LCLs. (A) Comparison of
enriched DNA sequence motifs discovered at CBF1 independent and dependent E2 binding sites in DG75 cell lines
using MEME-ChIP motif discovery tool (Machanick and Bailey, 2011). E-values for statistical significance of
discovery and the TF most likely to recognize them as predicted by TOMTOM (Gupta et al., 2007) (scanning
hocomoco v9 database) are shown. For this analysis 243 out of 1546 total CBF1 dependent E2 peaks were randomly
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chosen for better comparison of E-values between two different sized populations. No significantly enriched motifs
could be detected for CBF1 ko unique E2 peaks. (B) Anchor plots depicting mean normalized ChIP-seq signals for
TFs derived from LCL at E2 binding sites identified in DG75 cell lines. Peaks of each investigated TF were used as
references for average positive signals and model profiles. (C) The underlying data of panel (B) were used to generate
boxplots depicting signal distributions. An unpaired two-tailed t-test with Welch’s correction (**** p<0.0001) was
performed to determine significant differences between means. The differences between the means for CBF1
independent and dependent E2 peaks were -2.892 ± 9.972, -93.82 ± 12.89, and -1.17 ± 0.622, for CBF1, EBF1, and
CUX1 respectively and only statistically significant for the EBF1 signal (p= 0.772, 3.834E-12, and 0.069
respectively). Boxplot whiskers extend to 1.5x interquartile range.
Since EBF1 was also detected in the previous correlation analyses for E2 associated factors in
LCL (4.2.5.5.1), this finding was particularly interesting. To get further insights on the
contribution of TFs apart from CBF1 on E2 accession to chromatin, ChIP-seq information
derived from ENCODE in LCL was analyzed for enrichment at E2 binding sites as detected in
DG75, since those peaks show a very similar E2 signal distribution in DG75 and LCL (Fig. 33D).
While CBF1 enrichment in LCL was not significantly different between CBF1 independent and
dependent E2 binding sites, a highly significant enrichment of EBF1 at CBF1 independent over
dependent E2 sites could be detected (Fig. 35B and C). CBF1 independent and dependent E2
peaks were also investigated for CUX1 signal in LCL, the second TF identified in the EBNA
peak correlation analysis (4.2.5.5.1), but no significant enrichment of CBF1 independent over
dependent E2 peaks could be identified. Moreover, the CUX1 sequence motif could not be
identified in the MEME-ChIP motif enrichment analysis which indicates no important role for
CUX1 in the presence of CBF1 independent chromatin binding of E2.
In summary, the enrichment analysis for sequence motifs at CBF1 independent and
dependent E2 binding sites as well as the signal enrichment analyses for TFs in LCLs at those
sites revealed a potential role of EBF1 in mediating chromatin access of E2 in the absence of
CBF1.
Already the genome wide correlation analyses for TF binding patterns in LCL (4.2.5.3)
showed a strong positive correlation of E2 and EBF1, almost in the range of E2 and CBF1
interaction. Signal correlation analyses restricted to E2 peaks as reference regions did show
similar results (Fig. 36A). Here E2 showed an rs of 0.46 and 0.40 in comparison to CBF1 and
EBF1, respectively. For this analysis, also the correlation of E2 in comparison to PU.1 signal was
examined, since, as described in the introduction of chapter 4.3, PU.1 was considered to be a
potential adaptor protein for E2 several times in the literature. Nevertheless, neither correlation
analyses on an E2 peaks wide or on a genome wide scale (Fig. 36A and B) nor motif enrichment
analyses did show any potential involvement of PU.1 in CBF1 independent chromatin accession
of E2. EBF1 on the other hand was revealed as a potential adaptor protein or chromatin access
mediating factor for E2 action.
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Figure 36. EBF1 shows a strong binding pattern correlation to E2, similar to known adaptor protein CBF1.
In (A) E2 binding sites were investigated for signal intensities of other TFs. For every E2 peak the relative mean
normalized E2 signal was plotted against the ones of E2 (perfect correlation), CBF1, PU.1 and EBF1 respectively.
To obtain relative values, the highest peak signal was set to 1 and the other values were scaled accordingly. Each dot
represents one E2 peak. Correlation analyses were performed and Spearman correlation coefficients (rs) were
calculated.  E2  shows  an  rs of 1.0, 0.46, 0.19, and 0.40 in comparison with E2 itself, CBF1, PU.1, and EBF1
respectively. (B) Correlation matrix showing signal pattern correlations for different ChIP-seq experiments on a
genome wide scale. The human genome was divided in 100 bp bins and mapped reads for each experiment were
counted for each bin. A correlation coefficient using Spearman correlation was calculated for each pair and is
displayed and color coded in the matrix.
4.3.6.2 E2 and EBF1 protein-protein interaction in DG75 cell line
Since the bioinformatic analysis of CBF1 independent E2 binding sites in DG75 strongly
indicated a functional role of EBF1 in chromatin accession of E2, the protein-protein interaction
properties of E2 and EBF1 were assessed in Co-IP experiments (conducted by Cornelia Kuklik-
Roos). Here, EBF1 was pulled down from DG75doxHA-E2 cell lysates after transfection with an
EBF1 expression plasmid (kindly provided by Prof. M. Sigvardsson, Lund University, Sweden;
Mega et al. 2011) or corresponding empty plasmid and interaction with E2 was assessed in
western blot experiments (Fig. 37). To this end, DG75doxHA-E2 proficient but also deficient for
CBF1 were used to restore the environment in which CBF1 independent E2 binding to
chromatin could be detected. In a CBF1 competent DG75 background, a competition of CBF1
with EBF1 for E2 binding could be a possible scenario and a weak E2-EBF1 interaction might
be unable to detect by this method.
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Figure 37. E2 and EBF1 protein-protein interaction could be detected in DG75doxHA-E2/CBF1 wt and ko
cell lines. Co-IP experiments using EBF specific antibodies for IP were conducted 24 h after transfection of empty
(pCDNA3) or EBF1-myc expression plasmid (pCDNA3.EBF1-5xmyc). Induction of HA-E2 expression by addition
of Dox was performed directly after transfection. Total cell lysates (L) display 1% of the cells used for IP samples.
One representative experiment is shown (n=2).
However, the Co-IP experiments in DG75doxHA-E2/CBF1 wt and ko cells revealed a robust
interaction of E2 with EBF1 upon EBF1 transfection and induction of E2 expression (Fig. 37)
while the interaction between E2 with endogenously expressed EBF1 could only be detected in
the CBF1 ko upon longer exposure times (Fig. 37, bottom right panel). This interaction could not
be detected in the CBF1 wt situation (Fig. 37, bottom left panel), which is most probably due to
overall lower E2 expression levels in the CBF1 wt cells (experiments are currently repeated by C.
Kuklik-Roos with adjusted E2 expression levels). Furthermore, EBF1 is only expressed at very
low endogenous levels and therefore only detectable in cell lysates by western blot upon very
long exposure times, which lead to overexposure of other detected bands (data not shown).
Co-IP experiments pulling-down E2 from DG75doxHA-E2 cell lysates with subsequent testing
for EBF1 binding as well as confirmation of the interaction of endogenously expressed E2 and
EBF1 in LCL is currently in preparation and could not be included in this thesis but certainly will
shed light on the significance of E2-EBF1 protein-protein interaction.
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5 Discussion
5.1 Epitope tagged E3A or E3C expressing LCLs as a versatile
cellular system for studying chromatin interactions
The essential role of EBV encoded latent proteins E2, E3A, and E3C in infection and
immortalization of primary B cells has been subject to many studies and the mechanisms by
which they achieve specific gene regulation is still extensively researched (reviewed in Allday et
al., 2015, and Kempkes and Ling, 2015). One important aspect of their distinct functions as TFs
is the accession to chromatin and the targeting of certain functional elements. To gain
information on binding sites of TFs in the human genome, ChIP-seq is the current standard
method. However, the success of this method largely depends on the efficiency of the IP
reaction. In the case of E2 highly specific antibodies suitable for IP were available and also other
laboratories were able to perform successful E2 ChIP-seq experiments in LCL (Zhao et al.,
2011b) and Mutu III, a Burkitt’s lymphoma cell line showing type III latency expression pattern
(McClellan et al., 2012).
The precipitation of E3A and also E3C proofed to be more difficult since no antibodies
suitable for ChIP experiments were commercially available. Also other researchers were facing
the same challenge and thus were using antibodies which are not specific for one distinct E3
protein but rather recognize all three E3 members (McClellan et al., 2012). In this study,
individual E3 binding sites were further investigated by ChIP-qPCR in EBV negative Burkitt’s
lymphoma cell lines each ectopically expressing only one E3 protein. This approach could not
give information on genome wide binding and therefore other strategies had to be developed to
address this matter.
In the first part of this thesis the successful generation of LCLs, infected with recombinant
EBV genomes, expressing Flag-tagged E3A or E3C could be demonstrated. Applying the
recombineering technique (Warming et al., 2005), taking advantage of one selection marker which
could be used for both, positive and negative selection of targeted genomes, it was possible to
integrate the Flag-tag N-terminal and in frame to E3A or E3C respectively, without the
permanent integration of selection markers and or recombination sites by established methods
(as applied in Hertle et al., 2009, method adopted from Cherepanov and Wackernagel, 1995).
Recombineering is a trending technique in manipulation of γ-herpesvirus genomes in general
(reviewed in Warden et al., 2011) due to high targeting efficiencies (> 95%), the elegant usage of
galK as positive and negative selection marker with its subsequent traceless elimination, and the
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versatility of possible insertions, deletions, inversions, and point mutations. Furthermore, every
BAC construct containing the galK gene at a position of interest can serve as starting point for the
generation of various mutants e.g. for testing of different point mutations, and the cloning
procedure does not have to be repeated for the first targeting step. Thus, this method was not
only applied to generate recombinant EBV genomes (Seto et al., 2010, Jochum et al., 2012,
Steinbruck et al., 2015) but was also used for manipulation of other γ-herpesvirus genomes such
as KSHV (Wakeman et al., 2014, Bellare et al., 2015) and MHV68 (Rangaswamy et al., 2014,
Rangaswamy and Speck, 2014).
The recent discovery and now commercial availability of Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR)/Cas9 based genome editing strategies (Jinek et al., 2012), which
shows dramatic improvement in efficiency and feasibility of precisely targeting genomic regions
without leaving any traces, probably heralds a new age of genome editing possibilities. However,
the EBV genome is relatively small (approx. 172 kb) compared to the human genome (approx.
3,234 Mb), is present in the cell as multiple copies, and involves the possibility to use the
BACmid based EBV system. This includes the advantages of genome targeting and propagation
in bacteria as well as the traceability by eGFP and selection marker expression. Therefore
recombineering or related methods most probably will stay the method of choice for fast and
effective generation of recombinant EBV strains.
The recombinant LCLs generated in this work did show latent EBV protein expression
levels comparable to LCLs infected with wt EBV (Fig. 9C and D) and are not impaired in
viability. Neither they are impaired in their protein-protein interaction with the DNA binding
cellular protein CBF1, when pulled-down using Flag-tag specific antibodies (Fig. 10), nor in the
repression of three well described target genes compared to wt LCLs (Fig. 11). Thus, these LCLs
combine the advantage of ChIP specificity due to epitope-tagged proteins, as pointed out by the
ENCODE project (Landt et al., 2012), with endogenous expression levels, since the epitope-tag
coding sequence was integrated in the viral genome.
Simultaneously, other research groups were addressing the challenge of E3 protein
precipitation in ChIP experiments with similar approaches of generating recombinant EBV
genomes expressing epitope-tagged versions of E3 proteins. One group introduced a
combination of Flag- and HA-tag C-terminally fused to E3C (E3C-F-HA) (Jiang et al., 2014) and
E3A (E3A-F-HA) (Schmidt et al., 2015), respectively, in order to perform ChIP-seq experiments.
Another study inserted a Strep-Flag-tag C-terminally fused to E3C within the EBV BAC system
and subsequently infected BL31 EBV negative Burkitt’s lymphoma cells with the derived
recombinant viruses to perform E3C specific ChIP-qPCR experiments (Paschos et al., 2012). In
contrast to these studies, the 3x Flag-tag used in this work was inserted N-terminally to E3A and
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E3C, respectively. This choice was based on predicted secondary structures of the E3 proteins,
where the N-terminal regions, covering the E3-family homology domain, are predicted to form
α-helices and some β-strands while no ordered structures could be predicted for the C-terminal
regions (Yenamandra et al., 2009). It has been described that disordered structures within
proteins can display very important functions and might only form distinct secondary structures
upon binding to interaction partners (Uversky, 2013). Also within the E3 proteins several
functional repressor domains as well as many potential interacting proteins could be mapped to the
C-terminal regions (reviewed in Allday et al., 2015). In order to preserve potential and not well
understood functions of the C-terminal regions, the N-termini of E3A and E3C were targeted in
this thesis.
As mentioned above, E3A and E3C were not impaired in their protein-protein interaction
with CBF1 (Fig. 10), which have been described as very important for B cell transformation for
both viral proteins (Maruo et al., 2005, Maruo et al., 2009). E3A and E3C interaction could also
be detected by Flag-E3A as well as Flag-E3C pull-down in this thesis (Fig. 10). The formation of
E3A and E3C complexes has been described previously by a Y2H screen (Calderwood et al.,
2007) and could be confirmed by Co-IP experiments in B cells (Paschos et al., 2012). This
interaction could already be identified in LCLs by the Kempkes group and furthermore the
binding regions could be mapped to both N-terminal regions in HEK293 transfection
experiments (dissertation S. Petermann, 2009).
Interestingly, in this thesis the protein-protein interaction of E3A and E3B could be
demonstrated for the first time (Fig. 10) but was not further characterized.
Contrarily, a recent study to identify E3 protein interaction partners by tandem affinity
purification (TAP) followed by mass-spec analysis of Flag-HA-tagged E3A, E3B, and E3C proteins
did not reveal any E3 heterodimers but confirmed complexes of each investigated E3 with CBF1
and thus concluded the formation of distinct E3-CBF1 complexes (Ohashi et al., 2015). This
finding could be due to experimental settings such as the integration of C-terminal tags as
opposite to the N-terminal targeting in this thesis or harsher pull-down conditions. However, the
study by Ohashi and colleagues underlines the strong binding of each E3 protein to CBF1 but
the collective evidence by our group and Calderwood et al., collected in different cellular systems,
investigating endogenous and transfected proteins, strongly indicates the formation of E3A and
E3C as well as E3A and E3B heterodimers. The functional relevance and occurrence of those
complexes in association with chromatin has yet to be determined. Some aspects of E3A and
E3C binding within the human genome and their co-operation will be discussed in the following
chapter.
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5.2 EBNA transcription factors – exploiting enhancer elements
The overall aim of the second part of this thesis was the elaboration of the interplay of E2 as an
activator and E3A and E3C as potential repressors of transcription by investigating chromatin
binding and the associated prerequisites and co-occurring factors as the basis of EBNA protein
mediated gene regulation. This question was addressed by performing and analyzing ChIP-seq
experiments for E2, E3A, and E3C and the subsequent comparison with different data sets
published by the ENCODE consortium.
Identification of E3, E3A, and E3C binding sites by ChIP-seq5.2.1
At first the establishment of the ChIP-assay for Flag-tagged E3A and E3C was described and the
successful deep-sequencing of the associated DNA fragments as well as the bioinformatic
analysis and identification of significant binding sites could be shown. Here, each step from
biochemistry to bioinformatics was controlled carefully and high quality results were obtained as
discussed in the following.
Biochemistry
The cross-linking step of a standard ChIP-assay was successfully optimized to account for the
indirect binding to DNA of the EBNA proteins applying disuccinimidyl glutarate (DSG) as an
additional cross-linking reagent prior to formaldehyde (FA) treatment (Fig. 12). The beneficial
impact of performing a dual cross-link using NHS-esters like DSG on ChIP efficiencies when
precipitating TFs acting in complexes could already be described e.g. for NFκB (Nowak et al.,
2008), STAT3, CDK9, PolII (Hou et al., 2007), and FOXM1 (Khongkow et al., 2014).
Furthermore, the dual cross-linking procedure using DSG was applied for ChIP of the SWI/SNF
chromatin-remodeling complex subunit SNF5 (Wilson et al., 2010). More recently, DSG dual
cross-linking was applied in a genome wide approach to identify proteins which bind to enhancer
or promoter elements in a cell specific manner by ChIP of distinct histone modifications defining
functional chromatin elements and subsequent mass-spec analysis of associated proteins
(Engelen et al., 2015).
Further steps of the ChIP protocol, specific for subsequent deep sequencing, were
optimized and controlled mainly based on guidelines published by the ENCODE consortium
(Landt et al., 2012).
Bioinformatic Analysis – Comparison to other studies on EBNA proteins
The bioinformatic analysis pipeline (Fig. 13) was constructed independently using the Galaxy
platform (Giardine et al., 2005), which displayed the great advantage of traceability of each
performed step, since complete workflows can be downloaded, shared, and recapitulated using
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(the public) Galaxy server. Currently, more than 2,000 datasets are publicly available through
Galaxy (Afgan et al., 2016).
The primary ChIP-seq data obtained in this thesis displayed very good quality features as
assessed by FastQC (Table 16) and percentages of mapped reads (Table 17). Reads mapping to
the EBV genome for all three performed ChIP-seq experiments could be detected as well, with a
sequencing depth multiple times covering the entire EBV genome (Table 18). Applying MACS2
software significant binding sites for E2, E3A, and E3C could successfully be identified in the
human (Table 19) and EBV (Table 20) genome. To this end, two biological replicates per ChIP
were performed and sequenced as advised by the ENCODE project (Landt et al., 2012).
However, there is no clear agreement in the field how to deal with data from replicate
experiments. One way, also ENCODE suggests, is the application of Irreproducible Discovery Rate
(IDR) analysis methodology, were peaks only count when significantly identified in both
replicates (Li et al., 2011) but here the focus is drawn on highly enriched binding sites. Since in
this thesis a quantitative analysis of binding sites enrichment should be performed as well, a
different approach was chosen where mapped reads from biological replicates were merged and
then subjected to peak calling in order to identify low enrichment reads as well.
However, detailed observations on the obtained binding sites in the human genome
revealed the requirement for additional selection steps. To this end, “negative” peaks, which are
wrongly detected by MACS2, peaks located on black-listed regions (Derrien et al., 2012), and
finally peaks whose location were not compatible with the GM12878 genome were removed
(Table 21). After this selection step 96.5, 90.8, and 69.8% of for E2, E3A, and E3C peaks,
respectively identified by MACS2 remained in the final peak list. The peaks removed here, were
clearly false positives or not adaptable for the cell line to compare. Therefore, this additional peak
filtering strongly improves the overall significance of the final peaks lists.
The absolute numbers of detected peaks in the human genome, 22,500 E2, 13,490 E3A,
and 8,733 E3C peaks are in general comparable to datasets published by other groups. For
instance, the first E2 ChIP-seq study in IB4 cells, an LCL with two integrated EBV genomes,
which initially was described not to be an ideal cell line for studying viral latency (Hurley et al.,
1991), identified 5,151 E2 sites and also 10,529 CBF1 sites mapped to the human genome hg18
(Zhao et al., 2011b). It has to be noted, that in this study two biological replicates were reported
to be analyzed but an independently performed reanalysis of the uploaded raw data, in order to
update and compare these to data mapped to hg19, did not reproduce the results of the authors.
After personal communication, the authors of the publication (Zhao et al., 2011b) admitted that
only one replicate per experiment was used for the bioinformatic analysis respectively, since the
quality of the second biological replicate was very low. Finally, 19,177 E2 and 38,063 CBF1 peaks
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could be detected by applying the self-generated bioinformatics pipeline for peak calling to single
experiments for E2 and CBF1  used by Zhao and colleagues. Later on, the same research group
published different data sets which were compared with the E2 binding sites obtained by Zhao et
al. but each time they were re-calculated: In a comparison with an EBNA-LP (E-LP) ChIP-seq
19,224 E2 binding sites (Portal et al., 2013) and subsequently in another study, addressing the
potential occupation of super-enhancers by E2, even 42,251 peaks (Zhou et al., 2015) were
calculated, each time applying different software and standards.
Simultaneously, a study performed in Mutu III, an EBV positive Burkitt’s lymphoma cell
line showing type III latency expression pattern, identified 21,605 E2 binding sites (McClellan et
al., 2013).
However, the E2 ChIP-seq generated and analyzed in this thesis is based on two biological
replicates, passing very high quality standards, performed in LCLs, the B cell line used by
ENCODE for most of their experiments, and therefore displays the most reliable dataset for
studying E2 binding properties in LCLs at the moment.
Chromatin binding properties of the E3 proteins was also investigated by several research
groups. As already mentioned above, one study was conducted in Mutu III cells and revealed
7,044 E3 peaks but, due to antibody specificity issues, could not distinguish between E3A, E3B,
and E3C peaks (McClellan et al., 2012). Furthermore, the Flag-HA-tagged E3A and E3C
expressing LCLs were used for ChIP-seq experiments in LCLs, which could identify over 10,000
E3A (Schmidt et al., 2015) and over 13,000 E3C peaks (Jiang et al., 2014). These numbers very
much resemble the findings presented in this thesis, while the Mutu III derived peak numbers
differ noticeably. Even if Mutu III cells show a type III latency expression pattern, where all
latent EBV proteins are expressed as in LCLs, not much is known about the chromatin landscape
and TF expression pattern of these cells, which will turn out to be very important to chromatin
accession by EBNA proteins (chapter 4.2.3), in comparison to LCLs. Therefore, it is not entirely
clear how relevant the Mutu III derived data is when investigating E2 and E3 functions in
immortalization and establishment of latency III.
Characterization of E2, E3A, and E3C binding sites in the EBV5.2.2
genome
Performing ChIP-seq experiments in LCLs infected with recombinant EBV strains made it also
possible to investigate potential EBNA targeting of viral genomic sites. And indeed, 7 E2, 10
E3A, and 15 E3C binding sites could be identified (Table 20 and Fig. 14).
This finding was rather expected, since all three EBNA proteins were described to regulate
viral genes. Early after infection E2 induces expression of viral genes LMP1 and LMAP2A/B as
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well as transcription from Cp, which gives rise to a polycistronic RNA coding for all six EBNAs
(reviewed in Kempkes and Ling, 2015). Also the E3 proteins are known to regulate EBV
transcription, but the current picture is still controversial: All three E3 proteins, E3A, E3B, and
E3C, were described to repress E2 activated LMP1 expression (Le Roux et al., 1994) but another
study contrarily found E3C, in cooperation with E2, to induce LMP1 expression (Lin et al.,
2002). Furthermore, E3C was the only E3 protein so far, which was identified to bind to the
LMP1 promoter (Jimenez-Ramirez et al., 2006). E3A and E3C were also described to repress Cp
derived transcription in reporter assays (Radkov et al., 1997, Waltzer et al., 1996), which could
not be confirmed in EBV negative B cells with inducible E3C expression (Jimenez-Ramirez et al.,
2006).
In this thesis, direct targeting of the bidirectional LMP1/LMP2B and the LMP2A
promoter by E2 could be shown (Fig. 14, red columns). Also CBF1, the best described DNA
adaptor, could be identified at both sites as well by re-analysis of published raw data (Zhao et al.,
2011b). The B cell specific TF EBF1, which was described in this thesis to form complexes with
E2 and was shown to be enriched at CBF1 independent E2 binding sites in LCL, was also found
to bind to these promoters, with much higher enrichment at the LMP2A compared to the
LMP1/LMP2B promoter (Fig. 38). Very recently a study on E2 binding, with the focus on
comparing different latency states, identified E2, CBF1, and EBF1 binding sites in the viral
genome as well (Lu et al., 2016). Here, only the two E2 binding sites at LMP2A and
LMP1/LMP2B promoters could be identified, re-analyzing the data from Zhao et al., while the
new EBF1 and CBF1 ChIP-seq experiments revealed a similar binding pattern as the ENCODE
data shown in Fig. 38 (right panel). Furthermore, Lu and colleagues could show that E2 in fact
recruits CBF1 and EBF1 to LMP2A and LMP1/LMP2B promoters as well as to Cp. Now, in
this thesis it could be shown that also E3A and E3C are significantly enriched at the
LMP1/LMP2B promoter while only E3C can be detected at the LMP2A promoter. Of the
several TFs which were identified to correlate with E3 binding in the human genome (chapter
4.2.5), only BATF, BCL11A, and IRF4 were integrated in the EBV portal (Arvey et al., 2012) and
therefore included in the IGV view (Fig. 38). BATF and BCL11A showed only moderate
enrichment at these E3 peaks while IRF4 was not enriched. Due to the limited information on
E3 associated TFs, predictions on E3 accession to DNA is very difficult in this case. The PU.1
signal track was also integrated in this comparison since PU.1 has been described to be important
for E2 driven activation of the LMP1 promoter (Laux et al., 1994b, Laux et al., 1994a, Johannsen
et al., 1995), where E3C was characterized as a co-activating factor (Zhao and Sample, 2000, Lin
et al., 2002) which targets the LMP1 promoter as well (Jimenez-Ramirez et al., 2006). The data
derived from ENCODE also showed PU.1 binding to the LMP1/LMP2B but not to the LMP2A
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promoter. Therefore, a potential role of PU.1 in LMP1 gene regulation seems very plausible and
has to be further addressed in functional assays in the LCL system.
Figure 38. E2, E3A, and E3C binding sites in the EBV genome and co-occurrence of associated TFs.
Schematic maps depicting three details of the EBV genome (HHV-4 type I, NC_007605.1, map provided by the
EBV portal (Arvey et al., 2012)). Genes expressed during the lytic cycle are depicted in black and genes expressed
during latency are highlighted in color. Also marked is the EBNA regulated Cp, which gives rise to different
(polycistronic) splice variants coding for all EBNAs, including proteins of interest E2, E3A, and E3C. EBNA
regulated LMP1, LMP2A, and LMP2B genes are shown in red. In the upper panels ChIP-seq signal profiles and
underneath peaks called by MACS2 for E3A, E3C, E2, and CBF1 (Zhao et al., 2011b) are shown. Signal tracks of
TFs EBF1, PU.1, BATF, BCL11A, and IRF4 were directly uploaded to IGV through the EBV portal server and are
derived from ENCODE ChIP-seq experiments in GM12878, analyzed by the Lieberman group as described (Arvey
et al., 2012). All signal tracks were set to show maximal intensities of the respective ChIP-seq signal within the
genome.
Direct targeting of Cp in LCLs by E2 could be shown in this thesis (Fig. 38, left panel) as well as
by Lu et al. using ChIP-qPCR. Re-analysis of CBF1 ChIP-seq data did not show significant
binding sites in the Cp region. It was not possible to assess if this finding was due to low overall
read coverage or has biological relevance. Since E2 activation of Cp has been studied and
confirmed extensively, the former seems more likely. Also Lu and colleagues could detect
significant binding of both, CBF1 and EBF1, at Cp in ChIP-qPCR experiments in LCL (Lu et al.,
2016), which indicated CBF1 and/or EBF1 as E2 adaptors in this case. This time, E3A and E3C
could be detected in close proximity, but not at the very same site as E2 and rather showed
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enrichment over a larger genomic region of approx. 6.5 kb which is atypical for most TFs. The
oriP region is located within this signal stretch and consists of highly repetitive sequences, which
might lead to false positive repetitive ChIP signals. However, this was not the case for E2 or
other TFs and therefore most likely displays E3 specific binding behavior. This finding might be
due to higher order spatial organization of this genomic region mediated by E2 and the E3
proteins in order to tightly regulate Cp transcription but has to be further analyzed. The E3
associated factors BATF and BCL11A showed enrichment at the region boarders, while IRF4
shows no specific enrichment. PU.1 could be identified at only one boarder of the E3 stretch, 3’
of Cp, and therefore might be involved in E3 but not E2 chromatin accession which would have
to be verified by functional assays.
Also all four investigated TFs could be identified to bind at the promoter of the full length
transcript of RPMS1 (Fig. 38, middle panel), a putative ORF whose translation to a protein could
not be confirmed to date but gives rise to BART ncRNAs and BART miRNAs. The BARTs are
forming three clusters in the RPMS1 introns, which are largely deleted in the EBV B95.8
background. Only a few BARTs of cluster I and two further downstream are still present. BART
RNA can be detected during latent and lytic cycles of EBV infection but are found to be
expressed at especially high levels in latency II. The molecular functions of BART ncRNAs is still
to be determined but due to exclusive expression in the nucleus and no evidence of protein
expression from several splicing variants, a role in viral or host gene regulation seems likely. The
BART miRNAs show supporting functions in viral latency by targeting viral and cellular factors
crucial in cell growth, survival and signaling pathways, but also cellular factors important in anti-
viral immune responses (reviewed in Skalsky and Cullen, 2015). So far, no influence of E2 or E3
function on BART expression was reported to date. The signal enrichment for E2, E3A, E3C,
and CBF1 is quite low compared to the other EBV genomic binding sites, but displays a
significant peak for each factor at this co-occupied site. Also EBF1 was shown to be significantly
enriched at this site, while PU.1 was not detected here. BATF was the only E3 correlating factor
which was enriched here. In summary, a model where E2 is recruited to chromatin by CBF1 and
EBF1 while E3A and E3C are recruited (i.a.) by BATF seems very likely.
E2, E3A, and E3C preferentially target enhancer modules in the5.2.3
human genome
In this thesis it could be demonstrated that E2 as well as E3A and E3C primarily target enhancer
regions within the human genome in LCL and not, as suggested for some time in the past, mainly
promoters. To this end the css analysis in the wt LCL GM12878 by ENCODE (Ernst et al.,
2011), which segments the human genome into functional elements in a cell line specific manner,
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was applied to assign functional states to binding sites. This analysis revealed that 65.9% of E2
and even 71.0 and 67.6 % of E3A and E3C binding sites, respectively, are located on enhancers
(Fig. 15A). Interestingly, the percentage of E2 peaks at strong enhancers (47.0%) is higher than
the ones of E3A or E3C (43.1 and 41.2% respectively). This phenomenon was further dissected
and confirmed by enrichment analyses of enhancer defining histone modifications at E2
compared to E3A and E3C peaks (Fig. 16). All three investigated chromatin marks, H3K4me1
and H3K4me3, characteristic for enhancers, and H3K27ac, typical for active enhancer elements,
as well as RNA polymerase II (PolII), indicating poised or actual transcription, were elevated at
E2 peaks compared to E3A or E3C binding sites. Furthermore, this evaluation included the
average signal distribution of the investigated factors at their respective peaks, allowing
conclusions on the scale of the identified signal enrichments. Hence, it could be demonstrated
that E2 peaks show higher and also broader H3K4me1 and H3K27ac signals as the average
H3K4me1 or H3K27ac positive site respectively, which was far not as pronounced at E3 peaks.
Further examination of the EBNA binding sites at promoter regions, as predicted by css in
GM12878, revealed a striking absence of annotated promoters by RefSeq in the majority of these
peaks (Fig. 15B). According to RefSeq only 4.7% of E2 and 1.4 and 0.9% of E3A and E3C
peaks, respectively, formerly annotated by css as promoter associated, are located within 1 kb
upstream of a RefSeq gene. This can be explained by the criteria of css to annotate promoters,
which are based on histone modifications and PolII occurrence, but not annotated genes of any
kind. Therefore these “css only promoters” are most likely enhancers, which are frequently
transcribed (reviewed in Plank and Dean, 2014, Kulic et al., 2015).
Taken together, these findings demonstrate that all three investigated EBNA proteins
primarily target enhancer elements and E2 in particular is binding to strong enhancers, exhibiting
high H3K4me1 and H3K27ac marks, while E3 proteins rather bind to regular enhancers.
However, a significant percentage of E2 binding sites were also identified at RefSeq promoters,
indicating a role of E2 in promoter targeted gene regulation for a subset of E2 peaks.
In relative distance analyses of E2, E3A, and E3C peaks and their respective induced or
repressed genes, as identified by gene expression analyses in the Kempkes laboratory (Maier et al.,
2006, Hertle et al., 2009, and diploma thesis A. Nowak, 2008), direct targeting of E2 induced
genes by a small subset of E2 peaks could be revealed. This finding is consistent with a small
subset of E2 peaks (4.7%) which are located at RefSeq gene promoters. This feature could not be
observed towards E2 repressed genes and also E3A and E3C peaks seemed not to be shifted
nearer towards regulated genes as expected by random distribution. Only when focusing on
highly enriched E3A or E3C peaks a slight shift of shorter relative distances towards repressed
target genes could be observed. Thus, a model emerges, in which the majority of E2 and also E3
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proteins target enhancers and only a small subset of E2 and maybe E3A and E3C binding sites
are located directly at the targeted gene (Fig. 15B).
E2 was already described to target enhancer elements, conjointly with CBF1, rather than
promoters (Zhao et al., 2011b) and also genome wide studies on E3 binding sites in Mutu III
revealed promoter distal binding (McClellan et al., 2012). Very recently, further studies of E3A
and E3C binding sites in LCLs showed a similar picture, where enhancer targeting was outlined
(Schmidt et al., 2015, Jiang et al., 2014, Wang et al., 2015). However, these studies did not include
quantitative analyses and direct comparison of E2 versus E3A and E3C binding sites features
which was only provided by this thesis.
In order to draw conclusions on the connections between binding sites of the single
EBNAs and their target genes, experiments identifying three dimensional chromatin organization
dependent on EBNA protein expression, should be performed. Chromosome Conformation Capture
(3C), an assay to reveal chromatin interactions but only for distinct regions of interest, was
already applied in order to reveal E3A or E3C mediated or inhibited chromatin loop formation at
three model genomic loci harboring described target genes (McClellan et al., 2013). The authors
described one promoter-enhancer interaction which is inhibited by E3A expression and
presumable enhancer binding as well as two different E3C mediated repressive promoter-
enhancer interactions. However, in that study many different cell lines were used, among those
also Burkitts’ lymphoma cell lines, which exhibit a chromatin landscapes very different from
LCLs (discussed in chapter 5.3.1), and therefore are not displaying the ideal background for these
interaction studies. Furthermore, many different more advanced methods have been developed in
the recent past in order to study genome wide chromatin interactions. One example displays
high-resolution capture Hi-C (Chi-C), which detects long range interactions preselected for
promoter regions and was initially applied to investigate differences in promoter interactions
between CD34+ hematopoietic progenitor cells and GM12878 LCLs demonstrating changes
during differentiation processes (Mifsud et al., 2015). Therefore, information on promoter
interactions in wt LCL are already available and have been used to formulate hypotheses on
possible EBNA mediated interactions by combining these with E2 binding sites (Gunnell et al.,
2016). However, a genome wide comparison of promoter-enhancer interactions dependent on
the different EBNA proteins has not been performed yet and would certainly shed light on the
connection between binding sites and target genes.
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Enhancer signature is a prerequisite for accession of E2 to chromatin5.2.4
and is enriched upon E2 expression
The targeting of enhancers by all three EBNA proteins has been discussed extensively above but
did not consider the presence of enhancer specific histone modifications as a prerequisite for or
consequence of EBNA binding. In this thesis it could be demonstrated that enhancer signature is
not only a prerequisite for E2 binding but also increases upon E2 expression. To this end ChIP-
seq data on histone modification marks derived from CD19+ B cells (Bernstein et al., 2010) and
LCLs (ENCODE_Consortium, 2012) were analyzed in the bioinformatic analysis pipeline
designed and described in this thesis. Only E2 binding was studied in this context since E2 is the
first latent EBV protein to be expressed upon infection and therefore able to access chromatin in
the resting B cell prior to E3 protein expression which might interfere with E2 function. The
enrichment of H3K4me1 at E2 peaks has been described previously (Zhao et al., 2011b) and the
conclusion was drawn that E2 targets pre-existing enhancers in primary B cells. However, the
mentioned study did not include any kind of quantitative assessment of the observed ChIP-seq
signals, which have been derived from different laboratories applying different experimental
features and antibodies and are provided by the ENCODE consortium.
The data presented in this thesis represent a profound and detailed examination of these
two data sets with focus on E2 binding sites, including a normalization procedure which made it
possible to compare CD19+ with LCL derived experiments. The enrichment of each histone
modification and DNaseI HS was quantified relative to the absolute signal in the respective cell
line and the increase of H3K4me3, H3K27ac, and DNaseI HS signals in LCLs compared to
CD19+ cells could be demonstrated. Interestingly, H3K4me1, the enhancer hall mark, is not
further enriched upon E2 expression in LCL and already shows are broad signal distribution.
Therefore, E2 targets enhancers exhibiting broad H3K4me1 marks and subsequently might
recruit factors which further open the chromatin and possibly even recruit PolII to initiate
transcription.
Distinct combinations of cellular TFs characterize E2 versus E35.2.5
predominated chromatin regions
This thesis focused on the comparison between E2 and E3 modes of action and in particular the
mechanisms and prerequisites for chromatin accession. Since E2, E3A, and E3C share a certain
set of target genes, mostly in a counter-regulated manner, but also show uniquely regulated genes
(Fig. 4) a co-occupation of binding sites in the human genome seemed very likely. It could be
demonstrated that EBNA binding sites are shared to a certain degree, 27.4% of E2 sites are
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positive for at least one E3 protein and vice versa 43.2% and 43.5% of E3A and E3C peaks,
respectively, are E2 positive (Fig. 19). Furthermore, it was shown that the overlap of E2 and
CBF1 binding sites (61.6% of E2 sites) was more significant than the overlap of E3A or E3C and
CBF1 (45.4% and 45.3% respectively).
Different studies conducted in different cell lines and laboratories showed a partially similar
picture: E2 binding sites were also shown to largely overlap with CBF1 sites (Zhao et al., 2011b),
while the overlap between E3A or E3C with CBF1 binding sites was calculated to be smaller
than shown here (16 and 16% respectively)(Jiang et al., 2014, Schmidt et al., 2015). This
discrepancy is most likely due to the fact that for this analysis only the top 10,000 CBF1 binding
sites as defined by enrichment were used for these analyses and low enrichment peaks were
neglected. The intersection analysis of E2 and E3 proteins in MutuIII cells, which did not
distinguish between the different E3s, revealed 25% of combined sites to be shared (McClellan et
al., 2013). Studies in LCLs showed that only 9% of E3A and 9% of E3C sites were E2 positive
and only 44% of E3A sites were described to be E3C positive (Jiang et al., 2014, Schmidt et al.,
2015). Again, not the whole set of identified binding sites were used for this analysis in LCLs but
rather the top enriched sites were analyzed.
5.2.5.1 Quantitative analysis of signal enrichment at binding sites as a novel
strategy of determining possible interacting TFs
Now, the binding site co-occupation of E2 and E3 proteins was described and characterized in a
quantitative and genome wide way for the first time. A new picture emerged when binding sites
were not only compared for binding site overlaps, but sorted according to their signal enrichment
and correlated with the signal enrichment of other factors. E2 and CBF1 showed very high signal
intensity correlations at E2 peaks (Fig. 20A) as it could be shown for E3A and E3C at the
respective other peak set (Fig. 20B and C). This analysis was extended to a genome wide scale
including all TFs which were analyzed by ENCODE in LCL at that time
(ENCODE_Consortium, 2012). A genome wide pattern of TF binding networks emerged
(Fig. 21) which revealed TFs with high correlations to the EBNA proteins. Two subclusters
could be identified; one included E2 and CBF1 and the other one E3A and E3C. TFs with the
highest correlation values towards at least one EBNA protein were chosen for further analyses:
CBF1, EBF1, and CUX1 showed very high correlation to E2, while 16 TFs correlated highly with
both E3 proteins (Fig. 22). Also, the signal correlation between E3A and E3C was comparable to
the ones of known dimers or members of the same protein complex, indicating a conjointly
binding mechanism which could not be revealed by simple intersection analyses before.
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Furthermore, the co-occupation of E2 and E3 binding sites could be characterized in more detail
by including signal intensities for the analyses. An anti-correlation of E2 and E3A or E2 and E3C
signals, together with E2 or E3 associated factors, at EBNA binding sites could be demonstrated
and suggests reciprocal binding of most sites rather than actual shared sites (Fig. 23).
Some of the TFs identified to correlate with either E2 or E3 binding pattern have already
been described as co-occurring TFs based on a panel of TFs defined by educated guesses and co-
citations or motif enrichment analyses. In contrast, this thesis displays the first unbiased study
including a very big data set on TF binding without any preselection of possible interacting
factors. CBF1, the best described cellular protein to interact with all three EBNAs, could be
assigned to correlate definitely with E2 over E3 signals in an unbiased quantitative approach for
the first time. EBF1 has been suggested as co-occurring TF important for E2 binding by motif
enrichment analysis at E2 peaks and subsequent peak overlap analysis (Zhao et al., 2011b). Very
recently EBF1 has been proposed as recruiting factor for E2 (Lu et al., 2016). CUX1 on the other
hand has previously not been described as TF related to E2 binding. Also, most factors of the E3
cluster have been discussed to be important for E3 accession to DNA or mediating specificity for
E3 binding sites. These assumptions are mainly based on binding co-occurrences as determined
by peak overlap analyses (McClellan et al., 2013, Jiang et al., 2014, Schmidt et al., 2015, Wang et
al., 2015). However, only the interactions of E3A with BATF as well as E3C with IRF4 were
studied in more detail: E3A and BATF binding at the same genomic region was confirmed by
ChIP-re-ChIP-qPCR analysis (Schmidt et al., 2015), which only proofs the presence at the same
chromatin fragment but not direct or indirect binding to each other. The direct interaction of
IRF4 and E3C could be confirmed and mapped to E3C aas 130-159 (Banerjee et al., 2013). Only
TFs CEBPB, MTA3, and PML have not been discussed previously to be important for
chromatin accession of E3 proteins and display a novel piece of information.
5.2.5.2 Cluster analyses for E2 or E3 binding sites revealed subsets defined by
combinatorial TF sets
After the quantitative approach described above to identify EBNA associated TFs, these were
used for cluster searches of combinatorial TF co-occurrences. To this end E2 and E3 peaks were
analyzed separately, peak intersection analyses including the previously identified EBNA
correlating TFs were performed, and clusters were identified. For E2 and E3 peaks eight
different clusters of defined TF compositions could be identified which are characterized by
distinct histone modification patterns.
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E2 peak clusters
The E2 peak clusters included combinations of TFs CBF1, EBF1, and CUX1 (Fig. 26). The
highest E2 enrichment was observed for cluster I, which is positive for all three investigated TFs
and shows histone modifications characteristic for active enhancers. This implies that the
strongest enhancers with a combined composition of all three TFs display the most ideal E2
chromatin accession prerequisites. Cluster VII, which is devoid of EBF1 binding but shows the
highest enrichments for H3K4me3 and PolII, indicating the presence of transcription, probably
displays the E2 peaks subset comprised of mainly transcribed promoters and enhancers. Clusters
II, III, VI, and VII are very similar in their chromatin signature and display regular enhancers
bound by E2, while E2 sites of clusters IV and V are most likely poised enhancers, due to the
low but present H3K4me1/3 enrichment and elevated H3K27me3 levels. However, cluster V
also shows the highest percentage of sites located in heterochromatin, as defined by ENCODE
css. These binding sites could be due to indirect chromatin interactions or might display actual
targeting of heterochromatin by E2 for a subset of binding sites. Furthermore, clusters V and VI,
which are both negative for CBF1 and EBF1, show the lowest E2 signal enrichment and outline
the importance of these two factors on E2 binding and indicate an improving character. Recently,
it was suggested that E2 in fact recruits these two factors to certain E2 target sites in order to
access chromatin (Lu et al., 2016), a hypothesis which will be further discussed in the following
chapter 5.3.
Furthermore, the whole set of TFs investigated by ENCODE was also assessed for the E2
peak clusters and revealed that indeed the majority of TF which were enriched at all E2 sites,
showed the highest enrichment for clusters I and/or VII, while a depletion was apparent for
clusters IV and V. This finding underlines the enhancer and promoter characteristics of clusters I
and VII respectively, which are co-occupied by several TFs whose combinations of appearance
probably determine the accessibility of discrete genomic loci for E2 binding.
Interestingly, the E2 clusters also differ in enriched sequence motifs (Fig. 27) which display
another reference point for determining E2 binding sites. The enrichment of NFκB, EICE and
ISRE motifs at cluster I peaks indicates a supportive role of these factors for E2 chromatin
accession, since E2 showed the highest signal enrichment for this cluster. Interestingly, the NFκB
motif is noticeably enriched at the four EBF1 positive clusters, which might be due to a potential
interaction or support in mediating E2 specificity. Cluster VII which potentially depicts E2
accessible promoters reveals a role for TFs of the ETS family, like PU.1 and Spi-B, in this
context. PU.1 was not included in the cluster search since it was already excluded after the
genome wide (Fig. 22) and the EBNA peak wide (Fig. 23) correlation analyses due to a low or
even anti-correlation with E2 signal. However, PU.1 was described to be important for mediating
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E2 targeting of the LMP1 promoter (Laux et al., 1994a, Johannsen et al., 1995), and was also
considered as E2 specificity mediating TF in genome wide analyses by peak comparison analyses
which revealed an overlap of 22% (Zhao et al., 2011b). More recently the existence of EBNA
controlled super-enhancers, characterized by disproportionately high enrichment of enhancer
marks, PU.1, E2, E3A, and E3C was discussed (Zhou et al., 2015) but seems to be restricted to a
very small set of binding sites (187), which also show extraordinarily high enrichment for the vast
majority of TFs of the ENCODE set and therefore represents only a special case of chromatin
accession by E2. Enrichment analyses for PU.1 at the eight different E2 peak clusters were
performed as well (Fig. S4) and revealed the highest PU.1 enrichment at E2 peaks of clusters I
and VII, like most investigated TFs. Thus PU.1, maybe also in combination with or substituted
by other ETS TFs, might indeed be important for mediating E2 specificity of cluster VII sites,
lacking EBF1. Also RUNX3, which was described as E2 co-occurring and potential factor for
mediating chromatin accession (Zhao et al., 2011b, Portal et al., 2013) could not be confirmed to
correlate with E2 binding in a general manner. It displays the highest enrichment at E2 clusters I
and VII as well and therefore might indeed play a supporting role here.
The absence of the CUX1 sequence motif at all E2 binding sites indicates that either CUX1
does not only directly access DNA but is recruited to chromatin in an indirect fashion through
other factors or CUX1 is able to bridge connections between distal chromatin regions and such
indirect binding sites are also included in the binding site data set. The ability of CUX1 to
regulate distant target genes was described previously (Vadnais et al., 2013) and could account for
indirect chromatin binding sites.
E3 peak clusters
The E3 peaks could be divided into eight clusters as well by their combination of co-occurring
TFs BATF, ATF2, BCL11A, FOXM1, NFIC, and IRF4 (Fig. 28), which exhibit the most similar
binding patterns to E3 on EBNA peaks as identified in a first cluster analysis (Fig. 25). Cluster I,
positive for both, E3A and E3C, as well as all six investigate TFs displays the highest
enrichments for all enhancer defining histone modifications, E3A and E3C signals, implying a
supporting function of the concerted presence of all factors on E3A and E3C binding. The
clusters V, VI, VII, VIII consisting of E3A, E3C and different combinations lacking certain
factors are associated with lower enrichment of enhancer marks. These clusters may represent
weaker enhancers and E3 binding and might result in extenuated E3 mediated gene regulation.
Cluster III, E3A and E3C co-occupied sites positive for only BATF and IRF4 display only very
moderate enrichment of enhancer signatures. These sites could display a minimal prerequisite for
E3 accessible enhancers. Clusters II and IV lack all six cellular TFs and exhibit the lowest E3A
and E3C enrichment respectively. These sites might either represent indirect chromatin contacts
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of the E3A/C complex or actual direct independent binding of E3A or E3C respectively at non-
enhancer sites. However, the genome wide correlation analysis strikingly showed a very high
positive correlation between E3A and E3C, which could otherwise only be observed for known
dimers like BATF/IRF4 and MEF2A/MEF2C or members of the cohesion complex. In
addition, the interaction of E3A and E3C could be demonstrated by Y2H (Calderwood et al.,
2007) and Co-IP experiments in B cells (Paschos et al., 2012 and this thesis, Fig. 6). Therefore, a
model in which E3A and E3C target chromatin as a heterodimer is favored here.
In Summary, these clusters of EBNA binding sites and associated TF combinations could
represent a first list of prerequisites for E2 and E3 binding (Fig. 39) and a versatile starting point
for further experiments to determine the functionality of the single involved factors. Finally, one
might be able to describe such prerequisites of chromatin landscape and TFs combinations which
determine E2 or E3 specificity.
Figure 39. Hypothetical model of E2 and E3 targeted chromatin regions. (A) E2 is binding to enhancer
regions, represented by cluster I (left panel), by the concerted action of CBF1, EBF1, and CUX1. CBF1 and EBF1
can directly access DNA and no interaction between these two TFs was described. The direct interaction of E2 and
CBF1 has been demonstrated (Grossman et al., 1994, Henkel et al., 1994) (black arrow) and complex formation with
EBF1 could be shown in this thesis (grey arrow). At promoter regions (right panel), represented by cluster VII, E2 is
binding to DNA utilizing CBF1 and recruits PolII through yet unidentified factors. CUX1 is also important for
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complexes of both clusters, yet the CUX1 binding motif was not found at E2 sites and indirect binding was already
proposed in the past (Harada et al., 2008). Therefore it might bridge interactions between E2 and co-occurring
factors. In both scenarios the co-occurring TFs as identified by the motif search also show signal enrichment at the
respective clusters, yet they are not deterministic for cluster formation but might contribute to specificity. (B) E3A
and E3C are binding to enhancers through combinations of the TFs ATF2, BATF, BCL11A, FOXM1, IRF4, and
NFIC. The combined presence of all factors, as in cluster I, mediates the highest specificity for E3 proteins, while
enhancers lacking several factors, like cluster VII, display lower E3 signals. Cluster VII shows that binding of E3
without BATF and IRF4 is still possible if substituted by the other four TFs. Yet, BATF and IRF4 display the
minimal combination of TFs needed to mediate E3 specificity (cluster III). All six TFs specifying E3 clusters, can
bind to DNA directly, mostly in (hetero) dimers and the conjointly binding of BATF and IRF4 to DNA has been
shown (Glasmacher et al., 2012). However, it is not known in what combinations these TFs access DNA in this
specific case.
B cell TF networks exploited by E2 and E3 proteins5.2.6
In the previous section the E2 and E3 peak clusters and presence of distinct associated TFs were
discussed and now shall be analyzed from a functional perspective.
CBF1 or RBPJ of the E2 cluster displays the most intensively studied and discussed TF
and many functional aspects have been elaborated in the introduction (chapter 1.2.1.2). In this
context it is very interesting that CBF1 was described to strongly correlate with dynamic
NOTCH1 binding in T cells (Wang et al., 2014). Here, NOTCH1 function was induced and
subsequently ChIP-seq for NOTCH1 and CBF1 performed and revealed approx. 10% of
NOTCH1 peaks to be dynamic (only detectable upon induction) and predominantly located at
enhancer sites. Interestingly, the CBF1 sites which correlate with NOTCH1 only appeared upon
induction, thus indicating a stabilization of CBF1 binding to DNA by NOTCH1. Similar findings
could be demonstrated in drosophila as well (Krejci and Bray, 2007).
EBF1 the early B cell factor 1is a sequence specific DNA binding TF, which plays a crucial
role in defining B cell lineage specificity during differentiation and represses alternative cell fates.
In concerted action with PAX5, PU.1, RUNX1, Ikaros, E2A, and FOXO1 the B cell specific
transcription profile is established. EBF1 consists of a DBD, a helix-loop-helix dimerization
domain, and a C-term transactivation domain and is highly conserved during metazoan evolution
(reviewed in Boller and Grosschedl, 2014). The crystal structure of EBF1 which is binding to
DNA as a dimer could be solved (Treiber et al., 2010a, Siponen et al., 2010). In gain-of-function
and loss-of-function studies in pre-pro-B cells and pro-B cells, respectively, EBF1 was described
to activate and repress genes associated with B cell function and EBF1 binding was associated
with H3K4me2 (Treiber et al., 2010b). Furthermore, EBF1 was shown to induce DNA
demethylation at the CD79A prom in plasmacytoma cells (Maier et al., 2004) and was linked to
the chromatin remodeling complexes SWI/SNF and Mi-2/NuRD (Gao et al., 2009). Recently,
EBF1 was also considered to act as a “pioneer factor” in order to establish B cell identity since its
CTD, independent of its transactivating function, establishes chromatin accessibility and induces
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DNA demethylation in previously naive chromatin (Boller et al., 2016). Therefore, E2 might well
employ EBF1 to access important B cell lineage enhancers and drive B cell activation.
Moreover, a recent study reported E2 to recruit TFs CBF1 and EBF1 to its target sites rather
than exploiting preexisting CBF1 and EBF1 positive enhancers to achieve target gene regulation
(Lu et al., 2016). However, this study did show a significant decrease of both TFs, CBF1 and
EBF1, at selected E2 binding sites upon E2 depletion but did not show an absolute abolishment
of binding. Therefore, a second hypothesis, also supported by the dynamic NOTCH1 and CBF1
binding data, suggests complex stabilization of all factors involved by E2.
The third E2 correlating TF, CUX1, was described to act as activator and repressor of
transcription, depending on the promoter context and expressed transcript variant. Several
transcriptional roles of CUX1 in cell cycle progression, DNA damage response, and resistance to
apoptotic signals could be demonstrated. Furthermore, several cancer links were described for
CUX1, characterizing it as a haploinsufficient tumor suppressor gene (reviewed in Ramdzan and
Nepveu, 2014). A consensus DNA binding motif for the CUX1 p110 variant was described to be
enriched at genomic binding sites (ATCG/AAT) but also indirect DNA accession by protein-
protein interactions was proposed (Harada et al., 2008) and promoter distal binding of target
genes by CUX1, indicating enhancer binding, was described (Vadnais et al., 2013).
Interestingly, the CUX1 homologue in drosophila, Cut was described to be a downstream
effector or target gene of Notch signaling, since Cut expression was lost in SuH (the drosophila
homologue of CBF1) mutants and described to be activated or repressed by Notch function
(Nepveu, 2001).
Of the E3 associated TFs, IRF4, a member of the interferon regulatory factors (IRF), is the best
described so far. It is expressed in most cells of the immune system and during all developmental
stages of B cell activation but during the germinal center (GC) reaction and plays a key role in late
B cell differentiation. It was shown that IRF4 is upregulated by NFκB and represses BCL6, the
master regulator of the GC reaction in GC B cells. Furthermore it was shown to play a role in
class switch recombination and GC exit of centrocytes and aberrant IRF4 expression was linked
to oncogenic pathologies like multiple myeloma, Hodgkin and Non-Hodgkin lymphomas. IRF4,
which needs a cofactor to achieve DNA binding, was described as activator or repressor of
transcription dependent on the interacting cofactor and context (reviewed in De Silva et al.,
2012). The recruitment of IRF4 to DNA through ETS factors, like PU.1 and Spi-B, (Brass et al.,
1999) or AP-1 family members, like BATF, (Glasmacher et al., 2012) could be demonstrated.
Recently, the direct interaction of E3C and IRF4 was shown (Banerjee et al., 2013) and
enrichment at E3C binding sites could be demonstrated (Jiang et al., 2014), underlining the
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importance for E3C and E3A chromatin accession. Taken together, since IRF4 displays such a
crucial TF in B cell development, again an essential B cell TF network is targeted by the EBNA
proteins.
Also BATF (basic leucine zipper (bZIP) TF ATF-like) displays a TF with expression restricted
to the hematopoietic system and belongs to the AP-1 family of TFs. Unlike AP-1 factors Fos or
Jun, BATF is missing a transactivation domain and therefore is dependent on interacting factors
for mediating transcriptional regulatory functions. BATF was described to heterodimerize with
Jun and conjointly acts as repressors of transcription (Murphy et al., 2013). Recently, the
recruitment of IRF4 to AICE composite sites by JUNB-BATF heterodimer could be shown and
therefore allow an additional dimension of binding site specificity (Glasmacher et al., 2012).
Unfortunately, JUNB was not included in the ENCODE ChIP-seq TF set used in this thesis and
therefore it cannot be concluded what BATF heterodimer is recruiting IRF4 to composite sites.
However, it was demonstrated that these BATF-IRF4 interactions display a crucial mechanism
which is utilized by the E3 proteins to access specific regulatory regions and a mechanism by
which E3A is tethered to DNA involving BATF was suggested analyzing binding data (Schmidt
et al., 2015).
The remaining TFs of the E3 cluster were all described to co-occur at E3A or E3C binding
sites by peak overlap analyses (Jiang et al., 2014, Schmidt et al., 2015, Wang et al., 2015).
ATF2, which is also a member of the AP-1 family of TFs, characterized by a bZIP domain,
forms homo- or heterodimers with AP-1 members, like c-Jun, in order to specifically regulate
target gene transcription. Furthermore, an oncogenic transformation potential was attributed to
Jun-ATF dimers (reviewed in van Dam and Castellazzi, 2001). Jun-ATF activity is specifically
enhanced by Jun N-terminal Kinase (JNK) members of the Mitogen-Activated Protein Kinase (MAPK)
pathway, in contrast to Jun-Fos dimers, which are rather ERK targets (Karin et al., 1997, Davis,
1999).
BCL11A (B cell chronic lymphocytic leukemia/lymphoma 11A) displays a zinc-finger TF, which
was identified as a protooncogene, frequently implicated in numerous B cell malignancies
(Satterwhite et al., 2001). Initially, it was described as a crucial and specific factor for B cell
lymphopoiesis (Liu et al., 2003, Yu et al., 2012). Later a deterministic role in plasmacytoid
dendritic cell fate was shown and cell line specific binding sites were identified, which harbor the
same consensus motif as GM12878 cells (determined by ENCODE, accessible via
factorbook.org): EICE (Ippolito et al., 2014).
FOXM1 (Forkhead (FKH) box protein M1) is a member of the FOX family that consists of
more than 50 proteins and was described to be important in cell cycle regulation and progression
(reviewed in Carlsson and Mahlapuu, 2002) and therefore contributes to the pathogenesis of
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several cancers (reviewed in Myatt and Lam, 2007). FOXM1 was described to act, in concert with
MYB, as a master regulator of proliferation in germinal centers (Lefebvre et al., 2010). A recent
study could show that FOXM1, which in vitro binds the FKH consensus motif, is specifically
recruited to chromatin through co-factor interactions by direct binding to non-canonical DNA
motifs (Sanders et al., 2015).
NFIC (Nuclear Factor I C), displays a member of the NFI family of site-specific TFs
described to activate or repress transcription and bind DNA as dimers (reviewed in Gronostajski,
2000). The in vitro identified consensus DNA binding motif (Osada et al., 1996, Roulet et al.,
2002) could be verified by analyses of ChIP-seq experiments (Bailey and Machanick, 2012).
In summary, 3 TFs could be described to define E2 clusters of peaks, while 6 distinct factors are
responsible for E3 cluster formation. For both clusters distinct combinations of these TFs could
be described. Recent advances in NGS methods and large data set comparisons made it possible
to shed light on the importance of TF networks in mediating specific target gene regulation. For
instance, combinatorial interactions of TFs, rather than the actions of single factors, were
described to direct tissue-specific gene expression and determine cell fate (Ravasi et al., 2010).
Here, the network structure was described to be dominated by facilitator TFs expressed broadly
across tissues tended to interact with tissue restricted TF (specifiers) to result in specific
functional consequences.
Also the formation of tissue specific enhancers was found to be dependent on distinct
collaborative and hierarchical binding of TFs. A model was proposed where pioneer TFs, which
are able to bind their recognition motif within compacted chromatin, already act in concert with
further lineage specific TFs to select tissue specific enhancers and jointly displace nucleosomes.
In a second step broadly expressed TFs mediate the actual enhancer function to activate distal
target genes (reviewed in Heinz et al., 2015). One example for such a lineage defining and pioneer
TF displays PU.1, which is required for the development of macrophages and B cells and
influences the establishment of distinct gene expression programs in each cell type (Scott et al.,
1994). However, PU.1 targets different sites in B cells compared to macrophages and it could be
shown, that these differing binding sites were characterized by a set of B cell or macrophage
specific TFs (Heinz et al., 2010). In the B cell EBF1, E2A, and OCT factors were found to be
enriched at PU.1 sites, while in macrophages CEBP and AP1 factors could be identified. The
corresponding motifs were found in close proximity to PU.1 motifs, indicating ternary protein-
protein-DNA interactions and led to the conclusion that lineage defining TF composition might
be a contributing factor to the formation of transcriptionally active and active genomic
compartments (Pham et al., 2013).
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In the LCL background PU.1 can be frequently identified to co-occur at E2 and E3 peaks,
though it does not correlate significantly in signal intensity distribution Therefore, PU.1 could
display a lineage restricted TF, or specifier, which collocates with more broadly expressed
facilitator TFs, like EBF1 in the E2 or BATF, IRF4 or others in the E3 cluster, as it has been
described for TF networks which determine lineage identity (Ravasi et al., 2010). Also, the fact
that EBF1, BATF, IRF4, ATF2, and CBF1 are expressed at relatively high levels in GM12878
(Table S3) supports this argument. Interestingly, IRF4 displays the top expressed gene in
GM12878 overall, as identified by CAGE (Fantom_Consortium et al., 2014) (Table S4). Actually,
IRF4 was described to be expressed at low levels in the activated B cell and only re-expressed in
the plasmablast stage at high levels (reviewed in Nutt et al., 2015). LCLs have been described to
resemble activated B cells in their phenotype and expression pattern (Thorley-Lawson, 2001).
However, this apparently does not apply to IRF4 expression, which is also induced by E2 action
(DG75 expression data, S. Thumann) and IRF4 protein is stabilized by E3C (Banerjee et al.,
2013). Hence, E2 might induce one of the cellular TFs mediating EBNA binding specificity.
Therefore, it seems very likely that E2 and later E3 proteins exploit B cell specific
enhancers, which are already primed in CD19+ B cells, to achieve gene regulation of specific
target genes usually triggered upon B cell activation, where specificity is mediated by the distinct
sets of the co-occurring TFs. Finally, the clusters identified in this thesis display a first step on the
way to identify deterministic features and prediction of E2 and E3 binding to chromatin.
5.3 CBF1 as a determining factor for E2 access to chromatin?
In the third part of this thesis, the dependency of E2 on CBF1 for binding chromatin was further
elaborated. The usage of stable conditionally E2 expressing EBV negative DG75 B cell lines,
which are proficient or deficient for CBF1 (Fig. 29), allowed a profound conclusion on CBF1
effects on E2 binding.
The effect of cell line specific chromatin signature and TF expression5.3.1
profile on E2 binding
Interestingly, the comparison of E2 peaks in DG75/CBF1 wt with the data from LCL revealed a
difference in the chromatin landscape and therefore resulted in different E2 binding patterns
between these two cell lines (Fig. 31). It could be show that the E2 binding sites present in both
cell lines (LCL/DG75 shared) display the highest E2 enrichment in LCLs, while the E2 signal in
DG75 is comparable between these LCL/DG75 shared and DG75 unique sites. However, the
investigated enhancer characteristic histone modifications in both cell lines were enriched the
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most at LCL/DG75 shared sites, followed by the unique E2 sites in the respective cell line.
These findings showed that the E2 peaks detectable in both cell lines are in fact strong enhancers
in the respective cell line. Also, this implicates that both, LCL and DG75 unique E2 sites, are
indeed enhancer regions accessible for E2 binding only in the respective cell line. This conclusion
could be one possible explanation for the different sets of E2 sites in those two cell lines.
Furthermore it could be shown that the strong E2 binding sites from LCL which are associated
with strong enhancer signatures are in fact the ones, which can still be identified in DG75. In
contrast, the E2 binding intensities in DG75 are very similar between LCL/DG75 shared and
DG75 unique sites which is most probably due to a very different enhancer distribution and
intensities in this cell line. Moreover, expression patterns of E2 or E3 associated TFs in DG75,
and in particular the impairment in BATF and IRF4 expression in DG75 cell line (Fig. 32),
indicates a special role for these factors in mediating binding site specificity for E2. This might
either be due to pioneering activity, in concert with other cellular factors, to ensure accessibility in
the first place or they display cofactors in stabilizing chromatin binding per se. However, since
the majority of E2 sites in DG75 are also present in LCL, and there they display the subset of
strong binding sites associated with strong enhancer signatures, the ChIP-seq data derived from
DG75 exhibits very important information.
CBF1 displays the key adaptor for E2 access to chromatin5.3.2
The comparison of E2 binding sites in DG75/CBF1 wt and CBF1 ko revealed a strong
dependency of E2 on CBF1 (Fig. 33), since 86.4% of E2 sites are lost in the ko situation. Also
the analysis of E2 signal strength comparing the two situations showed a direct supportive effect
of CBF1 on E2 binding for the first time. Furthermore, the examination of E2 peak subsets
showed that the CBF1 independent E2 sites exhibit the strongest E2 signal in the CBF1 wt as
well as in the CBF1 ko, although the mean signal in CBF1 wt is much higher than in the
CBF1 ko. Investigation of these E2 peak subsets in LCL revealed a similar pattern, where the
CBF1 independent peaks showed the highest signal. Even 28 CBF1 ko unique E2 peaks could be
detected, which might be explained by peak detection thresholds, since they show a lower overall
signal in the CBF1 ko line than the CBF1 independent peaks  and still show a slight but not
significant enrichment in the CBF1 wt cell line.
Since E2 signal strength was associated with strong enhancer signatures in LCLs, one
explanation for the CBF1 independent peaks to exhibit stronger E2 signals in DG75/CBF1 wt
might be due to a difference of enhancer signatures in DG75 for these two subsets. To stress this
idea, data on histone modification patterns in DG75 (Kretzmer et al., 2015) were analyzed
independently in the course of this thesis and E2 peak subsets were compared (Fig. 34).
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Interestingly, the distribution of H3K4me1, H3K4me3, and H3K27ac was almost identical for
CBF1 independent and dependent peaks, implying that not the DG75 cell line specific chromatin
signature is responsible for higher E2 signals at the CBF1 independent peaks in the CBF1 wt line.
Instead it becomes more evident that co-occurring factors besides CBF1 are responsible for
strong E2 binding at enhancers.
EBF1 as a determining factor for E2 binding site specificity?5.3.3
It could be shown that the consensus motif of the TF EBF1, which is essential for B cell lineage
specification (reviewed in Hagman et al., 2012, and Boller and Grosschedl, 2014), was the only
identified TF to be significantly enriched at CBF1 independent E2 binding sites (Fig. 35A). CBF1
dependent E2 sites were enriched for CBF1 and the EBF1 motif, but with less significance. In
addition, the investigation of TF binding signal derived from LCL at these E2 peaks revealed a
strong enrichment of EBF1 signal at CBF1 independent peaks (Fig. 35B and C). EBF1 already
showed the highest correlation coefficient in the comparison with E2 signal distribution on a
genome wide level (Fig. 21/22) and also when concentrating on EBNA peaks (Fig. 23). The
correlation between E2 signal and EBF1 pattern became even more obvious when a special focus
was directed on E2 peaks only (Fig. 36). The correlation between E2 and EBF1 (rs = 0.42) almost
scored the one of E2 and CBF1 (0.50), while the often discussed B cell lineage defining TF PU.1
only displayed moderate correlation with E2 signal distribution at E2 peaks. Combined these data
strongly support the importance of EBF1 and CBF1 in mediating E2 accession of specific
chromatin sites, while PU.1 might be important in priming enhancers in B cells to be accessibly
for further TFs in the first place but does not recruit or stabilize E2 binding.
Eventually, the protein-protein interaction of E2 and EBF1 could be demonstrated for the
first time in Co-IP experiments upon EBF1 transfection and E2 induction in DG75doxHA-EE2 cells
(Fig. 37). Complex formation could be detected in CBF1 wt and ko situations which
demonstrated that CBF1 is not mediating E2-EBF1 interaction. These experiments now have to
be repeated using E2 as IP target to confirm this interaction. Also, Co-IP experiments are not
harboring information on direct interaction but interaction partners of complexes, directly or
indirectly binding to each other, also mediated by DNA molecules can be identified. Therefore
pull-down experiments applying heterologous expressed purified proteins need to be performed
to distinguish between these scenarios. However, these data could demonstrate the complex
formation of E2 and EBF1, also in the absence of CBF1, and underline the importance of this
interaction.
In summary, it could be demonstrated that CBF1 displays the key adaptor for E2 in
accessing chromatin and that EBF1 seems to support this interaction. EBF1 could not
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completely replace CBF1s function as anchor to DNA but was sufficient for E2 binding at actual
strong binding sites. Ongoing research in the Kempkes laboratory could already demonstrate a
reduction in E2 binding intensity upon EBF1 knock-down (experiments conducted by S. Rieger)
and support a hypothesis where both cellular TFs are needed to mediate accession to chromatin
and specificity of binding sites.
The data obtained and analyzed in this thesis collectively point towards a B cell specific
network of TFs and associated regulatory elements which are exploited by E2 and E3 proteins in
order to regulate distinct target gene sets. PU.1, which does not correlate with E2 or E3 signals
but frequently is found to co-occupy EBNA sites, was described as a pioneer factor for opening
nucleosome occupied TF target sites (Barozzi et al., 2014), which is already expressed in
hematopoietic precursor cells (reviewed in Choukrallah and Matthias, 2014). Recently, the
pioneering activity of the C-terminal domain of EBF1 could be described in B cell fate decision
(Boller et al., 2016). The additive and combinatorial effects of pioneer factors and rather broadly
expressed TFs in the selection of cell type specific enhancers has been shown (Heinz et al., 2015)
and together with the information on EBF1 expression and function displays the basis for E2
specificity.
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7 Appendices
7.1 Supplementary figures
Figure S1. Identification of E2, E3A, and E3C binding sites in the EBV genome. Schematic map of the EBV genome (HHV-4 type I, NC_007605.1) as provided by the EBV portal
(Arvey et al., 2012) depicting gene positions (lower panel). Genes expressed during the lytic cycle are depicted in black, microRNAs in grey and genes expressed during latency are highlighted
in color. Also marked is the EBNA regulated Cp, which gives rise to different (polycistronic) splice variants coding for all EBNAs, including proteins of interest E2, E3A, and E3C. The light
grey box to the right encompasses a region, which is deleted in the B95.8 EBV genome used for EBV BACmid generation compared to HHV-4 type I reference genome. Genes affected by
the B95.8 deletion are highlighted in blue and green. Thus it is not possible that reads from ChIP-seq analysis derive from this genomic region. EBNA regulated LMP1, LMP2A, and
LMP2B genes are shown in red, with the bidirectional promoter controlling LMP1 and LMP2B expression as well as the LMP2A promoter highlighted with light red columns. In the upper
panels ChIP-seq signal profiles and underneath peaks called by MACS2 for E2, E3A, and E3C are shown. (*) Additionally published data for E2 and CBF1 (Zhao et al., 2011b) is shown for
comparison.
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Figure S2. Signal distribution of histone modifications, histone variant H2AFZ, and RNA polymerases at
E2 peak clusters. Anchor plots depicting mean signal distributions of available histone modifications, histone
variants, and RNA polymerases (variants) at the 8 different E2 peak clusters. A region of 2 kb in each direction of
the peak center was analyzed. ChIP-seq signals from ENCODE were normalized to their respective input samples
and RPKM (see chapter 3.6.1).
Figure S3. Signal distribution of TFs found to cluster with E3A and E3C in EBNA peak wide correlation
analysis at E2 peak clusters. Anchor plots depicting mean signal distributions of TFs, which are positively
correlating with E3 signals (as detected by correlation analysis using EBNA peaks as reference) at the 8 different E2
peak clusters. A region of 2 kb in each direction of the peak center was analyzed. ChIP-seq signals from ENCODE
were normalized to their respective input samples and RPKM (see chapter 3.6.1).
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Figure S4. Signal distribution of TFs analyzed by ENCODE, which were not identified in E2 or E3 clusters
in EBNA peak wide correlation analysis but showed enrichment at E2 peak clusters. Anchor plots depicting
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mean signal distributions of TFs, which are positively correlating with E3 signals (as detected by correlation analysis
using EBNA peaks as reference) at the 8 different E2 peak clusters. A region of 2 kb in each direction of the peak
center was analyzed. ChIP-seq signals from ENCODE were normalized to their respective input samples and
RPKM (see chapter 3.6.1).
Figure S5. Signal distribution of TFs analyzed by ENCODE, which were not identified in E2 or E3 clusters
in EBNA peak wide correlation analysis and were not enriched at E2 peak clusters. Anchor plots depicting
mean signal distributions of TFs, which are positively correlating with E3 signals (as detected by correlation analysis
using EBNA peaks as reference) at the 8 different E2 peak clusters. A region of 2 kb in each direction of the peak
center was analyzed. ChIP-seq signals from ENCODE were normalized to their respective input samples and
RPKM (see chapter 3.6.1).
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7.2 Supplementary Tables
Table S1. TF and histone modification ChIP-seq experiments by the ENCODE project used in this study
ChIP
Experiment
Name
Narrow Peaks
(bed)
Broad Peaks
(bed)
ENCODE
Reanalyzed Lab
Release
Date Antibody
ATF2 ENCSR000BQK -
ENCFF001TWB,
ENCFF001TWC ENCFF002CGO R. Myers, HAIB 29.02.12 ENCAB000ASU
ATF3 ENCSR000BJY -
ENCFF001TWD,
ENCFF001TWE ENCFF002CGP R. Myers, HAIB 18.07.11 ENCAB000ADZ
BATF ENCSR000BGT -
ENCFF001TWF,
ENCFF001TWG ENCFF002CGQ R. Myers, HAIB 18.07.11 ENCAB000AED
BCL11A ENCSR000BHA -
ENCFF001TWH,
ENCFF001TWI ENCFF002CGR R. Myers, HAIB 18.07.11 ENCAB000AEE
BCL3 ENCSR000BNQ -
ENCFF001TWJ,
ENCFF001TWK ENCFF002CGS R. Myers, HAIB 18.07.11 ENCAB000AEG
BCLAF1 ENCSR000BJZ -
ENCFF001TWL,
ENCFF001TWM ENCFF002CGT R. Myers, HAIB 18.07.11 ENCAB000AEH
BHLHE40 ENCSR000DZJ ENCFF001VDW - ENCFF002COK M. Snyder, Stanford 29.10.11 ENCAB000AEK
BRCA1 ENCSR000DZS ENCFF001VDX - ENCFF002COL M. Snyder, Stanford 29.10.11 ENCAB000AEL
CEBPB ENCSR000BRX -
ENCFF001TWN,
ENCFF001TWO ENCFF002CGU R. Myers, HAIB 10.09.12 ENCAB000AFB
CHD1 ENCSR000DZE ENCFF001VEA - ENCFF002CON M. Snyder, Stanford 14.05.12 ENCAB000AFE
CHD2 ENCSR000DZR ENCFF001VEB - ENCFF002COO M. Snyder, Stanford 29.10.11 ENCAB000AFG
CREB1 ENCSR000BUF -
ENCFF001TWP,
ENCFF001TWQ - R. Myers, HAIB 10.09.12 ENCAB000AFN
CTCF ENCSR000AKB - ENCFF001SUB ENCFF002CDP B. Bernstein, Broad 10.02.11 ENCAB000AXY
CUX1 ENCSR000DYR ENCFF001VDY - - M. Snyder, Stanford 20.08.12 ENCAB000AFA
E2F4 ENCSR000DYY ENCFF001VEE - ENCFF002COR M. Snyder, Stanford 14.05.12 ENCAB000AFV
EBF1 ENCSR000DZQ ENCFF001VEF - ENCFF002COS M. Snyder, Stanford 29.10.11 ENCAB000AFX
EGR1 ENCSR000BRG - ENCFF001TWS ENCFF002CGW R. Myers, HAIB 29.02.12 ENCAB000ASX
ELF1 ENCSR000BMB -
ENCFF000NVE,
ENCFF001TWX ENCFF002CGX R. Myers, HAIB 18.07.11 ENCAB000AGA
ELK1 ENCSR000DZB ENCFF001VEG - ENCFF002COT M. Snyder, Stanford 14.05.12 ENCAB000AGB
EP300 ENCSR000DZD ENCFF001VEX - ENCFF002CPE M. Snyder, Stanford 14.05.12 ENCAB000AJM
ESRRA ENCSR000DYQ ENCFF001VEH - - M. Snyder, Stanford 20.08.12 ENCAB000AGE
ETS1 ENCSR000BKA -
ENCFF001TWZ,
ENCFF001TXB ENCFF002CGY R. Myers, HAIB 18.07.11 ENCAB000AGG
EZH2 ENCSR000ARD - ENCFF001SUC ENCFF002CDQ B. Bernstein, Broad 06.03.12 ENCAB000AGH
FOS ENCSR000EYZ ENCFF001VDZ - ENCFF002COM S. Weissman, Yale 29.10.11 ENCAB000AEQ
FOXM1 ENCSR000BRU -
ENCFF001TXC,
ENCFF001TXD ENCFF002CGZ R. Myers, HAIB 29.02.12 ENCAB000AGP
GABPA ENCSR000BGC -
ENCFF001TXE,
ENCFF001TXF ENCFF002CHA R. Myers, HAIB 18.07.11 ENCAB000AGR
H2AFZ ENCSR000AOV - ENCFF001SUD - B. Bernstein, Broad 10.02.11 ENCAB000ASY
H3K27ac ENCSR000AKC - ENCFF001SUG - B. Bernstein, Broad 10.02.11 ENCAB000ANA
H3K27me3 ENCSR000AKD - ENCFF001SUI - B. Bernstein, Broad 10.02.11 ENCAB000ANB
H3K36me3 ENCSR000AKE - ENCFF001SUJ - B. Bernstein, Broad 10.02.11 ENCAB000ADU
H3K4me1 ENCSR000AKF - ENCFF001SUE - B. Bernstein, Broad 10.02.11 ENCAB000ADW
H3K4me2 ENCSR000AKG - ENCFF001SUL - B. Bernstein, Broad 10.02.11 ENCAB000ANF
H3K4me3 ENCSR000AKA - ENCFF001SUF - B. Bernstein, Broad 10.02.11 ENCAB000BLJ
H3K79me2 ENCSR000AOW - ENCFF001SUN - B. Bernstein, Broad 10.02.11 ENCAB000ANH
H3K9ac ENCSR000AKH - ENCFF001SUO - B. Bernstein, Broad 10.02.11 ENCAB000ANK
H3K9me3 ENCSR000AOX - ENCFF001SUP - B. Bernstein, Broad 10.02.11 ENCAB000ANX
H4K20me1 ENCSR000AKI - ENCFF001SUQ - B. Bernstein, Broad 10.02.11 ENCAB000ANZ
IKZF1 ENCSR000EUJ ENCFF001VEJ - ENCFF002COU P.Farnham, USC 14.05.12 ENCAB000AHV
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IRF3 ENCSR000DZX ENCFF001VEK - - M.l Snyder, Stanford 29.10.11 ENCAB000AHY
IRF4 ENCSR000BGY -
ENCFF001TXG,
ENCFF001TXH ENCFF002CHB R. Myers, HAIB 18.07.11 ENCAB000AHZ
JUND ENCSR000EYV ENCFF001VEM - ENCFF002COV M. Snyder, Stanford 29.10.11 ENCAB000AID
KAT2A ENCSR000DNO ENCFF001VEI - - K. Struhl, HMS 29.10.11 ENCAB000AHA
MAFK ENCSR000DYV ENCFF001VEN - - M. Snyder, Stanford 20.08.12 ENCAB000AIJ
MAX ENCSR000DZF ENCFF001VEO - ENCFF002COW M. Snyder, Stanford 14.05.12 ENCAB000AIL
MAZ ENCSR000DZA ENCFF001VEQ - ENCFF002COX M. Snyder, Stanford 14.05.12 ENCAB000AIM
MEF2A ENCSR000BKB -
ENCFF001TXI,
ENCFF001TXJ ENCFF002CHC R. Myers, HAIB 18.07.11 ENCAB000AIQ
MEF2C ENCSR000BNG -
ENCFF001TXK,
ENCFF001TXL ENCFF002CHD R. Myers, HAIB 18.07.11 ENCAB000AIR
MTA3 ENCSR000BRH -
ENCFF001TXM,
ENCFF001TXN ENCFF002CHE R. Myers, HAIB 29.02.12 ENCAB000AIS
MXI1 ENCSR000DZI ENCFF001VER - ENCFF002COY M. Snyder, Stanford 29.10.11 ENCAB000AIT
MYC ENCSR000DKU ENCFF001USG - ENCFF002DAI V. Iyer, UTA 17.03.11 ENCAB000AET
NFATC1 ENCSR000BQL -
ENCFF001TXO;
ENCFF001TXP ENCFF002CHF R. Myers, HAIB 29.02.12 ENCAB000AJE
NFE2 ENCSR000DZY ENCFF001VES - ENCFF002COZ M. Snyder, Stanford 29.10.11 ENCAB000AJB
NFIC ENCSR000BRN -
ENCFF001TXQ,
ENCFF001TXR ENCFF002CHG R. Myers, HAIB 29.02.12 ENCAB000AJF
NFYA ENCSR000DNN ENCFF001VEU - ENCFF002CPB K. Struhl, HMS 29.10.11
NFYB ENCSR000DNM ENCFF001VEV - ENCFF002CPC K. Struhl, HMS 29.10.11 ENCAB000AJD
NR2C2 ENCSR000EUL ENCFF001VFP - ENCFF002CPS P.Farnham, USC 29.10.11 ENCAB000AMA
NRF1 ENCSR000DZO ENCFF001VEW - ENCFF002CPD M. Snyder, Stanford 29.10.11 ENCAB000AJI
PAX5 ENCSR000BHD -
ENCFF001TXY,
ENCFF001TXZ ENCFF002CHJ R. Myers, HAIB 18.07.11 ENCAB000AJS
PBX3 ENCSR000BGR -
ENCFF001TYC,
ENCFF001TYD ENCFF002CHL R. Myers, HAIB 18.07.11 ENCAB000AJU
PML ENCSR000BQM -
ENCFF001TYE,
ENCFF001TYF ENCFF002CHM R. Myers, HAIB 29.02.12 ENCAB000AKA
POLR2A ENCSR000EAD ENCFF001VFA - ENCFF002CPG M. Snyder, Stanford 14.05.12 ENCAB000AOC
POLR3G ENCSR000EYU ENCFF001VFC - ENCFF002CPJ S. Weissman, Yale 29.10.11 ENCAB000AKB
POU2F2 ENCSR000BGP -
ENCFF001TYK,
ENCFF001TYL;
ENCFF001TYM ENCFF002CHP R. Myers, HAIB 18.07.11 ENCAB000AKC
RAD21 ENCSR000BMY -
ENCFF001TYQ,
ENCFF001TYR ENCFF002CHR R. Myers, HAIB 18.07.11 ENCAB000AKG
RCOR1 ENCSR000DZC ENCFF001VEC - ENCFF002COP M. Snyder, Stanford 14.05.12 ENCAB000AFK
RELA ENCSR000EAG ENCFF001VET - ENCFF002CPA M. Snyder, Stanford 14.05.12 ENCAB000AJG
REST ENCSR000BQS -
ENCFF001TXS,
ENCFF001TXT ENCFF002CHH R. Myers, HAIB 29.02.12 ENCAB000AJK
RFX5 ENCSR000DZW ENCFF001VFF - ENCFF002CPL M. Snyder, Stanford 29.10.11 ENCAB000AKJ
RUNX3 ENCSR000BRI
ENCFF001TYS,
ENCFF001TYU ENCFF002CHS R. Myers, HAIB 29.02.12 ENCAB000AKM
RXRA ENCSR000BJD -
ENCFF001TYT,
ENCFF001TYV ENCFF002CHT R. Myers, HAIB 18.07.11 ENCAB000AKN
SIN3A ENCSR000DYX ENCFF001VFG - ENCFF002CPM M. Snyder, Stanford 14.05.12 ENCAB000AKR
SIX5 ENCSR000BJE -
ENCFF001TYW,
ENCFF001TYX ENCFF002CHU R. Myers, HAIB 18.07.11 ENCAB000AKV
SMC3 ENCSR000DZP ENCFF001VFH - ENCFF002CPN M. Snyder, Stanford 29.10.11 ENCAB000AKX
SP1 ENCSR000BHK -
ENCFF001TYZ,
ENCFF001TYY ENCFF002CHV R. Myers, HAIB 18.07.11 ENCAB000AKY
SPI1 ENCSR000BGQ -
ENCFF001TYN,
ENCFF001TYO,
ENCFF001TYP ENCFF002CHQ R. Myers, HAIB 18.07.11 ENCAB000AKF
SREBF1 ENCSR000DYU ENCFF001VFJ - - M. Snyder, Stanford 20.08.12 ENCAB000ALC
SREBF2 ENCSR000DYT ENCFF001VFK - - M. Snyder, Stanford 20.08.12 ENCAB000ALD
SRF ENCSR000BGE -
ENCFF001TZA,
ENCFF001TZB ENCFF002CHW R. Myers, HAIB 18.07.11 ENCAB000ALE
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STAT1 ENCSR000DZM ENCFF001VFL - ENCFF002CPO M. Snyder, Stanford 29.10.11 ENCAB000ALF
STAT3 ENCSR000DZV ENCFF001VFM - ENCFF002CPP M. Snyder, Stanford 29.10.11 ENCAB000ALH
STAT5A ENCSR000BQZ -
ENCFF001TZE,
ENCFF001TZF ENCFF002CHX R. Myers, HAIB 29.02.12 ENCAB000ALI
SUPT20H ENCSR000DNP ENCFF001VFI - - K. Struhl, HMS 29.10.11 ENCAB000ALB
TAF1 ENCSR000BGS -
ENCFF001TZG,
ENCFF001TZH ENCFF002CHY R. Myers, HAIB 18.07.11 ENCAB000ALM
TBL1XR1 ENCSR000DYZ ENCFF001VFN - ENCFF002CPQ M. Snyder, Stanford 14.05.12 ENCAB000ALP
TBP ENCSR000DZZ ENCFF001VFO - ENCFF002CPR M. Snyder, Stanford 29.10.11 ENCAB000ALR
TCF12 ENCSR000BGZ -
ENCFF001TZI,
ENCFF001TZJ ENCFF002CHZ R. Myers, HAIB 18.07.11 ENCAB000ALT
TCF3 ENCSR000BQT -
ENCFF001TZK,
ENCFF001TZL ENCFF002CIA R. Myers, HAIB 29.02.12 ENCAB000ALU
USF1 ENCSR000BGI -
ENCFF001TZM,
ENCFF001TZN ENCFF002CIB R. Myers, HAIB 18.07.11 ENCAB000AMF
USF2 ENCSR000DZU ENCFF001VFQ - ENCFF002CPT M. Snyder, Stanford 29.10.11 ENCAB000AMH
WRNIP1 ENCSR000EAA ENCFF001VFS - ENCFF002CPU M. Snyder, Stanford 29.10.11 ENCAB000AMJ
YY1 ENCSR000BNP -
ENCFF001TZO,
ENCFF001TZP ENCFF002CIC R. Myers, HAIB 18.07.11 ENCAB000ANT
ZBTB33 ENCSR000BHC -
ENCFF001TZQ,
ENCFF001TZR ENCFF002CID R. Myers, HAIB 18.07.11 ENCAB000AML
ZEB1 ENCSR000BND -
ENCFF001TZS,
ENCFF001TZT ENCFF002CIE R. Myers, HAIB 18.07.11 ENCAB000AMO
ZNF143 ENCSR000DZL ENCFF001VFU - ENCFF002CPW M. Snyder, Stanford 29.10.11 ENCAB000AMR
ZNF274 ENCSR000EUK ENCFF001VFT - ENCFF002CPX P. Farnham, USC 29.10.11 ENCAB000AMU
ZNF384 ENCSR000DYP
ENCFF001VFW, ENCFF000WGY
(bigbed) - M. Snyder, Stanford 20.08.12 ENCAB000AMW
ZZZ3 ENCSR000DNQ ENCFF001VFV - ENCFF002CPY K. Struhl, HMS 29.10.11 ENCAB000AMX
ChIP-seq experiments for TFs and histone modifications used in this thesis are listed. All supplied information
including experimental procedures and all submitted files can be found at www.encodeproject.org. Peak files (bed)
which were used for e.g. cluster analyses are highlighted in bold letters. Signal tracks published by the ENCODE
project were not used in this thesis, since they are not normalized to input samples. To correct for input reads signal
tracks from aligned reads (bam files) were generated using a Galaxy workflow described in 3.6.1.
Table S2. Accession numbers for data published by other laboratories used in this thesis
Name Cells Line
Data Deposit
Platform
Accession No.
(Experiment)
Accession No.
(Sample)
ENCODE
experiment Description Publication
DNaseI HS GM12878 ENCODE/GEO GSE29692 GSM736620 ENCSR000EMT DNase-seq -
H3K4me1
CD19+
primary cells GEO GSE18927
GSM1027296 - ChIP-seq
Bernstein et
al. (2010)
H3K4me3 GSM1027300 - ChIP-seq
H3K27ac GSM1027287 - ChIP-seq
Input GSM1027304 - ChIP-seq control
DNaseI HS GSM701507 - DNase-seq
H3K4me1
DG75
EMBL-EBI
European
Nucleotide
Archive (ENA)
PRJEB1912
(study)
ERS333899
(sample = DG75)
ERX297414 - ChIP-seq
Kretzmer et
al. (2015)
H3K4me3 ERX297407 - ChIP-seq
H3K27ac ERX297417 - ChIP-seq
Input ERX297450 - ChIP-seq control
ChIP-seq and DNase-seq experiments used in this thesis are listed including accession details. For all listed
experiments fastqsanger files were downloaded and read mapping as well as further down-stream processing was
conducted as explained in chapter 3.6.
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Table S3. Expression levels of the TFs included in the ENCODE ChIP-seq data set used in this thesis
Expression Level Expression Level
Gene ID G
en
e
N
am
e
H
1-
hE
SC
CD
20
+
B
ce
lls
G
M
12
87
8
Cl
us
te
r
Gene ID G
en
e
N
am
e
H
1-
hE
SC
CD
20
+
B
ce
lls
G
M
12
87
8
Cl
us
te
r
ENSG00000115966 ATF2 8 10 26 ENSG00000001167 NFYA 8 10 7
ENSG00000162772 ATF3 4 22 4 ENSG00000120837 NFYB 6 2 10
ENSG00000156127 BATF 6 32 ENSG00000177463 NR2C2 7 13 9
BCL11A ENSG00000106459 NRF1 8 10 6
BCL3 ENSG00000196092 PAX5 92 8
ENSG00000029363 BCLAF1 8 27 36 ENSG00000167081 PBX3 8 6 49
ENSG00000134107 BHLHE40 0.9 18 39 ENSG00000140464 PML 3 9 1
ENSG00000012048 BRCA1 3 0.6 12 ENSG00000028277 POU2F2 1 45 7
ENSG00000172216 CEBPB 4 10 0.8 ENSG00000164754 RAD21 16 18 58
ENSG00000153922 CHD1 3 7 12 ENSG00000168214 RBPJ 21 4 32
ENSG00000173575 CHD2 4 16 9 ENSG00000089902 RCOR1 7 7 6
ENSG00000118260 CREB1 4 9 10 ENSG00000173039 RELA 6 35 4
ENSG00000102974 CTCF 18 25 17 ENSG00000084093 REST 5 6 10
ENSG00000257923 CUX1 3 2 1 ENSG00000143390 RFX5 13 71 38
ENSG00000205250 E2F4 65 54 16 ENSG00000020633 RUNX3 35 9
ENSG00000164330 EBF1 22 6 ENSG00000186350 RXRA 3 0.6 0.9
ENSG00000120738 EGR1 18 98 1 ENSG00000169375 SIN3A 13 10 5
ENSG00000120690 ELF1 2 40 34 SIX5
ENSG00000126767 ELK1 15 8 8 ENSG00000108055 SMC3 9 7 24
ENSG00000100393 EP300 22 24 3 ENSG00000185591 SP1 20 15 21
ENSG00000173153 ESRRA 10 9 3 ENSG00000066336 SPI1 55 2
ENSG00000134954 ETS1 4 39 21 ENSG00000072310 SREBF1 10 9 1
ENSG00000106462 EZH2 12 6 31 ENSG00000198911 SREBF2 70 43 27
FOS ENSG00000112658 SRF 57 20 18
ENSG00000111206 FOXM1 23 1 5 ENSG00000115415 STAT1 10 9 168
ENSG00000154727 GABPA 2 6 16 ENSG00000168610 STAT3 14 14 17
ENSG00000185811 IKZF1 36 17 ENSG00000126561 STAT5A 2 17 8
ENSG00000126456 IRF3 23 43 7 ENSG00000102710 SUPT20H 8 6 8
ENSG00000137265 IRF4 35 148 ENSG00000147133 TAF1 2 5 5
ENSG00000140968 IRF8 155 70 ENSG00000177565 TBL1XR1 7 8 18
ENSG00000130522 JUND 16 1432 4 ENSG00000112592 TBP 10 16 13
ENSG00000108773 KAT2A 22 71 13 ENSG00000140262 TCF12 11 7 10
MAFK ENSG00000071564 TCF3 64 98 7
ENSG00000125952 MAX 9 32 17 ENSG00000158773 USF1 16 98 11
ENSG00000103495 MAZ 26 20 4 ENSG00000105698 USF2 16 62 12
ENSG00000068305 MEF2A 6 19 17 ENSG00000124535 WRNIP1 12 14 7
ENSG00000081189 MEF2C 18 21 ENSG00000100811 YY1 13 14 13
ENSG00000057935 MTA3 16 3 6 ENSG00000177485 ZBTB33 2 4 16
ENSG00000119950 MXI1 2 6 3 ENSG00000148516 ZEB1 5 12
ENSG00000136997 MYC 15 40 24 ENSG00000166478 ZNF143 7 8 8
NFATC1 ENSG00000171606 ZNF274 3 12 3
NFE2 ENSG00000126746 ZNF384 12 13 7
NFIC ENSG00000036549 ZZZ3 3 4 8
List of all the TFs used by ENCODE for ChIP-seq in GM12878 at the time of this analysis and their expression
levels as determined and quantified by RNA-seq analysis of long poly adenylated RNA in different ENCODE cell
lines (E-GEOD-26284) (Djebali et al., 2012). Data was downloaded via EMBL-EBI Expression Atlas. Expression
levels cannot be directly compared between factors since e.g. RNA stability and translation rates are not represented
by this analysis. Expression levels are color coded from very low (white ≤ 10% of max. observed) to high (blue ≥
90% of max. observed) expression. TFs which were not included in this analysis are labeled grey, while IRF8 is
highlighted because it is not represented by the ENCODE TF set. TFs which were used for the E2 or E3 peak
cluster analysis are marked in orange or dark blue, respectively.
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Table S4. Highly expressed TFs in GM12878 as identified by CAGE
Expression
value
(log10) TPM TF
Expression
value
(log10) TPM  TF
2.6 395.59 IRF4 1.24 38.59 TCF4
2.46 288.23 PLEK 1.24 16.28 CREB5
2.37 235.43 POU2AF1 1.21 68.7 TCF7
2.07 117.22 IRF8 1.21 21.24 NFKBIZ
2.05 111.79 SPIB 1.2 26.21 IKZF2
2.04 107.59 RUNX3 1.2 17.04 MSC
1.89 77.41 ASCL1 1.18 88.56 ELF1
1.84 68.31 IKZF3 1.18 22.24 MSC
1.83 67.01 SP140 1.16 26.52 IRF7
1.77 57.46 EOMES 1.16 13.45 BATF
1.72 94.52 RUNX3 1.15 15.97 HOXC4
1.71 50.2 SP140 1.14 12.91 DMRT2
1.69 47.53 PLEK 1.13 12.61 PLEK
1.69 47.53 CREB5 1.13 12.38 IKZF2
1.59 38.28 ZBTB32 1.11 159.7 HMGA1
1.56 71.68 EGR2 1.11 12 NR3C1
1.53 33.09 IFI16 1.11 11.92 LHX2
1.52 32.4 HNF4G 1.1 15.44 SOX18
1.5 30.72 HNF1B 1.09 87.26 MEF2C
1.46 27.81 ZBED1 1.09 51.66 ZNF296
1.45 35.76 BATF 1.09 18.03 IRF5
1.43 25.67 EOMES 1.08 11.16 ZFAT
1.42 25.52 MEF2C 1.08 11.16 IRF8
1.41 50.97 C11orf9 1.08 11.08 PRRX1
1.4 65.94 POU2F2 1.08 11 IKZF1
1.4 34.77 NFATC2 1.07 48.22 TOX2
1.4 24.38 SPI1 1.05 28.43 AKNA
1.4 24.15 TP73 1.04 9.86 E2F8
1.38 23.08 ASCL1 1.03 9.63 IKZF2
1.34 20.94 MEF2B 1.02 19.33 MSC
1.32 24.61 IRF2 1.02 9.55 IKZF1
1.32 19.71 IKZF1 1.02 9.55 LHX2
1.31 19.64 NR3C1 1.02 9.48 SP110
1.31 19.64 TP63 1.01 60.75 NFKB2
1.3 19.1 PAX5 1 11 ZBTB38
1.27 17.8 TBX21 1 9.02 TFDP2
1.26 42.26 EBF1 1 9.02 RUNX3
1.26 17.12 HNF4G
Ranked list of TF promoter expression in GM12878 relative to the median expression in the FANTOM5 collection
is shown as determined by Cap Analysis of Gene Expression (CAGE, library ID: CNhs12331, experiment accession ID:
DRX007776) (Fantom_Consortium et al., 2014). TPM = tags per million. TFs assigned to the E2 cluster or the E3
cluster of TFs are highlighted in orange or blue, respectively.
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